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1 Introduction
1 Introduction
Cancer  one of three women and one of two men receive this diagnosis during their
lifetime (US National Cancer Institute, 2013a, 2013b, 2013c). Although many new ther-
apies have been developed in the past decades, the lifetime risk of dying from cancer is
still about 20% (22.94% and 19.34% in 2012 in the US for males and females, respec-
tively).
Tumorigenesis is caused by an imbalance of proliferation and programmed cell death.
Genes that regulate these mechanisms are altered (Croce, 2008) and can be divided into
two categories. Oncogenes are responsible for proliferation and cell growth, and tumor
supressor genes promote cell death (Wilbur, 2009). Recent research aims to get detailed
insights into cancer biology to target mechanisms responsible for tumor development
and progression.
Changes in gene expression is one of several indications for genetic alterations in cancer.
Knudson (2001) discovered that typically many genes are needed to change a normal cell
into a tumor cell with uncontrolled growth. Microarray technology, and most recently
RNA-seq, is used to measure the expression of thousands of genes simultaneously. Hun-
dreds of cancer-related gene expression datasets are publicly available in databases like
Gene Expression Omnibus (Edgar et al., 2002).
Since modulation of gene expression is caused by either chromatin domains, transcrip-
tion, post-transcriptional modiﬁcation, RNA transport, translation or mRNA degrada-
tion (Gilbert, 2003), thousands of simultaneously measured gene expressions are promiss-
ing to reveal mechanisms changing under certain conditions.
With the ﬁrst microarray experiments, researchers have been started to look for diﬀeren-
tially expressed genes between disease and control samples, diﬀerent stages of a disease
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or diﬀerent tissues. For example, Ismail et al. (2000) identiﬁed 160 and 95 genes up-
regulated in normal human ovarian surface epithelium and ovarian tumors, respecively.
Welsh et al. (2001) found several diﬀerentially expressed genes between prostate tumors
and normal prostate tissue and proposed the secreted macrophage inhibitory cytokine
(MIC-1) as diagnostic marker.
In this thesis, our goal is to improve statistical methods for high-dimensional data to gain
deeper insights into cancer biology by analyzing gene expression data. We focus on two
topics. First, the large number of available gene expression datasets is used to validate
diﬀerentially expressed genes or biomarkers in cancers. Second, genes are not consid-
ered alone but in interaction networks that might change during disease progression or
between diﬀerent disease stages. We detect diﬀerential interaction networks from gene
expression data by testing gene sets derived with and without biological prior knowledge.
Despite the knowledge of multi-gene involvement in tumorigenesis, many publications
describe single genes as predictive or prognostic markers. Trock et al. (1997) found that
MDR1/gp170 expression in breast cancer tumors is associated with poor response to
chemotherapy and Yamabuki et al. (2007) identiﬁed Dikkopf-1 as a novel serologic and
prognostic biomarker for lung and esophageal carcinomas.
The growing number of available data oﬀers the opportunity to validate or disprove
ﬁndings. A common approach to evaluate the prognostic or predictive impact of a gene
is meta-analysis (Whitehead, 2002). E.g. Griﬃth et al. (2006) identiﬁed important di-
agostic biomarkers of thyroid cancer via meta-analysis. Mehra (2005) discovered GATA3
as prognostic marker in breast cancer by global gene expression meta-analysis.
Common meta-analysis treats all considered datasets equally except for diﬀerent weight-
ing. But often ﬁndings are discovered on one dataset and shall be validated on other
homogeneous cohorts. Moreover, in all genome-wide expression analyses prognostic or
predictive genes may be misleadingly found due to the high number of performed tests.
To control the number of false positives a correction for multiple testing is required and
commonly performed.
Bonferroní (Hochberg and Tamhane, 1987) published a simple procedure to control the
global number of false positive results. Holm (1979) proposed a less conservative method
and shows that it still controls the global type one error. A less strict approach was pro-
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posed by Benjamini and Hochberg (1995) by controlling the proportion of false positives
among all signiﬁcant ﬁndings. The latter is commonly used for correction for multiple
testing in high-dimensional genetic data, particularly because expression proﬁles of genes
are not independent.
Taking the validation idea and the adjustment for multiple testing into consideration,
Miller et al. (2001) proposed "a two-stage design in which signiﬁcance testing applied to
explorytory data is used to guide a second round of hypothesis-testing experiment con-
ducted in a separate set of experimental studies". Victor and Hommel (2007) combine
an adaptive design with the control of the false discovery rate and argue for a generalized
deﬁnition for a global p-value. Zehetmayer and Posch (2012) proposed an integrative
approach that is based on the pooled data from both stages in a two stage approach
controlling the FDR.
However, the idea behind the listed approaches is to reduce experimental costs, but not
to validate previous ﬁndings. In this thesis, we propose two new approaches to vali-
date biomarkers derived from high-dimensional data. The ﬁrst strategy combines an
exploratory screening for markers with a common meta-analysis of validation datasets.
The second approach is based on sequential validation of considered datasets. By suc-
cessively reducing the number of genes through the validation steps less adjustment for
multiple testing is required. Both approaches are already puplished by Lohr et al. (2012)
and Botling et al. (2013), respectively.
In the past years biological network interference has become a major research topic,
because researchers realized that  especially cancer  biology is more complex and
cannot be assessed by analyzing the expression of single genes.
Many methods for network inference have been proposed in the past decades. Butte et
al. (2000) published the concept of relevance networks that use the Pearson correlation
and a ﬁxed threshold to determine which edges are present in a graph. A more sophis-
ticated approach for graph estimation are Bayesian Networks (Pearl, 2000). Sampling
from the posterior distribution of the graph given the observed data via Markov Chain
Monte Carlo (MCMC) simulations (Grzegorczyk and Husmeier, 2008), the posterior
probability for each edge is determined by the average of simulated samples. Although
Friedman et al. (2000) applied this method to expression data, inference of Bayesian
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Networks is computational expensive due to the MCMC simulations and therefore not
suitable for high-dimensional data.
An alternative method for network inference is the Covariance Selection or Graphical
Gaussian Models based on an idea from Dempster (1972). Whittaker (1990) developed
the theory of Graphical Gaussian Models assuming a multivariate normal distribution
of the data. Zero entries of the inverse covariance matrix, i.e. the precision matrix, and
therefore in the matrix of partial correlations are interpreted as absent edges in a graph,
while none-zero entries in the matrix of partial correlations denote present edges. Partial
correlation denotes the correlation of two variables if the inﬂuence of other variables is
removed. For the calculation of the partial correlation matrix, the inverse of the covari-
ance matrix is required. The covariance matrix can only be inverted if it has full rank,
i.e. more observations than variables must be considered. However, gene expression is
often measured for only few samples.
Many researchers adopt the idea of the Graphical Gaussian Models and developed meth-
ods that allow sparse estimation of the covariance or rather precision matrix for genetic
data.
Schäfer and Strimmer (2005a) proposed a linear shrinkage approach for the estimation
of the covariance matrix. By combining the unconstrained estimation of the covariance
matrix with a constrained estimator  a diagonal matrix with the variances of genes 
the resulting estimation of the covariance matrix will be positive deﬁnit and therefore
invertible.
Friedmann et al. (2008) applied a Lasso penalty to the covariance matrix. Their pro-
posed algorithm ﬁts a modiﬁed Lasso regression iteratively for each variable. The idea
for the algorithm was adopted from Meinshausen and Bühlmann (2005). They com-
bined neighborhood selection that estimates the conditional independence restrictions
separately for each node with the Lasso as an alternative to standard covariance selec-
tion for sparse high-dimensional graphs.
Another approach for the regularized estimation of the covariance and thereof partial
correlation matrix was proposed by Tenenhaus et al. (2010). They applied a Partial
Least Squares Regression to assess the strength of independence of any two genes in a
small-sample-size and high-dimensional network setting.
A general framework for combining regularized regression methods with the estimation
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of Graphical Gaussian models was introduced by Krämer et al. (2009). They sug-
gested to use various existing methods like Partial Least Squares Regression as well as
two new approaches based on ridge regression and two-stage adaptive lasso, comparing
sparse and non-sparse methods for gene-association estimation. Extensive simulations
and comparisons resulted in the conclusion that the shrinkage approach proposed by
Schäfer and Strimmer (2005a) is more stable than regression based methods like the one
from Meinshausen and Bühlmann (2005).
Recently many methods for graph comparisons in the context of microarray data have
been developed. De la Fuente (2010) resumes the recent ideas published from diﬀerential
expression of single genes to diﬀerential coexpression and further to diﬀerent (interac-
tion) networking. Choi et al. (2005) compared tumor and normal tissue by estimating
Relevence Networks for each phenotype. Assuming the same number of edges to be
present in both graphs, edges that are exclusive in one of the two graphs are called
subtype-speciﬁc links.
A method to detect changes between multiple ordered groups, e.g. time series, was pro-
posed by Gillis and Pavlidis (2009). Diﬀerential co-expression between multiple groups
is assessed by a measure based on Haar-wavelets (Haar, 1909).
Jacob et al. (2012) combined both steps  ﬁrst testing individual genes, then testing
gene sets for enrichment of diﬀerentially expressed genes  in a single procedure. Their
method takes the network topology, e.g. from KEGG pathways (Kanehisa and Goto,
2000), into account to gain more power.
These methods for graph comparison depend on diﬀerential co-expression of gene net-
works. An alternative approach is to quantify a change in the interaction structure of
gene expression.
Gill et al. (2010) proposed a framework for the detection of diﬀerential connectivity.
They use a connectivity score to test whether the overall modular structure of two
graphs, the connetivity of a speciﬁc set of "interesting genes", or the connectivity of a
single gene between two networks is diﬀerent. Therefore, a permutation test using the
mean distance of partial correlations derived by the shrinkage approach of Schäfer and
Strimmer (2005a) is applied.
A method for Indirect Comparisons of Interaction Graphs was proposed by Mansmann
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et al. (2010). A hierarchical top-down testing approach using resampling technique
is applied beginning with the global null-hypothesis "no node in the network shows a
diﬀerent interaction".
To assess whether the interaction of genes is diﬀerent under two conditions, it is not fea-
sible to consider the entire collection of measured genes. Hence, strategies for hypothesis
generation of diﬀerential networks are required.
Kostka and Spang (2004) detected sets of diﬀerentially co-expressed genes under two con-
ditions by calculating a score based on an ANOVA model for diﬀerential co-expression
and application of an algorithm that ﬁnds high scoring gene sets.
Gambardella et al. (2013) developed a procedure named DINA (DIﬀerential Network
Analysis) that is able to identify a set of genes, whose co-regulation is condition-speciﬁc.
DINA starts with a set of genes, e.g. a KEGG pathway, and a set of networks, for exam-
ple derived by Spearman Correlation analysis. A co-regulation probability is calculated
and its variability across networks is assessed based on permutation testing of an en-
tropy which describes the uncertainty associated with a random variable, i.e. the genes
have a high co-regulation probability only in one network, i.e. the pathway activity is
condition-speciﬁc, the entropy will be low.
Another approach is to test gene sets deﬁned by biological prior knowledge. For exam-
ple Jacob et al. (2012) proposed to apply their testing procedure to all KEGG pathways.
However, due to the large number of genes and constrains of used methods, the detec-
tion of diﬀerential interaction networks remains challenging. In this thesis, we propose
a new algorithm for Diﬀerential Networks Gene Selection(DiNGS). Starting with a suit-
able pair of genes a forward selection is performed on a criterion ensuring diﬀerential
co-regulation between two groups.
Adopting the idea of diﬀerential expression to our aim to ﬁnd diﬀerential interaction
networks, we perform a Gene Set Enrichment Analysis in Gene Ontology (GO) groups
(Edgar et al., 2002) of genes known to have impact on breast cancer prognosis. En-
riched gene sets are afterwards tested for diﬀerences in their corresponding interaction
networks of breast cancer patients with and without metastasis by several permutation
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tests. These tests use test statistics based on partial or orinary correlations including
the test proposed by Gill et al. (2010). The properties of the permutation tests are
explored in an extensive simulation study.
Most of the permutation tests are already published in Lohr et al. (2010).
This thesis is organized as follows: In Chapter 2 we provide the biological background
of cancer and describe the datasets considered in this thesis. Chapter 3 introduces the
validation approaches for high-dimensional gene expression data. Within this chapter,
Section 3.1 presents methods for meta-analysis and validation. The sequential valida-
tion procedure and the two-step meta-analysis approach are introduced in Sections 3.2
and 3.3, respectively. Section 3.4 summarizes the results of both methods applied to
non-small cell lung cancer and compares them with an ordinary meta-analysis.
In Chapter 4, concepts for the detection of diﬀerential networks are introduced. The
corresponding methods are described in Section 4.1. Section 4.2 presents explicit ways to
discover diﬀerential interaction networks. A simulation study to explore the properties
of the permutation tests introduced in Section 4.1 is presented in Section 4.3. Results
of this chapter are summerized in Section 4.3.
Chapter 5 discusses methods and ﬁndings from both topics  the validation approaches
for high-dimensional gene expression data and the detection of diﬀerential gene interac-
tion sub-networks  and gives an outlook to possible extensions and provides concluding
remarks of this work.
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2 Biological background and datasets
2.1 Cancer
In Germany cancer is the most frequent cause of death after cardiovascular diseases
(Kaatsch et al., 2012). Worldwide, more than 12 million people are newly diagnosed
with cancer per year (Jemal et al., 2011). In fact, cancer comprises more than 200 dif-
ferent diseases (Schulz, 2005). Though all cancers share the same elementary features
in matters of malignancy, it shows a large range of diversity, which requires diﬀerent
therapeutic strategies.
The DNA contains the information that is required for an organism to develop its mass
and shape, and the information about every protein that is needed for biological pro-
cesses. The central dogma of molecular biology describes the ﬂow of information in
a biological organism consisting of replication, transcription, and translation. In the
replication the DNA sequence is copied to transfer it from a mother to a daughter cell.
In the transcription, DNA is rewritten into mRNA. Afterwards the information can be
translated through the mRNA to a protein speciﬁed by the DNA sequence (Alberts et
al., 2007). Although the organism has developed many controls to avoid errors in repli-
cation, errors sometimes do occur, which might lead to erroneous incorporation into the
newly synthesised DNA strand due to mutated nucleotides and may cause a disequilib-
rium between cell growth and apoptosis. Though the diversity of cancers is high, some
cancer types aﬀect the people more than others. This thesis is focused on breast and
non-small cell lung cancer that play a major role in terms of world-wide incidence and
mortality.
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Breast cancer
Carcinomas of the breast are the most frequent cancer types in women by far with a
age-standardized incidence of 123.1 per 100 000 female inhabitants in 2008 in Germany
(Kaatsch et al., 2012). Breast cancer caused 458 503 deaths worldwide which is 13%
of all cancer-related deaths in women. Although women are 100 times more frequently
aﬀected than men, men may also be aﬀected and they tend to have poorer outcomes
due to delays in diagnosis (American Cancer Society, 2013). The risk for breast cancer
increases with age, i.e. postmenopausal, but also younger women are aﬀected and often
with poorer prognosis due to hereditary predispositions. Other known risk factors are
long (life-)time exposure of estrogens, ionizing radiation, cigarette smoking, alcohol, and
a high-fat diet (Schulz, 2005), where several factors might interact, also synergistically.
Breast carcinomas are classiﬁed by several aspects. The main aspects, histopathology,
stage, grade, and receptor status, are considered for treatment selection and conclusions
may be drawn for prognosis.
First, breast cancer is classiﬁed by its histological appearance. About three quarters
of all breast cancers are invasive ductal carcinomas (55%), ductal carcinomas in situ
(13%), and invasive lobular carcinomas (5%) (Eheman et al., 2009). The World Health
Organization (WHO) recommends further subdivision of breast cancers according to
pathological type (WHO, 2003).
The determination of amount and location of the cancer in the organism or body is called
staging. We know two diﬀerent kinds of staging, the clinical staging that is obtained
by mammography, x-rays and CT scans before surgery, and the pathological staging ob-
tained by surgery which is more accurate (American Joint Committee on Cancer, 2010).
The TNM classiﬁcation system, a commom used scheme for several cancer types, that is
based on the size of the tumor (T), the invasion of surrounding organs and lymph nodes
(N), and the presence of distant metastasis (M) (Sobin and Compton, 2010). The classi-
ﬁcation is explained below in the following section about non-small lung cancer, because
staging information is available for the lung cancer datasets but not for all breast cancer
data used in this thesis.
However, the grading is used for breast cancer classiﬁcation in this thesis. It depends on
the microscopic appearance of the breast cancer cells compared to normal breast cells.
9
2 Biological background and datasets
Grading classiﬁes the tissue in well diﬀerentiated (low grade), moderately diﬀerentiated
(intermediate grade), and poorly diﬀerentiated (high grade) tumors. In the following,
the Nottingham (also called Elston-Ellis) scale system (Elston and Ellis, 1991) is used
as modiﬁcation of the Scarﬀ-Bloom-Richardson grading system (Bloom and Richardson,
1957), which grades breast carcinomas by summing scores for tubule formation, nuclear
pleomorphism, and mitotic count. The score ranges from I to III, where I stands for well
diﬀerentiated, while a poor or undiﬀerentiated tumor is given a higher score of III.
Another classiﬁcation criterion is the status of hormon receptors like estrogen receptors
(ER), progesterone receptors (PR) and HER2/ERBB2. The presence of receptors is
often identiﬁed by immunohistological analysis. Estrogen in combination with its recep-
tor is a key regulator of growth in a normal breast (Schulz, 2005). ER positive (ER+)
tumors depend on estrogen for their growth and therefore may be treated with drugs
to reduce the eﬀect of estrogen, e.g. Tamoxifen. HER2 (human epidermal growth factor
receptor 2) is a protein encoded by the ERBB2 gene (Coussens et al., 1985). It stimu-
lates cell proliferations and inhibits apoptosis. Patients with overexpression of ERBB2
("HER2 positiv") have a poorer prognosis, but treatment by a monoclonal antibody
"Trastuzumab" that binds at HER2 is indicated. PR is a protein inside cells that is ac-
tivated by progesterone (Law et al., 1987) and has functions in maintaining pregnancy,
in estrous and menstrual cycles. Hence, the combination ER+/PR+/ERBB2- indicates
a comparatively good prognosis.
Non-small cell lung cancer
Lung cancer is the leading cause of cancer-related death worldwide (Ferlay et al., 2010).
More than 1.6 million people were newly diagnosed and about 1.38 million died due to
lung cancer in 2008. Among men, lung cancer is more frequently diagnosed than among
women, but the incidence in women has considerably increased over the last decades
and has just recently begun to stabilize (Jemal et al., 2004). This fact can be explained
by the ampliﬁed tobacco usage in women (Lum et al., 2008). Tobacco smoke is the most
prominent risk factor that causes about 80 − 90% of all lung carcinomas (Horn et al.,
2012). Other known risk factor are genetic factors, radon gas, asbestos, and air pollution
(Alberg and Samet, 2010; O`Reilly et al., 2007) including second-hand smoke (Carmona,
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2006). Most patients diagnosed with lung cancer are older than 60 years (DKFZ, 2013).
Compared to smoking-related lung cancer, carcinomas in non-smokers occur more often
in women and are more often classiﬁed as so called adenocarcinomas (Subramanian and
Govindan, 2007). In gerenal, lung cancer can be divided into small cell lung cancers
(SCLC) that account for approximately 15% of all lung cancers and non-small cell lung
cancers (NSCLC) (Travis, 2011). SCLC is assumed to have its origin in neuroendocrine
cells of the lung (Rosti et al., 2006). Patients diagnosed with SCLC show a promising
response to chemotherapy at ﬁrst, but often develop a therapy resistance followed by
metastatic disease within ﬁve years. In this thesis we focus on datasets consisting of
NSCLC.
By cellular morphology, three main subgroups of histological substypes are deﬁned which
are the above mentioned adenocarcinomas, squamous cell and large cell carcinomas that
make up 40%, 21%, and 14% of all diagnosed lung cancers, respectively. A microscopic
examination of the stained tissue is a standard procedure after surgery. The classiﬁca-
tion of histological subtype is essential for the choice of therapy (Langer et al., 2010).
The glandular structure is characteristic for adenocarcinomas as well as the production
of mucin (Cooper et al., 2011). It is the most common type in non-smokers as mentioned
above and in men younger than 50 years as well as in women of all ages. Adenocar-
cinomas are also associated with KRAS or EGFR mutations (Sequist et al., 2007).
Keratinisation and intercellular bridges are typically seen in squamous cell carcinomas,
while large cell carcinomas are undiﬀerentiated with no sign of glandular or squamous
diﬀerentiation. Other minor histological subtypes of NSCLC are adenosquamous carci-
nomas, sacromatoid carcinomas and typical/atypical carcinoids (Travis, 2011).
The staging of a tumor as already mentioned in the breast cancer section above is deﬁned
by the TNM system (Goldstraw et al., 2007; Sobin and Compton, 2010). Here, the stage
of cancer is evaluated by the tumor size (T1-T4), the invasion of lymph nodes and organ
structures (N0-N4) and the presence of distant metastasis (M0-M1). Detailed informa-
tion on the classiﬁcation can be found in Table 20 in the appendix. By combining the
classiﬁcation of T, N, and M a stage in range of I to IV is assigned (cf. Table 1). The
stages are further subdivided in "a" and "b", except for stage IV. If distant metastases
are present, the size of the tumor or whether lymph nodes are aﬀected does not matter.
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Stage TNM subset Stage TNM subset
IA T1a/T1b N0 M0 IB T2a N0 M0
IIA T1a/T1b N1 M0 IIB T2b N1 M0
T2a N1 M0 T3 N0 M0
T2a N0 M0
IIIA T1/T2 N2 M0 IIIB T4 N2 M0
T3 N1/N2 M0 any T N3 M0
T4 N0/N1 M0
IV any T any N M1a/M1b
Table 1: Tumor stage based on TNM (7. edition), reproduced from Tsim et al. (2010).
All metastatic cancers are classiﬁed as stage IV. The prognosis and treatment decision
depend on the tumor stage.
Frequently, NSCLC is diagnosed at late stage, because of the absence of lung-cancer
speciﬁc symptoms. First symptoms may be respiratory ones, like coughing, hoarseness,
or chest pain. Further symptoms such as weight loss, headache, and fatique might
indicate late stage cancer with presence of distant metastases. In stage I and II surgical
resection is recommended with the chance of total remission, hence 30− 40% of stage I
patients experience a tumor relapse (Spiro et al., 2007). Stage II patients are treated with
adjuvant chemotherapy, but for stage I it is controversially discussed (Scott et al., 2007).
Stage III is quite heterogeneous. Patients diagnosed with stage IIIa have a considerably
higher 5-year survival rate than stage IIIb patients with 23% and 7%, respectively. Often
patients with stage IIIa are surgically treated followed by adjuvant chemotherapy, while
stage IIIb tumors are inoperable and recommended to be treated with a combination of
radio- and chemotherapy (Jett et al., 2007). NSCLC with metastatic disease, i.e. stage
IV, is considered to be incurable and patients are treated with combinated therapies to
improve life quality and gain some more months or even years (Socinski et al., 2007).
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2.2 Datasets
A biomarker is an indicator of underlying biology (Biomarker Deﬁnitions Working
Group, 2001). We distinguish between predictive biomarkers that provide information
about e.g. response to treatment and prognostic biomarkers which predict the outcome
of individual patients e.g. in terms of overall survival times or relapse-free survial. For
the breast and non-small cell lung cancer datasets that will be described below, diﬀer-
ent event-free survival times are available. The discovery and validation of prognostic
biomarkers will be part of this thesis. The challenge is due to the data structure.
All considered datasets comprise gene expression data of thousands of genes measured
on Aﬀymetrix microarrays. In general, microarray technology bases on hybridisation
of complementary DNA or RNA nucleotide strands located on a chip to ﬁxed DNA
molecules so that each spot represents a speciﬁc gene or transcript for thousands of
genes in parallel. On the high density DNA Probe arrays of Aﬀymetrix synthetic DNA
fragments are sythesized on the GeneChip c© (Lipshutz et al., 1999). Here, every gene is
represented by one or more probe sets that in turn consists of up to 20 oligonucleotide
probe pairs. Each probe pair is divided in two probe cells, and each probe cell consists
of approximately 107 identical 25-mer oligonucleotides. In the ﬁrst probe cell, the so
called Perfect Match (PM), the nucleotide stretches matches perfectly with the one of
the gene. The second probe cell is a kind of control of hybridisation signal where the
sequence contains a non-matching nucleotide (MM). The 1120 probe pairs of a probe
set are randomly distributed on the array to avoid spatial eﬀects. The values for each
probe on an array is provided in the so called Cel-File and needed to be combined in a
suitable way to one value for each probe set.
In addition, the low-level analysis ensures the comparability of values from diﬀerent
samples. It proceeds in four steps: Background correction, normalisation, probe speciﬁc
background correction and ﬁnally combining to one value per chip and probe set. Many
methods for this steps have been proposed in the literature (e.g. Lazaridis et al., 2002;
Bolstad et al., 2003). We use the RMA (robust multi-array average) method (Irizarry
et al., 2003) as implemented in the R (R Core Team, 2013) package "affy" (Gautier et
al., 2004) available on Bioconductor (http://www.bioconductor.org/ ).
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2.2.1 Breast cancer datasets
In this thesis, three breast cancer datasets where gene expression of node-negative (N0)
patients is measured on Aﬀymetrix GeneChip c© HG U133A are considered. For all three
cohorts, information on metastasis-free survival times are available.
The ﬁrst data set derives from a population-based cohort study consisting of 200 pa-
tients consecutively treated at the Department of Obstetrics and Gynecology of the
Johannes Gutenberg University Mainz between 1988 and 1998 (Schmidt et al., 2008).
Therefore, this data set is referred to as "Mainz cohort". After surgical intervention
in form of a modiﬁed radical mastectomy (75 patients) or a breast-conserving surgery
followed by irradiation (125 patients), none of the women received a systemic therapy.
During surgery no patient showed evidence of regional lymph node nor distant metasta-
sis. From the original pathological report established prognostic factors like histological
grade, tumor size, and steroid receptor status as well as data of the age at diagnosis date
were recorded. The median age of the 200 patients at surgery was 60 years (34 to 89
years). The median follow-up time was 7 years and 8 months. Data is acessible through
Gene Expression Omnibus (GEO, Edgar et al., 2002), accession number GSE11121.
Frozen tissue samples were selected from the tumor bank of the Erasmus Mediacal Cen-
ter in Rotterdam (Netherlands). All 286 patients were diagnosd with node-negative
breast cancer and surgically treated between 1980 and 1995 with a breast-conserving
therapy or modiﬁed radical mastectomy, 219 and 67 patients, respectively. As in the
Mainz cohort, none of them received any sytemic neoadjuvant or adjuvant chemotherapy
(Wang et al., 2005), but 248 patients received a radiotherapy. Median patient age at
surgery was below the median age in the Mainz cohort with 52 years (range from 26 to
83 years). Median follow-up time was about 7 years and 2 months, examinations were
dated every 3 months in the ﬁrst two years after surgery, every 6 months up to the ﬁfth
year and afterwards annual examinations were scheduled. This data set can be found
by accession number GSE2034 in the GEO data base.
The third data set consists of two cohorts reported through accession numbers GSE6532
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and GSE7390 in the GEO data base. The TRANSBIG cohort formed a collection of
untreated node-negative breast cancer samples from patients of ﬁve European centers:
Institut Gustave Roussy in Villejuif, France; Karolinska Institute in Stockholm, Swe-
den; Center René Huguenin in Saint-Cloud, France; Guy`s Hospital in London, United
Kingdom, and John Radcliﬀe Hospital in Oxford, United Kingdom (Buyse et al., 2006).
Further criteria of inclusion were that patients were diagnosed between 1980 and 1998
with node-negative breast cancer with tumor size ≤ 5 cm and without previous ma-
lignancies or bilateral synchronous breast carcinomas, had not received any systemic
adjuvant therapy, and were younger than 61 years at diagnosis. The latter fact was not
consequently complied, but it makes the TRANSBIG cohort the study with with the
youngest median age of 49 years (range from 24 to 73 years). It has the longest median
follow-up time with about 13 years and 7 month. Assessment of grading according to
Elston and Ellis was missing for 15 patients, while the grading for all 200 patients of the
Mainz cohort was available. The data set of the Rotterdam cohort contains no grading
information at all.
2.2.2 Non-small cell lung cancer datasets
The second collection of datasets used in this thesis consists of patients diagnosed with
non-small cell lung cancer (NSCLC). Again, we require information about event times
and gene expression data measured on Aﬀymetrix HG U133A with 22 283 or HG U133
Plus 2.0 array. With the latter, 54 675 probe sets are measured. Except for 6 features,
all probe sets of the HG U133A can be found on the HG U133 Plus 2.0 array. Therefore,
the overlap of 22 277 probe sets is considered for the analysis performed in this thesis.
For all cohorts, overall survival or censoring times are available.
The ﬁrst NSCLC dataset, which is denoted as our basic cohort and is used for gener-
ating hypotheses, derives from patients operated in Uppsala University hospital in the
years 19952005 with primary lung tumors and reported to the Uppsala-Örebro Regional
Lung Cancer Registry (Botling et al., 2013). Further criteria of inclusion were that fresh
frozen tumor tissue must be available in the Uppsala frozen tissue Biobank, the tumor
must be larger than 5 mm, it must be conﬁrmed as adenocarcinoma, squamous or large
cell carcinoma/other NSCLC (NSCLC not otherwise speciﬁed (NOS)), and the fraction
15
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Figure 1: Kaplan-Meier curve for overall survival of the Uppsala NSCLC cohort.
of tumor cells must be above 50%. Patients who had received a neoadjuvant treatment
were excluded. In total, 196 patients were included in the study. Information on several
clinical and histopathological variables are available through the Uppsala-Örebro Re-
gional Lung Cancer Registry like sex, age at diagnosis, performance status according to
WHO (Oken et al., 1982) and the reports of the pathologists of the Uppsala University
hospital on TNM staging. 106 (54.1%) patients were diagnosed with adenocarcinomas,
and 66 and 24 with squamous and large cell carcinomas/NOS, respectively. This ap-
proximately complies with the proportions of all NSCLC cases (cf. Section 2.1). The
median follow-up time was about 3 and a half years, no observation was censored within
ﬁve years after surgery as we can see in Figure 1. Here, the Kaplan-Meier curve (e.g.
Klein and Moeschberger, 2003) for all patients of the Uppsala lung cancer cohort is
shown. Although patients with late stage NSCLC are usually not operated, 10 patients
diagnosed with stage IIIb or even stage IV were operated and included in this study.
This dataset, also referred to as the Uppsala cohort, is available via Gene Expression
Omnibus, accession number GSE37745.
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dataset AC SCC other histology total Aﬀymetrix array
GSE37745 106 66 24 196 HG U133 Plus 2.0
Jacob 448 - - 448 HG U133A
GSE4573 - 130 - 130 HG U133A
GSE31547 30 - - 30 HG U133A
GSE3141 58 52 - 110 HG U133 Plus 2.0
GSE29013 30 25 - 55 HG U133 Plus 2.0
GSE31210 204 - - 204 HG U133 Plus 2.0
GSE19188 40 24 18 82 HG U133 Plus 2.0
GSE14814 28 52 10 90 HG U133A
Table 2: Overview of considered non-small cell lung cancer datasets.
In addition to the Uppsala NSCLC cohort where gene expression is measured on HG
U133 Plus 2.0 arrays, 8 more datasets are considered for validation in this thesis. An
overview of these cohorts is given in Table 2.
The dataset "Jacob" provided by Shedden et al. (2008) on the caArray platform
(https://array.nci.nih.gov/caarray/ ) of the National Cancer Institute with experiment
identiﬁer "jacob-00182" consists of 448 early-stage (Ib and II) lung adenocarcinomas.
Extended information on clinical data like age at diagnosis, sex, but also additional
event times such as progression-free survival is available for these samples collected from
the treatment institutions University of Michigan Cancer Center, Moﬃtt Cancer Center,
Memorial Sloan-Kettering Cancer Center, and the Dana-Farber Cancer Institute, USA.
Gene expression of this multi-center cohort was measured on Aﬀymetrix HG U133A
arrays.
From the Gene Expression Omnibus platform the dataset with accession number
GSE31547 was used in addition. Gene expression was also measured on the Aﬀymetrix
HG U133A chip and the cohort consists also of the histological subtype of adenocarci-
nomas. This dataset is contributed by Girard from the Hamon Center for Therapeutic
Oncology Research at Southwestern Medical Center, Dallas, USA, but the study had
not been published yet. The original dataset as stored in GEO with accession num-
ber GSE31547 contains 30 primary lung adenocarcinomas and 20 adjacent normal lung
controls. In this thesis, only the 30 adenocarcinomas are used for which additional in-
formation on clinical parameters are available. One more dataset that consists only of
adenocarcinomas is considered in this thesis. GSE31210 (Okayama et al., 2012) contains
required information on overall survival times of patients as well as gene expression mea-
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surements on HG U133 Plus 2.0 arrays of 204 patients that were diagnosed with stage I
or II between 1998 and 2008 at the National Cancer Center Hospital, Japan. These pa-
tients did not receive any neoadjuvant therapy nor a postoperative chemotherapy and/or
radiotherapy after complete resection of tumor tissue.
In contrast, the study with accession number GSE4573 consists of 130 samples from 129
patients diagnosed with squamous cell carcinomas only (Raponi et al., 2006). For one
patient two samples from diﬀerent areas of the same tumor were taken and microarrays
were prepared. Common clinical information of the patients diagnosed with stage Ia to
IIIb and received surgically resection of tumor are available.
Besides these datasets containing only one histological subtype, we consider four more
mixed cohorts. GSE3141 (Bild et al., 2006) has nearly balanced numbers of patients with
adenocarcinomas and squamous cell carcinomas as well as GSE29013 (Xie et al., 2011).
In contrast to GSE3141, the latter contains many clinical parameters such as TNM stage
and age at diagnosis, but the microarrays are made of formalin-ﬁxed paraﬃn-embedded
(FFPE) samples which has disadvantages in terms of RNA degradation (Zhu et al.,
2010). GSE19188 (Hou et al., 2010) contains tumor samples of 40 adenocarcinomas, 24
squamous cell, and 18 large cell carcinomas. Also GSE14814 (Zhu et al., 2010) provides
data of 10 large cell carcinomas in addition to the two most frequent histological sub-
types of early-stage patients. One criterion of inclusion here was that tumor cellularity
was higher than 20% which is considerably low compared for example with the tumor
cell fraction of at least 50% in the Uppsala NSCLC cohort.
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3 Validation approaches for high-dimensional genetic
data
Validation has become a major issue in biological analysis especially since high-dimensional
data are available. Due to the enormous numbers of genes that are analyzed, the chance
of observing signiﬁcant results just by chance is high. Hence, adjustment of the α-level
or rather p-values is required. Thereby the global α-level is controlled.
In this thesis we present diﬀerent approaches for the validation of signiﬁcant features on
high-dimensional datasets applied to the cohorts introduced in Section 2.2. Signiﬁcant
features can be obtained e.g. from two sample t-tests that compare the means of gene
expression values between two groups of patients or from Wald tests that identify genes
correlated with survival. The performance of the methods will be analyzed by a simula-







































Figure 2: Illustration of validation and simultaneous adjustment for multiple testing on
K > 1 high-dimensional datasets.
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Actually, for validation on other datasets, adjustment must be performed on every con-
sidered cohort. Whether the true signiﬁcant features stand out in another dataset de-
pends on the quality of the studies. We assume quality to be a composition of sample
size of a study and the underlying noise. The noise might originate from diﬀerences in
speciﬁc technical procedures performed in a speciﬁc medical center, to diﬀerences be-
tween compositions of the samples in diﬀerent medical centers, or maybe unconsidered
biological diﬀerences of the study individuals.
Though, to identify the true positive, which means true signiﬁcant, genes will be quite
diﬃcult after strict adjustment due to diﬀerences between the studies. Hence less strin-
gent adjustment methods are required. The issue of validation and simultaneous need
of adjustment for multiple testing is illustrated in Figure 2. Due to the large number
of tested genes the number of erroneously rejected hypotheses must be controlled and
concurrently we aim for a validation of ﬁndings on other datasets.
The combination of two or more datasets to one combined cohort and subsequent analyz-
ing and trying to conﬁrm the results e.g. by cross-validation seems to be a poor concept.
In most cases a batch eﬀect occurs. An example is given in Figure 3. Here, we see the
expression values exampliﬁed for the ﬁrst common probe set "1007_s_at" representing
gene "DDR1" in the list of the nine non-small cell lung cancer datasets introduced in
Section 2.2.2. for every patient. The expression values of each cohort are painted in an
distinct color. We recognize that values of one cohort are often strictly separated from
the values of the others. Combining those values without batch normalization will bias
the result of most analyses.
A better approach for combined results is the ordinary meta-analysis. One advantage
which might be concomitant a disadvantage is that many small signals may be suﬃcient
for a signiﬁcant result in a meta-analysis. Besides it takes all studies into account simul-
taneously. However, our focus is on another strategy: We have a basic dataset that we
use to identify interesting genes. Afterwards these genes should be validated on other
datasets. Though, we have to ﬁnd a tradeoﬀ between validation and strict adjustment
for multiple testing to receive as many relevant genes as possible and simultaneously
eliminating all false positive, i.e. non-relevant genes.
In the following section we give a short introduction to multiple testing and particularly
the adjustment of p-values by controlling the False Discovery Rate (FDR). Further some
20


































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Figure 3: Expression values of probe set "1007_s_at" representing gene "DDR1" of all
nine non-small cell lung cancer cohorts.
methods for survival analysis and meta-analysis used in this chapter are described. A
sequential validation strategy is proposed in Section 3.2. We demonstrate the use of this
procedure concerning the elimination of false positive results and simultaneously maxi-
mizing the power of the procedure in a simulation study, as well as the use in assessing
the quality of datasets. We also apply the strategy to several cancer datasets that are
introduced in Section 2.2. Another validation approach is introduced in Section 3.3, and
performed on non-small cell lung cancer datasets. The special feature of this strategy is
the 2-step procedure of ﬁrst on unadjusted screening and than a meta-analysis for vali-
dation. In addition, an ordinary meta-analysis is performed on the lung cancer datasets.
In Section 3.5, the results of the three approaches are compared and discussed.
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3.1 Methods
3.1.1 Multiple testing
If a statistical test is performed, two outcomes are possible: The null hypothesis (H0)
can be rejected, i.e. the test is signiﬁcant, or there is no suﬃcient proof against H0 and
the test is not declared to be signiﬁcant. On the other hand the null hypothesis can be
true or false. If H0 is true and it is not rejected we obtain a correct decision, just as if the
null hypothesis is not true and the test is signiﬁcant. Hence, two (types of) errors can be
committed (Dudoit and van der Laan, 2008). We call a decision type I error or true posi-
tive if a true null hypothesis is rejected and a type II error or false negative is committed
if a non-true null hypothesis is not rejected. In modern testing theory the main focus
is on the type I error that is controlled by a level α, i.e. P (rejectingH0|H0 is true) ≤ α
and we merely try to minimize the type II error given a ﬁxed value for α.
Number Number
Number of not rejected rejected Total
true H0 A V g0
non-true H0 F B g1
g −R R g
Table 3: Number of correct decisions and type I and type II errors committed in multiple
testing of g hypotheses (reproduced from Benjamini and Hochberg, 1995).
In many ﬁelds like the analysis of gene expression data thousands of hypotheses are
tested simultaneously. If we test lots of hypotheses at a speciﬁed signiﬁcance level the
probability of committing type I errors increases with the number of hypotheses. There-
fore, an adjustment for multiple testing is required to control the type I error rate. Let
us assume we want to test g null hypotheses H i0, i = 1, . . . , g of which g0 are true and
g1 = g− g0 hypotheses are false. Both parameters, g0 and g1 are unknown. The number
of rejected and not rejected null hypotheses are treated as random variables denoted by
R and g−R, respectively. Table 3 (cf. Benjamini and Hochberg, 1995) summarizes the
numbers of true/non-true and (not) rejected hypotheses. A,F, V , and B are unobserv-
able random variables where V are the false positives or type I errors and F denotes
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the number of false negatives or rather type II errors. As mentioned above, it is the
philosophy of signiﬁcance testing to control the number of type I errors. In the following
the two most common type I error rates are introduced as well as one multiple testing
procedure for each error rate.
The family-wise error rate
We deﬁne the family-wise error rate (FWER) as the probability of rejecting at least
one null hypothesis when it is true, i.e. committing at least one type I error under all
decisions (Dudoit et al., 2003):
FWER = P (V ≥ 1).
To control the FWER on a global level α the p-values have to be adjusted. One common
procedure that is used in this thesis is the Holm procedure (Holm, 1979) which is a further
development of the Bonferroni procedure (Dudoit and van der Laan, 2008). Compared
to Bonferroni as a single-step procedure the Holm procedure adjusts the p-values step-
down which is an advantage because it is less conservative.
Let p1 ≤ p2 ≤ . . . ≤ pg denote observed and ordered raw p-values and let H10 , H20 , . . . , Hg0
be the corresponding null hypotheses. We deﬁne
i? = min {i : pi > α/ (g − i+ 1)} .
If such i? exists, reject all null hypotheses H i0, with i = 1, 2, . . . , (i
? − 1). When no such




{min ((g − l + 1) pl, 1)} .
Afterwards, these adjusted p-values can be compared with the local level α.
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The false discovery rate
The false discovery rate (FDR) described by Benjamini and Hochberg (1995) is deﬁned
as the expected proportion of type I errors among the reject hypotheses:
FDR = E(O)
where O is deﬁned by O = V
R
. This error rate tolerates some type I errors, but the
proportion of errors among all rejected hypotheses is controlled. If all null hypotheses
are true, the false discovery rate is equilavent to the family-wise error rate because b = 0,
where b denotes an observation of B and V = R. Let v denote an observation of V and
deﬁne 0
0
:= 0. If the numbers of true as well as false null hypotheses are greater then 0,
we have to consider two cases:
1. v = 0 (no H0 is rejected) ⇒ O = VR = 0 ⇒ P (V ≥ 1) = E(O)
2. v > 0⇔ v ≥ 1 (at least one H0 is misleadingly rejected):
v
r
≤ 1⇒ I(V≥1) ≥ VR = O ⇒ P (V ≥ 1) ≥ E(O)
Thus, by controlling the FWER, the FDR is also controlled in the weak sense.
Benjamini and Hochberg (1995) provide a procedure for controlling (only) the FDR for
independent tests which is less stringent and power is gained, i.e. we yield a smaller
number of type II errors. Other procedures for the control of the FDR under certain
dependence structures are provided for example by Benjamini and Yekutieli (2001).
Therefore, let p1 ≤ p2 ≤ . . . ≤ pg denote observed and ordered raw p-values as in the
last paragraph and we deﬁne
i?? = min {i : pi ≤ (i/g)α} .
If all hypotheses H i0, with i = 1, 2, . . . , i
??, were rejected the FDR is controlled at level
α. If no such i?? exists, we reject no hypothesis. The corresponding adjusted p-values
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These adjusted p-values can be compared with the local level α as for the Holm proce-
dure.
3.1.2 Cox proportional hazards model
Survival analysis deals with the problem of analyzing time-to-event data. In our case
of biological data, events could be, for example, death, recurrence of cancer, or distant
metastasis. Not for all patients the event of interest can be observed in the period ﬁxed.
If the event has not occured until at the end of the period or a patient drops out of
the study for other reasons, the corresponding observation will be (right) censored. High
censoring rates are often seen in cancer data. But instead of eliminating all patients with
missing endpoints, the censored data is integrated in survival analysis. Even if we do not
know the exact event time of a censored patient, we know that he or she has not seen
the event until his or her drop-out. An important assumption for the following methods
of survival analysis is that censoring is independent from the event of interest. Before
we specify the Cox proportional hazard model, the notation and some basic quantities
will be introduced.
Let T be the time from a starting point t = 0 to the event of interest, i.e. a non-negative
random variable, and f(t) its density with distribution function F (t) (see Klein and
Moeschberger, 2003). The survival function is the probability of observing the event
after time point t, deﬁned as
S(t) := P (T > t).
Since T is a continuous random variable S(t) is a continuous, strictly decreasing function
with limt→0 S(t) = 1 and limt→∞ S(t) = 0 and moreover the complement of the distri-
bution function S(t) = 1 − F (t) = 1 − P (T ≤ t). Alternatively, the survival function
can be speciﬁed by the integral of the density, f(t), i.e.




The probability that an individual experiences the event in the next instant, conditional
on that the person was event-free until t, is called risk function or hazard rate (function)
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P (t ≤ T < t+ ∆t|T > t)
∆t
,




P (t ≤ T < t+ ∆t)
∆t
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Beside the plain hazard rate, the probability of an individual experiences an event in the
next instant time, conditional on survival time t with a speciﬁc value of a covariate is
considered. Possible candidates for covariates that might have impact on the probability
that an individual experiences an event in the next instant may be e.g. gender, a special
treatment, or gene expression. This conditional probability can be described by the Cox
proportional hazards model (Cox, 1972).
Let the data consist of n samples. For each sample or patient the triple (Tj, δj,Zj),
j = 1, . . . , n is available, where Tj is the time that patient j spent in the study, δj
the indicator whether the j−th patient experienced the event (δj = 1) or was censored
(δj = 0), and Zj = (Zj1, . . . , Zjp)‘ is a vector of p covariates for individual j. Cox (1972)
deﬁnes the basic model as follows:











where h0(t) is an arbitrary baseline hazard rate (function), and β = (β1, . . . , βp)‘ is a
parameter vector. The Cox proportional hazards model is a semiparametric model be-
cause it consists of a nonparametric part, the baseline hazard rate, and a parametric part
since the eﬀect of the covariates is assumed to be parametric. An important assumption
of the model is couched in its name: the proportionality of hazard rates. If we have
two patients with covariate values Z1 and Z2, then the ratio of the two hazard rates is







h0(t) · exp (β ‘Z2) =
h0(t) · exp (
∑p
k=1 βkZ1k)












This ratio is called relative risk or hazard ratio (HR) and describes the relative risk
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of a patient with covariate vector Z1 experiencing the event of interest in the next
instant compared to a patient with covariate vector Z2. In this thesis, we restrict on
the analysis of univariate Cox proportional hazards models. If so, and the covariate
has two categories, e.g. treatment and control, exp(β1) =
h(t|Z1)
h(t|Z2) describes the risk for
the occurence of the event of a patient who received the treatment relative to the risk
for an individual of the control group. A similar interpretation is possible for hazard
ratios of multivariate Cox proportional hazards models, however, the values of all other
covariates that are considered in the model must be the same in both groups.
The parameter vector β can be estimated by a Maximum Likelihood approach. Suppose
that there are no ties between the observed event times, and let t1 < t2 < . . . < tD
denote the ordered event times with corresponding k-th covariate Z(i)k, i = 1, . . . , D
for the patient with event time ti. The risk set at time point ti, denoted by R(ti), is
deﬁned as the set of all individuals who have not seen the event till time ti or dropped
out of the study, i.e. they are still under risk and might see the event in the future.
The partial likelihood is based on hazard rates and is composed of the information of
an individual patient i experiencing the event (in the numerator) and the information













The name "partial" likelihood refers to the fact that this expression ignores the actual
event times but takes the order of the latter into account. Instead of maximizing the











































Solving the equation system ∂
∂βk
LL(β) = 0, ∀k = 1, . . . , p leads to the maximum likeli-
hood estimation βˆ of the regression coeﬃcients β .
After the estimation of the parameter vector βˆ , the baseline hazard rate h0(t) is esti-
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with di as the number of events at time point ti. As mentioned before, we assume to
have no ties between the event times since time is continuous and therefore we have
di = 1 ∀i = 1, . . . , D.
Finally, when the Cox proportional hazards model with the chosen variables is estimated,
it will be of interest which covariates have a signiﬁcant eﬀect on the individual risk. In
this thesis we restrict to univariate Cox proportional hazards models, as mentioned
above. Therefore, testing the hypothesis H0 : β1 = 0, that is equivalent to H0 : HR = 1,
vs. H1 : β1 6= 0 is suﬃcient to answer the question if the covariate Z1 has a signiﬁcant
inﬂuence on the event time, e.g. survival. The statistic of the local (Wald like) test (see












or rather − ∂2
∂2β1





p,1−α is the (1 − α)-quantile of the χ2 distribution with p = 1
degrees of freedom.
3.1.3 Meta-analysis
Since meta-analysis was ﬁrst deﬁned by Glass (1976) as "the statistical analysis of a
large collection of analysis results from individual studies for the purpose of integrating
the ﬁndings", it has become indispensable in todays clinical research. Especially in the
context of evidence-based medicine meta-analyses are essential for the highest level of
evidence (Evidence-Based Medicine Working Group, 1992). Many statistical methods for
conducting meta-analyses were developed and reﬁned (see Sutton et al., 2000, or Stangl
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and Berry, 2000). We restrict to one or rather two mainstream statistical approaches
(cf. Whitehead, 2002).
A main focus of controversy is the choice between the ﬁxed eﬀect and the random eﬀects
model that enable an estimate of the overall eﬀect of interest. In the ﬁxed eﬀect model
the eﬀect of every study is considered to be out of the same (normal) distribution, while
in the random eﬀects model an additional between study eﬀect is assumed. The biggest
disadvantages of the ﬁxed eﬀect model are that it does not hold under heterogeneity
(see e.g. Schumacher and Schulgen, 2006) and it holds only for the particular studies
included in the meta-analysis, i.e. a generalization of the results is quite problematic.
The random eﬀects model consideres this issue and is more generazible. However, it
must be taken into account that often the trials included in the meta-analyses are not
representative for the total polulation. Moreover, if only a small number of studies are
taken into consideration, the between-study eﬀect ﬁtted by a random eﬀects model might
be unreliable. Before both models are brieﬂy introduced, we deﬁne some notation.
Let K be the number of independent studies and θ the true eﬀect of interest that shall
be estimated by θˆ. θk, k = 1, . . . , K denotes the single study eﬀect of the k-th study
that is estimated by θˆk.
The ﬁxed eﬀect model
In Whitehead (2002) the general ﬁxed eﬀect model is deﬁned by
θˆk = θ + ek, θk = θ ∀k = 1, . . . , K
for k = 1, . . . , K, where the errors ek are realizations of normally distributed random
variables k ∼ N(0, ξ2k). It follows that
θˆk ∼ N(θ, ξ2k).








as the inverse estimated variance of θˆk. Then we assume that
θˆk ∼ N(θ, w−1k ).
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Using a test for heterogeneity we are able to test the hypothesis H0 : θ1 = θ2 = . . . = θK
against H1 : θk 6= θl for at least one pair (k, l), 1 ≤ k, l ≤ K, k 6= l (see Whitehead,









If the null-hypothesis is true, i.e.
all study eﬀects are homogeneous, Q follows a χ distribution with (K − 1) degrees of
freedom. Thus, we can reject the null-hypothesis if Q > χ2K−1,1−α, where χ
2
K−1,1−α is the
(1− α)-quantile of the χ2 distribution with (K − 1) degrees of freedom.
The random eﬀects model
In a random eﬀects model we assume the single study eﬀects θ1, θ2, . . . , θK to follow
a normal distribution with mean θ and variance τ 2. The general random eﬀects model
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is deﬁned as follows:
θˆk = θ + νk + k,
for k = 1, . . . , K. Here, νk are random eﬀects (or between study eﬀects) with νk ∼
N(0, τ 2) and k is a normally distributed error with k ∼ N(0, ξ2k) as before. Assuming
that νk and k are independently distributed, it follows that
θˆk ∼ N
(




The between study variance τ 2 can be estimated by τˆ 2 from the data using the method
of moments described by DerSimonian and Laird (1986):
τˆ 2 =








With this estimator we made the assumption that
θˆk ∼ N
(














As in the ﬁxed eﬀect model, we treat (w?k)










as maximum likelihood estimate of θ. Analogously to the ﬁxed eﬀect model, the standard
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The weights wk and w?k of the ﬁxed eﬀect and the random eﬀects model, respectively,
will not diﬀer much if the estimate of the between study eﬀect τˆ 2 is close to zero. The
obtained estimates of the overall eﬀect, the standard errors as well as the conﬁdence
intervals will be hardly the same in this case. However, if τˆ 2 is large the standard error
will be larger for the random eﬀects model and with it the conﬁdence interval for θ.
Besides, the estimate of the latter model will move closer to the arithmetic mean. The
amount depends on the study with the largest weights in the ﬁxed eﬀect model.
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3.2 Sequential validation strategy
Clearly discriminated from the concept of the ordinary meta-analysis we propose a step-
wise validation procedure (Lohr et al., 2012). We assume that some characteristic shall
be tested genome-wide, e.g. diﬀerential expression among two conditions or patient
groups by conducting t-tests or the correlation with a speciﬁc event time by a Wald
tests, on serveral datasets. Here, we restrict on gene expression data, but the algorithm
is also applicable for other types of high-dimensional data, e.g. SNP (single-nucleotide
polymorphisms) data. Suppose K datasets are available and g genes are measured in
each cohort. In total we obtain K · g p-values that require a reasonable adjustment.
We propose the following algorithm that is brieﬂy explained for K = 3 datasets. As-
sume the datasets are ordered according to an arbitraty preference. For all genes in each
datasets raw p-values have been calculated. In a ﬁrst step, we adjust the p-values of the
ﬁrst dataset for multiple testing with method M1. All genes related to p-values above
the signiﬁcance level α are excluded from further analysis. In a second step, the p-values
belonging to the remaining genes are adjusted on the second dataset using method M2.
Usually the number of signiﬁcant genes after adjustment for multiple testing in the ﬁrst
step is much smaller then the entire number of screened genes. For that reason the size
of the adjusted p-values will increase. Again, we take the genes whose adjusted p-values
are smaller then the α-level of the second dataset and reduce the third dataset to these
genes. The remaining p-values of the third dataset are adjusted for multiple testing with
method M3 once more. Conducting this procedure the number of potential signiﬁcant
genes decreases from step to step. The general algorithm for K > 3 can be found in
Figure 4 (see Lohr et al. 2012, p. 449).
Tuning at several points of the algorithm is possible. The signiﬁcance level α can be
selected as well as the methods of adjustment. We apply the algorithm to simulated data
and to real cancer data. In simulation studies we have tested lots of combinations of these
parameters and the results are summarized in Section 3.2.2. It will turn out that the
best setting in simulations was to use the Benjamini-Hochberg procedure that controls
the False Discovery Rate (FDR) as adjustment for multiple testing in combination with
an signiﬁcance level of α = 5% in every step (M1 = M2 = . . . = MK). This setting is
used to analyze three breast cancer datasets via the sequential validation algorithm.
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Input: Raw p-values for K ordered datasets and g genes,
sorted sequence of length K of methods M1, . . . ,MK for multiple testing,
critical level α for selection of signiﬁcant features
Output: List of signiﬁcant features genes after sequential validation in allK datasets
Algorithm:
Step 1. Adjust the raw p-values of the ﬁrst dataset for multiple testing with
method M1 and select the remaining signiﬁcant genes with p-value below α
step k = 2, . . . ,K.
Reduce dataset k to selected features, adjust the corresponding raw p-values for
multiple testing with method Mk, and select the remaining signiﬁcant features
with p-value below α
step K + 1. Select ﬁnal list of genes whose adjusted p-values are below α in step
K.
Figure 4: Algorithm for stepwise p-value adjustment for K datasets (reproduced from
Lohr et al., 2012).
3.2.1 Stepwise validation on breast cancer datasets
All three breast cancer cohorts of Mainz, Rotterdam, and TRANSBIG described in Sec-
tion 2.2.1 were divided into two groups. A major challenge is the prediction of clinical
outcome. Therefore we are looking for diﬀerentially expressed genes or rather probe sets
in patients with and without metastastes as an indicator of recurrence free survial. The
ﬁrst group consists of patients that developed metastases, the second one of patients
which had been observed for at least ﬁve years and did not develope any metastases.
Patients that dropped out of the studies within ﬁve years without metastases were ex-
cluded from this analysis. Through this classiﬁcation the metastases groups include 47,
107, and 72 patients and the metastases-free groups contain 136, 168, and 189 patients
for the Mainz, Rotterdam, and TRANSBIG cohorts, respectively.
We apply t-tests to every probe set on all three datasets and apply the algorithm for
every possible order of the studies. A basic dataset, to explore signiﬁcant features in, is
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sequence 1st step 2nd step 3rd step
Mainz → Rotterdam → TRANSBIG 32 8 2
Mainz → TRANSBIG → Rotterdam 32 12 2
Rotterdam → Mainz → TRANSBIG 133 43 24
Rotterdam → TRANSBIG → Mainz 133 45 24
TRANSBIG → Mainz → Rotterdam 0 0 0
TRANSBIG → Rotterdam → Mainz 0 0 0
Table 4: Numbers of signiﬁcant probe sets in each step for the six validation sequences
(using FDR for signiﬁcance adjustment in every step and a α-level of 5%) for
the three breast cancer cohorts (reproduced from Lohr et al., 2012).
not determined here, the purpose is to observe the results for all sequences. The numbers
of signiﬁcant probe sets in each step are shown in Table 4. We notice the number of
signiﬁcant probe sets after three steps only depends on the dataset that is adjusted ﬁrst.
Diﬀerences between the numbers after the second step are compensated in the third
adjustment step. If we adjust the Rotterdam cohort ﬁrst most probe sets are detected,
while starting the adjustment with the dataset of TRANSBIG leads to no signiﬁcant
probe sets even in the ﬁrst step. It is obvious that there must be crucial diﬀerences
between the datasets regarding the size of signals. The TRANSBIG cohort seems to be
associated with the smallest number of signals since the number of signiﬁcant genes is
regarded as an indication for the strength of signals. Only the less strong adjustment of
the TRANSBIG cohort in a validation step, i.e. second or third step, yields signiﬁcant
genes.
The disagreement in the number of signiﬁcant genes depending on the order of adjust-
ment may be caused by two reasons: 1. the diﬀerent sample sizes of the cohorts and/or
2. the underlyding noise in the data. While the TRANSBIG cohort is associated with
the smallest number of signiﬁcant probe sets and has a larger sample size than the Mainz
dataset we expect the TRANSBIG cohort to be the dataset with the highest noise level.
To draw any conclusions about the eﬀect of sample sizes and noise levels, in the follow-
ing the inﬂuence of varying noise levels and afterwards sample sizes on simulated data
section is analyzed.
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3.2.2 Performance check via simulation studies
Since real data is not suitable to analyze the properties of an algorithm, we performed
extensive simulation studies. A selection of the results is presented in the following
subsection. First we describe how the data is designed. As mentioned above we expect
diﬀerent underlying noise levels and sample sizes to be reasons for diﬀering data qualities
that are responsible for the varying numbers of signiﬁcant probe sets. Therefore, we
analyze the eﬀect of varying noise levels ﬁrst by simulating data with equal sample sizes.
Afterwards we examine the additional inﬂuence of diﬀerent sample sizes based on the
breast cancer datasets.
Design of data
Data for two groups of patients, here for simpliﬁcation we call them cases and controls,
has to be generated. We assume the expression values of both groups to be normally
distributed. For a subset of genes, that is assumed to be signiﬁcant, the expression
values of one group are shifted by realizations of an also normally distributed random
variable C. Let n1 and n0 be the number of patients in the cases and the control group,
respectively. We deﬁne g as the total number of measured genes and m, m ≤ g the
number of diﬀerentially expressed genes between cases and controls. Let the baseline
expression values for both groups ai,j, i = 1, . . . , g, and j = 1, . . . , (n0 + n1) be realiza-
tions of a normally distributed random variable A, where A ∼ N (0, σ2k), σ2k > 0 and
let ci,j, i = 1, . . . ,m, and j = 1, . . . , n1 be realizations of a normally distributed shift-
variable C, C ∼ N (µs, σ2s), µs ∈ R, and σ2s > 0. The matrix of the simulated expression
values x is then composed of
xi,j =
ai,j + ci,j, i = 1, . . . m, j = 1, . . . , n1,ai,j, i = m+ 1, . . . , g, j = n0, . . . , n0 + n1.
For the simulated data we determine some basic settings. The number of measured genes
is set to g = 20 000 and the number of diﬀerentially expressed genes is ﬁxed to m = 100.
In the following simulations we generate ci,j from a normal distribution with mean and
variance 1, thus the eﬀect in every study is assumed to be the same. We generate K = 3
datasets for each simulation and carry out the algorithm as described above. For the
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three datasets we assume diﬀerent quality levels which depend on the sample sizes and
the underlying noise, that is variance. In the following section we assume equal sample
sizes in the cases and the control group and all three datasets to be able to recognize
the eﬀect of diﬀerent noise intensities σ2k of the datasets. We denote the dataset with
the lower quality, i.e. higher variance, by σ2lq, the one with medium quality by σ
2
mq, and
the dataset with highest quality, i.e. lowest variance, by σ2hq.
Stepwise validation for simulated data with equal sample sizes
First, we set the number of patients per group to n1 = n2 = 50 in each dataset. Though,
the qualities of the datasets are deﬁned by their underlying noise level. Table 5 shows
the results of the validation algorithm assuming a standard deviation of σhq = 0.8 on
the high quality dataset (denoted by hq), a moderate noise level of σmq = 1.1 on the
dataset with medium quality (mq), and a third low quality dataset (lq) with σlq = 1.5.
In extended simulations these noise levels turned out to be realistic and the eﬀect of the
adjustment can be well studied. The median of the true positives as well as the median
of the false negatives of 1000 simulations for all three steps are presented, on the left
for adjustment with Bonferroni-Holm (Holm) and on the right side controlling the FDR
with the Benjamini-Hochberg procedure at an α-level of 5%.
σhq = 0.8, σmq = 1.1, σlq = 1.5
Holm FDR
sequence 1st step 2nd step 3rd step 1st step 2nd step 3rd step
1: hq → mq → lq 45 / 0 44.5 / 0 31 / 0 85 / 4 84 / 0 77 / 0
2: hq → lq → mq 45 / 0 31 / 0 31 / 0 85 / 4 78 / 0 77 / 0
3: mq → hq → lq 17 / 0 17 / 0 15 / 0 53 / 2 53 / 0 49 / 0
4: mq → lq → hq 17 / 0 15 / 0 15 / 0 53 / 2 49 / 0 49 / 0
5: lq → hq → mq 4 / 0 4 / 0 4 / 0 15 / 1 15 / 0 15 / 0
6: lq → mq → hq 4 / 0 4 / 0 4 / 0 15 / 1 15 / 0 15 / 0
Table 5: Median true positives/false positives in each step of the six adjustment se-
quences for simulated gene expression data (reproduced from Lohr et al., 2012).
Independent of the method of adjustment for multiple testing the median number of
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true positives decreases from step to step as well as the median number of false posi-
tives. The optimal result would be to identify all true positives which means signiﬁcant
genes and reduce the number of false positives to zero, simultaneously. By performing
the algorithm using Bonferroni-Holm correction no false positives are found even after
the ﬁrst adjustment step for all sequences of datasets in this setting. After the second
adjustment step we observe no false positives even using the FDR. We get closest to our
aim of 100 true positives and zero false positives if the dataset with the highest quality,
i.e. here the lowest noise level, is adjusted ﬁrst. Whether the dataset with medium or
high underlying noise is adjusted next is less important because the diﬀerence in true
positives after the second adjustment step is equalized after the third step.
We tested various parameter settings for the noise, adjustment methods (see Table 21
and 22 in the appendix), distributions for the shift-variable and (equal) number of ob-
servations as well as adapted settings on diﬀerent kinds of data performing other tests.
Beside simulating gene expression data and applying t-tests on it, we analogous gener-
ated SNP data with diﬀerential allele frequencies of 0.53 in the cases and 0.48 for the
control group and apply χ2-tests to test the hypothesis whether the allele frequencies
are signiﬁcantly diﬀerent (see Lohr et al. 2012). Although, adapting the number of
true positives after the ﬁrst adjustment step by modulating the number of patients per
group, we observe less true positives in the second step. We see, the type of data as well
as the properties of the test procedure play a role for the amount of the true positive
rate.
In summary, in all scenarios it is advantageous to use the study with highest quality for
selecting candidate features at the beginning. In later steps we cannot compensate the
eﬀect of lost signals due to the application of a multiple testing adjustment on datasets
with large noise.
Stepwise validation for simulated data with unequal sample sizes
As mentioned above, we assume that the quality of a dataset depends on the sam-
ple size(s) and the underlying noise. The eﬀect of the latter was analyzed in the last
paragraph, now our focus is on the inﬂuence of diﬀerent sample sizes. We reduce the
following descriptions to adjustment for multiple testing by controlling the FDR at a
level of 5% because it seems suﬃcient at least for all parameter settings that we have
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conducted.
The sample sizes of the three breast cancer datasets are used to generate simulated
expression data. Hence, the simulated datasets have sample sizes of n1M = 47 cases
(metastasis) and n0M = 136 controls (no evidence of metastasis) as in Mainz, n1R = 107
cases and n0R = 168 controls as in Rotterdam and n1T = 72 cases and n0T = 189 con-
trols as in TRANSBIG. If we assume a diﬀerent underlying noise in all datasets there
are six possible arrangements for variance on datasets due to the diﬀerent sample sizes.
Analogously to the notation lq, mq, and hq for low, medium, and high quality we use
the acronyms lv, mv, and hv for low, medium, and high variance, respectively. Tables 6
to 8 show the median of the true positives as well as the median of the false positives as
before for the standard deviations 1.1, 1.5, and 2.3 for all possible sequences. We simu-
late a higher noise of 2.3 instead of 0.8, because in the previously described analyses one
cohort (TRANSBIG) turned out to have a considerably higher noise than the other two
studies. For example, σM < σR < σT denotes that the variance of the data based on the
sample sizes of the Mainz cohort is the lowest σ2M = 1.1, the one based on the sample
sizes of the Rotterdam study is medium σ2R = 1.5, and the variance of the dataset with
the sample sizes of TRANSBIG is the highest σ2T = 2.3.
If we adjust the datasets with sample sizes of Rotterdam ﬁrst and these datasets have low
or medium variance, high numbers of true positives, 85 and 79, respectively, are obtained
by the corresponding sequences after the third adjustment step. These numbers are only
outperformed when the datasets with the sample sizes of TRANSBIG have the lowest
underlying noise level and is adjusted ﬁrst with 86 true positives. We obtain the worst
results, i.e. smallest number of true positives, if a Mainz-like dataset is adjusted ﬁrst.
Especially, if this dataset has the highest underlying variance only three of the aimed
100 true positives were observed.
Summary
The simulation scenarios with equal sample sizes per group of patients suggest that
it is the best strategy to start the sequential adjustment with the dataset of highest
quality, i.e. lowest variance. Here, the highest number of true positives is obtained after
three steps, independent of the order of the datasets used in the second and third step.
Furthermore, as there are already no false positives after two adjustment steps, control-
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σM < σR < σT σM < σT < σR
sequence 1st step 2nd step 3rd step 1st step 2nd step 3rd step
1: lv → mv → hv 73 / 5 73.0 / 0 65 / 0 73 / 5 72 / 0 68.5 / 0
2: lv → hv → mv 73 / 5 64.0 / 0 64 / 0 73 / 5 69 / 0 68.0 / 0
3: mv → lv → hv 89 / 5 88.0 / 0 79 / 0 72 / 4 72 / 0 68.0 / 0
4: mv → hv → lv 89 / 5 79.0 / 0 79 / 0 72 / 4 68 / 0 68.0 / 0
5: hv → lv → mv 16 / 1 15.0 / 0 15 / 0 32 / 2 32 / 0 32.0 / 0
6: hv → mv → lv 16 / 1 15.5 / 0 15 / 0 32 / 2 32 / 0 32.0 / 0
Table 6: Median true positives/false positives in each step of the six possible adjustment
sequences for setting σM < σR < σT and σM < σT < σR with low variance (lv)
1.1, medium variance (mv) 1.5 and high variance (hv) 2.3 (reproduced from
Lohr et al., 2012).
σR < σM < σT σR < σT < σM
sequence 1st step 2nd step 3rd step 1st step 2nd step 3rd step
1: lv → mv → hv 99 / 5 95 / 0 85 / 0 99 / 5 99 / 0 72 / 0
2: lv → hv → mv 99 / 5 88 / 0 85 / 0 99 / 5 71 / 0 71 / 0
3: mv → lv → hv 36 / 3 36 / 0 32 / 0 72 / 4 72 / 0 52 / 0
4: mv → hv → lv 36 / 3 32 / 0 32 / 0 72 / 4 52 / 0 52 / 0
5: hv → lv → mv 16 / 1 16 / 0 15 / 0 3 / 0 3 / 0 3 / 0
6: hv → mv → lv 16 / 1 15 / 0 15 / 0 3 / 0 3 / 0 3 / 0
Table 7: Median true positives/false positives in each step of the six possible adjustment
sequences for setting σR < σM < σT and σR < σT < σM with low variance (lv)
1.1, medium variance (mv) 1.5 and high variance (hv) 2.3 (reproduced from
Lohr et al., 2012).
σT < σM < σR σT < σR < σM
sequence 1st step 2nd step 3rd step 1st step 2nd step 3rd step
1: lv → mv → hv 95 / 6 91 / 0 86 / 0 95 / 6 95 / 0 68.5 / 0
2: lv → hv → mv 95 / 6 90 / 0 86 / 0 95 / 6 68 / 0 68.0 / 0
3: mv → lv → hv 36 / 3 36 / 0 34 / 0 89 / 5 89 / 0 65.0 / 0
4: mv → hv → lv 36 / 3 34 / 0 34 / 0 89 / 5 64 / 0 64.0 / 0
5: hv → lv → mv 32 / 2 32 / 0 31 / 0 3 / 0 3 / 0 3.0 / 0
6: hv → mv → lv 32 / 2 31 / 0 31 / 0 3 / 0 3 / 0 3.0 / 0
Table 8: Median true positives/false positives in each step of the six possible adjustment
sequences for setting σT < σM < σR and σT < σR < σM with low variance (lv)
1.1, medium variance (mv) 1.5 and high variance (hv) 2.3 (reproduced from
Lohr et al., 2012).
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ling the FDR seems suﬃcient. A third or even more adjustment steps are unnecessary
in this scenario. Since we do not know the real underlying noise or the eﬀect size we
must be very careful about making generalizations from these conclusions.
The simulation study with unequal sample sizes suggests that ﬁrst adjusting a dataset
with largest sample size (as in the TRANSBIG cohort) and lowest variance yields the
highest number of true positives. If the dataset with sample sizes of TRANSBIG is sim-
ulated with highest variance and the dataset with sample sizes of the Rotterdam cohort
with lowest or at least medium variance, one should use the dataset with sample sizes of
Rotterdam in the ﬁrst adjustment step. Because we observe most signiﬁcant probe sets
when the real Rotterdam cohort is adjusted ﬁrst, one may conclude that TRANSBIG
has higher variance than Rotterdam and that Rotterdam has the highest quality, if we
take the sample size and the underlying noise into account. Since TRANSBIG has no
signiﬁcant probe set when it is adjusted ﬁrst, we may infer that is has lowest quality.
Whether this depends on a high underlying variance or a diﬀerent composition of the pa-
tient population remains unclear just as which of the datasets has the lowest or medium
variance. Thus we can say that the 45 probe sets in the real breast cancer datasets,
that are found to be signiﬁcant after the second adjustment step, are very likely true
positives and are therefore of biological interest.
3.2.3 Application to non-small cell lung cancer datasets
Next we apply the sequential validation algorithm to the non-small cell lung cancer
datasets. Since the lung cancer datasets are hybridized on two diﬀerent Aﬀymetrix mi-
croarrays we take the overlap of 22 277 probe sets for further analyses. Instead of dividing
the patients strictly in two distinct groups and looking for diﬀerential expressed genes
or probe sets, we examine the correlation of expression values and the overall survival
time of the patients. Therefore univariate Cox proportional hazards models are ﬁtted
to the expression values of every probe set in every dataset. We test the hypothesis
"H0 : HR = 1" which is equivalent to "H0 : β = 0" versus "H1 : HR 6= 1" with a Wald
test. Altogether nine non-small cell lung cancer datasets are available. Thus, we have
9 · 22 277 = 200 493 p-values. In Table 9 the numbers of probe sets that are signiﬁcant
at a local α-level of 5% and 1% and on the same signiﬁcance levels controlling the FDR
for every single dataset are shown. The distributions of the unadjusted p-values can be
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found in Figure 19 in the appendix. We see that the number of signiﬁcant probe sets
at an α-level of 5% for most datasets lies between 1 000 and 2 000. Exceptions are the
Jacob dataset and GSE31210 that contain clearly more signiﬁcant probe sets as well as
GSE14814 that contains only 638 signiﬁcant features at an α-level of 5%. After adjust-
ment by controlling the FDR we ﬁnd at least one signiﬁcant probe set at an α-level of
5% (or 1%) only in the Jacob dataset, GSE31210, and GSE29013.
dataset unadjusted 5% unadjusted 1% FDR 5% FDR 1%
Uppsala 1875 450 0 0
Jacob 3402 1354 258 20
GSE4573 1118 189 0 0
GSE31547 1656 318 0 0
GSE3141 1492 366 0 0
GSE29013 1564 419 2 1
GSE31210 7597 4390 4355 1381
GSE19188 1177 190 0 0
GSE14814 638 128 0 0
Table 9: Numbers of signiﬁcant probe sets unadjusted and after adjustment using FDR
at a α-level of 5% and 1%, respectively, for all nine non-small cell lung cancer
datasets.
In the last section two adjustment steps seemed suﬃcient to eliminate all false positive
features. We apply one additional adjustment step, now then three adjustment steps,
to the lung cancer datasets, because the power properties of the local Wald test might
diﬀer from the t-test and we might have missed the true underlying noise or the eﬀect
size in the real lung cancer datasets in our simulations. Thus 9!
(9−3)! = 504 orders of three
datasets out of the nine are possible. However, it makes less sense to consider sequences
where one of the datasets that contain no signiﬁcant features after simple adjustment
controlling the FDR is set on ﬁrst position. In fact, we merely ﬁnd 13 sequences that
yield at least one signiﬁcant probe set after three adjustment steps. The numbers of sig-
niﬁcant probe sets in each step for those validation sequences are shown in Table 10. We
see the datasets Jacob and GSE31210 as well as GSE31547 (on the third position) are
rife in the list. For the sequences "Jacob → GSE31210 → GSE31547" and "GSE31210
→ Jacob→ GSE31547" the highest numbers of signiﬁcant features are observed, 18 and
21, respectively. The six possible sequences for these three datasets and the correspond-
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ing number of signiﬁcant probe sets are listed in Table 23 in the appendix. In contrast
GSE4573 and GSE14814 do not occur in any relevant sequence. GSE4573 consists of pa-
tients with the histological subtype of squamous cell carcinomas and GSE14814 contains
almost twice as much squamous cell carcinomas as adenocarcinomas, while all patients
in the Jacob dataset, GSE31547, and GSE31210 are diagnosed as adenocarcinomas. We
may hypothesize that the squamous cell carcinomas biased the results in some way.
sequence 1st step 2nd step 3rd step
Jacob → Uppsala → GSE31547 258 5 1
Jacob → Uppsala → GSE31210 258 5 2
Jacob → Uppsala → GSE19188 258 5 3
Jacob → GSE29013 → GSE31210 258 2 2
Jacob → GSE31210 → Uppsala 258 120 2
Jacob → GSE31210 → GSE31547 258 120 18
Jacob → GSE31210 → GSE29013 258 120 2
GSE29013 → GSE31547 → Jacob 2 1 1
GSE31210 → Jacob → Uppsala 4355 241 2
GSE31210 → Jacob → GSE31547 4355 241 21
GSE31210 → Jacob → GSE29013 4355 241 4
GSE31210 → GSE29013 → Jacob 4355 9 7
GSE31210 → GSE29013 → GSE3141 4355 9 2
Table 10: Numbers of signiﬁcant probe sets in each step for the validation sequences
(using FDR for signiﬁcance adjustment and a α-level of 5%) that consider at
least one signiﬁcant probe set after three adjustment steps on the non-small
cell lung cancer datasets.
For that reason the analyses are repeated restricted on the subgroup of adenocarcino-
mas. Eight datasets contain patients with adenocarcinomas and remain in the analysis,
therefore 8!
(8−3)! = 336 combinations of the datasets with respect to the order are possible.
All orders are analyzed, but only six sequences yield at least one signiﬁcant probe set
after the third adjustment step. The six sequences and the numbers of signiﬁcant fea-
tures in each step regarding these sequences are listed in Table 24 in the appendix. The
sequences "Jacob→ GSE31210→ GSE31547" and "GSE31210→ Jacob→ GSE31547"
that reached the highest numbers of signiﬁcant probe sets through all non-small cell lung
cancer patients are in the list of relevant sequences for the adenocarcinomas, again, as
we expected because all three datasets only contain patients with diagnosis adenocarci-
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noma. In the four remaining sequences the dataset GSE3141 is represented at second or
third position. If we have a look at the histogramms of the p-values of the Wald tests
in the Cox proportional hazards models for all probe sets just containing the patients
with an adenocarcinoma (see Figure 20 in the appendix), the distribution of those in
GSE3141 has considerably changed compared to the distribution of all lung cancer pa-
tients in this dataset. The number of signiﬁcant probe sets at a local α-level of 5% has
increased to 2 722. The Uppsala dataset and GSE29013 are not contained in the list of
sequences that lead to at least one signiﬁcant feature after the third adjustment step of
the algorithm.
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3.3 Two-step meta-analysis approach
As mentioned at the beginning of the chapter the common approach to evaluate ﬁndings
on several datasets is to apply meta-analyses to the eﬀects of interest. In Botling et al.
(2013) the meta-analysis approach is combined with the validation idea. In contrast to
the sequential validation strategy above that uses at most three datasets in practise, all
cohorts should be used in the following two-step approach. Since the Uppsala cohort is
our basic dataset we start the procedure with this dataset. If we have a look on the p-
values of the univariate Cox proportional hazards models in the Uppsala cohort as they
were calculated in Section 3.2.3, again, no probe set holds a False Discovery Rate of 5%
(cf. Table 9). This requires less strict adjustment on the Uppsala dataset to receive
any potentially interesting probe set. Thus, all probe sets that pass an unadjusted
signiﬁcance-level of p < 0.01 in this ﬁrst step are selected as possibly relevant genes.
Again, like in the sequential approach in Section 3.2, all other features are ignored in
the following second step. For the remaining 450 probe sets, meta-analyses are performed
on the eight lung cancer datasets excluding the Uppsala cohort. Assuming a random
eﬀects model 59 probe sets show a raw p-value less than 0.01 and 13 p-values hold a FDR
of 1%. We choose the random eﬀects model instead of a ﬁxed eﬀects model, because
we want to avoid testing for heterogenity for every probe set. Since eight datasets are
available for the meta-analyses we can estimate an additional parameter, namely the








1149 patients 450 probe sets 13 probe sets 
Figure 5: Workﬂow of the two-step meta-analysis (reproduced from Botling et al., 2013).
If we restrict to the histological subtype of adenocarcinomas, 658 probe sets are identiﬁed
in the Uppsala cohort to be possibly interesting (raw p-value < 0.01). In the meta-
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analysis less evidence for the signiﬁcance of these features is found and only 32 probe
sets yield an unadjusted p-value in the random eﬀects model p < 0.01 and merely seven
if the FDR of 1% is controlled.
Since dataset GSE31210 has most signiﬁcant features of all cohorts and adjusting it ﬁrst
leads to the highest number of signiﬁcant probe sets after three adjustment steps (cf.
Section 3.2.3), we perform the analysis once more with GSE31210 as screening dataset.
Like before we take the 4390 probe sets whose p-values in the univariate Cox proportional
hazards model that pass the local α-level of 1% (cf. Table 9) as candidates to validate in
the next step. In the meta-analysis 426 of the 4390 probe sets show a raw p-value < 0.01
assuming a random eﬀects model and 63 hold a FDR of 1%. For the sake of completeness
we restrict the analysis to the histological subgroup of adenocarcinomas once more. Due
to the fact that all patients of dataset GSE31210 are diagnosed as adenocarcinomas,
the ﬁrst step remaines unchanged. Only the meta-analyses in the second step has to be
restricted on the histological subgroup of adenocarcinomas on the other datasets. Then
we observe 371 probe sets with a raw p-value less than 0.01 and 52 signiﬁcant ones after
adjustment with the Benjamini-Hochberg procedure with a FDR of 1%.
In Figure 6 we see the overlap of the signiﬁcant probe sets at the end of the two-step
Figure 6: Visualisation of the signiﬁcant features at the end of the two-step meta-analysis
for all patients comparing the proceeding when Uppsala and GSE31210 are
used as basic dataset, respectively.
meta-analysis when Uppsala is used as basic dataset compared with the results if dataset
GSE31210 is used for preselection. The overlap is only seven probe sets that are listed
with their corresponding gene symbols and gene names in Table 25 in the appendix.
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3.4 Summary and comparison
Since microarray technology has become comparatively low priced, more and more gene
expression data is freely available in appropriate databases. This information can help
for validation of ﬁndings. Coinstantaneous, due to the large number of measured genes
and possibly resulting statistical tests, it is necessary to control the probability for false
positive ﬁndings. But after a strict adjustment for multiple testing and a subsequent just
as stringent adjustment on every dataset, no signiﬁcant results will be left. A common
approach to combine the information of several datasets is the ordinary meta-analysis.
However, this approach does not take the validation idea into account, but treats all
datasets equally due to their variance. Hence, strategies that consider the validation
idea and that are less strict in adjustment for multiple testing are required. In this
chapter we presented two new approaches that meet the required demands.
The ﬁrst approach was a sequential validation strategy that was proposed by Lohr et
al. (2012). Here, an order of the considered datasets must be determined. The FDR or
the FWER is controlled on the ﬁrst dataset and only those features that hold the given
α-level after adjusting the p-values by the Benjamini-Hochberg or rather Bonferroni-
Holm procedure are examined on the next cohort. We applied this procedure to the
Mainz, Rotterdam and TRANSBIG breast cancer datasets, performed extensive simu-
lation studies and adopt the strategy to nine non-small cell lung cancer cohorts at last.
A ﬁnding of the simulation study was that two adjustment steps and the control of the
FDR seemed suﬃcient to eliminate all false positive features in the conducted settings.
For the reliability of non-false positive results a conservative additional step was car-
ried out on the lung cancer datasets. However, the application of this 3-step strat-
egy remained challenging, since merely three datasets, namely Jacob, GSE31210, and
GSE29013, yield at least one probe set that is signiﬁcant after adjustment by controlling
the FDR on a level of 5%. The sequences "Jacob → GSE31210 → GSE31547" and
"GSE31210 → Jacob → GSE31547" render the highest numbers of signiﬁcant features
(18 and 21, respectively) after the third step. The top results remain the same if the
analysis is restricted to patients with the histological subtype of adenocarcinomas, since
these three cohorts consist only of patients that are diagnosed as adenocarcinomas. If
we consider all patients eleven more 3-step sequences lead to at least one signiﬁcant
probe set, in the subgroup of adenocarcinomas only four sequences. But the numbers of
signiﬁcant probe sets after three steps are generally higher in the mentioned sequences
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when we restrict to the adenocarcinomas instead of analyzing all patients, although the
number of patients decreases. On the other hand particularly the Uppsala cohort seems
to have less impact if constrained to the adenocarcinomas in comparison to all patients.
That points to a common issue of subgroup analysis. If we want to draw any conclusion
about a subgroup and use another, hopefully similar, subgroup besides the group of
interest, the results will be biased. If the patients of other subgroups are ignored we
have a smaller sample size and the variance will increase. For example Netzer (2013)
has a closer look on the bias-variance-tradeoﬀ in subgroup analysis. Here, all patients
are considered for the analysis of a special subgroup but depending on their similar-
ity/characteristics with diﬀerent weights.
The greatest advance in the sequential valididation approach is that the quality of a
dataset, that we deﬁne by sample size and the underlying noise in the data, may be
assessed compared to other datasets in some situations. If we have a look on the results
of the breast cancer datasets in Section 3.2.1, again, it is obvious that TRANSBIG will
have the highest underlying noise, because there are more patients in this study than in
the Mainz cohort and adjusting TRANSBIG (ﬁrst) we ﬁnd no signiﬁcant features. We
may conjecture that it is caused by a batch eﬀect because this cohort consists of patients
data from ﬁve diﬀerent European centers. Rotterdam is the dataset with highest quality
in terms of sample size and variance. But whether Mainz or Rotterdam has less under-
lying noise remains unclear since more patients are included in the Rotterdam cohort.
Another important issue of the sequential validation approach remains unsolved.
The simulation study pointed out that two adjustment steps are suﬃcient to eliminate all
false positive features, which was our priority objective. However, in simulation studies
it is impossible to regard all scenarios since we do not know the true number of signiﬁ-
cant features, the true eﬀect size, and so on. In addition, all settings cannot be repeated
for every testing procedure. Therefore, we applied an additional, third adjustment step
to the real lung cancer datasets. Yet, it is questionable that three adjustment steps are
the optimal strategy in either case. Three steps may be not suﬃcient to eliminate all
false positives, e.g. if the number of true positives might be exceeding high or the eﬀect
size is quite small. In other situations, as in the simulations, two steps are suﬃcient
and through a third step the power of the procedure decreases. A better approach will
probably be to take all available datasets for the validation of results into consideration.
In Section 3.3 a workﬂow that includes all given datasets is introduced. This approach
does not require a selection among the available datasets nor an assessment of the com-
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plete order for the validation. The procedure is simple. A preselection of potentially
interesting candidate features is made without any adjustment on the basic dataset and
afterwards the eﬀects of these genes are validated via meta-analyses on the remaining
cohorts. The adjustment in the ﬁrst step is missing because as few as possible true posi-
tive features shall be overlooked. Pursuing this workﬂow, we yield 450 probe sets whose
p-values hold a local α-level of 1% in the Uppsala dataset. Performing meta-analyses
on the other eight non-small cell lung cancer datasets for these 450 preselected probe
sets yields 13 features that are signiﬁcant even when controlling the FDR (59 with a
raw p-value < 0.01). The histological subgroup of patients with adenocarcinomas were
analysed with this approach, too. Here, 658 interesting probe sets with a raw p-value
< 0.01 are found in the Uppsala cohort, which is nearly one and a half times as much
as in all non-small cell lung cancer patients, although just half the amount of patients
are considered. Applying meta-analyses to the adenocarcinoma patients of the remaing
seven datasets that contain patients of this histological subtype to these 658 features
only yields seven probe sets whose p-values hold a FDR of 1% (32 with a raw p-value
< 0.01). It seems as there are less signals in the subgroup of adenocarcinoma patients
than in the other datasets which might be up to the smaller sample size but also to qual-
ity criteria as e.g. minor fraction of tumour cells in the samples or inaccuracy among
the histological grading. Since cohort GSE31210 brings up most signiﬁcant probe sets
(4355 hold a FDR of 5% and 4390 a local α-level of 1%) we repeat the procedure with
GSE31210 as basic dataset. Following the workﬂow we yield 63 probe sets that hold a
FDR of 1% (426 probe sets with corresponding p-values < local α-level of 0.01) if all
non-small cell lung cancer patients are considered and 52 probe sets that hold a FDR
of 1% (371 probe sets < local α-level of 0.01) after all if we restrict to the subgroup of
adenocarcinoma patients. We see that even in this approach it is crucial which dataset is
considered ﬁrst. If we assume the dataset with the highest number of signiﬁcant features
to have highest quality, it would be beneﬁcial to start with even this cohort to obtain
most (true) signiﬁcant genes.
As a comparision with the two validation approaches we perform a common meta-
analysis that ignores the validation idea. A random eﬀect model is assumed for each
probe set of the overlap of the two diﬀerent Aﬀymetrix arrays to avoid an additional test
for heterogenity. Analyzing all non-small lung cancer patients 123 of the 22 277 probe
sets hold a FDR of 1% (1665 raw p-values < 0.01), while 120 probe sets are signiﬁcant on
a FDR of 1% if only the adenocarcinomas are considered. Most of the features that were
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identiﬁed in the validation meta-analysis approach using Uppsala as well as GSE31210
as basic dataset were found with the common meta-analyses.
The probe set with the smallest p-value in the random eﬀects model of all nine non-
small cell lung cancer datasets that is also signiﬁcant in the validation meta-analysis
if Uppsala as well as if GSE31210 is taken as basic dataset represents gene "AGFG1"
that encodes a protein that is related to nucleoporins that are responsible for mediating
nucleocytoplasmic transport (Fritz et al., 1995). The corresponding forest plot is illus-
trated in Figure 7.
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Figure 7: Forestplot of the meta-analysis for probe set "218092_s_at" that represents
the gene "AGFG1" including all nine non-small cell lung cancer datasets. The
p-value (bottom right) corresponds to the random eﬀects model.
ies quite agree with each other, all conﬁdence intervals comprise the overall study eﬀect.
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For this reason the ﬁxed eﬀect and the random eﬀects model yield very similar results.
Four of the studies are even signiﬁcant considering the single study eﬀect, particularly
Uppsala and GSE31210. The estimated hazard ratios of the datasets with smallest sam-
ple sizes (GSE31457 and GSE29013) have the largest conﬁdence intervals. Altogether
the p-value < 0.0001 of the random eﬀects model indicates that the true hazard ratio
is unequal to zero. More precisely, if the expression of AGFG1 increases, the overall
survival time of non-small lung cancer patients decreases. Thus, AGFG1 seems to be an
oncogene.









Figure 8: Visualisation of the signiﬁcant features at the end of the best 3-step sequential
validation approach, the combined meta-analysis for all patients comparing
the proceeding when Uppsala is used as basic dataset, and the common meta-
analyses assuming a random eﬀects model.
The comparison of the results of the validation meta-analysis, the common meta-analysis,
and the sequential validation approach is visualized in Figure 8. Since all 3-step se-
quences were considered in the latter we look at the results of the sequence that yields
the highest number of signiﬁcant features. In Figure 8 it is recognizable that the great-
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est overlap of signiﬁcant features can be found between common and validation meta-
analyses, while there is no overlap between the signiﬁcant probe sets of the ordinary
meta-analyses and the best 3-step validation analysis, and therefore neither in the over-
lap of all three aproaches. The validation meta-analyses and the best 3-step valida-
tion share only one signiﬁcant feature: The probe set "218451_at" represents the gene
"CDCP1" which encodes the "CUB domain containing protein 1". From Brown et al.
(2004) it is known that CDCP1 is overexpressed in carcinomas, and that CDCP1 mRNA
is highly elevated in human lung cancer cells (Scherl-Mostageer et al., 2001). Ideka et al.
(2006) even discovered that tumors with higher expression of CDCP1 show a higher level
of proliferation than tumors with low CDCP1 expression. Thus, our results emphasize
the known ﬁndings from literature.
In Figure 21 in the appendix the forest plot of the probe set "218451_at" that repre-
sents CDCP1 can be seen. Except for the estimated hazard ratio of study GSE3141 all
single study eﬀects are greater than 1. Five of the nine studies are signiﬁcant if con-
sidered seperately. The combined study eﬀect of the random eﬀects model is 1.41 (CI:
[1.16 − 1.71]) which leads to a p-value of 0.0005. Due to the high number of analyzed
features that require adjustment for multiple testing the p-value does not hold a FDR
of 5%.
Since the best 3-step validation sequence starts with GSE31210, it is more suitable to
compare the results of this sequence with a validation meta-analysis where GSE31210
is used as basic dataset. The overlap of the signiﬁcant features hereof and the ordinary
meta-analyses are visualized in Figure 22 in the appendix. We ﬁnd 426 signiﬁcant probe
sets with the validation meta-analysis when GSE31210 is screened at the beginning.
Although the number of signiﬁcant features increases with this proceeding the overlap
with the results of the common meta-analyses is not considerably higher. Again, there
is no overlap of the signiﬁcant features between the validation meta-analyses and the
ordinary meta-analyses. However, the validation meta-analyses and the best 3-step val-
idation sequence have six signiﬁcant probe sets in common. The list of signiﬁcant probe
sets including the genes that they are representing can be found in Table 11.
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probe set symbol gene name
201251_at PKM2 pyruvate kinase, muscle
201546_at TRIP12 thyroid hormone receptor interactor 12
209313_at GPN1 GPN-loop GTPase 1
218451_at CDCP1 CUB domain containing protein 1
212581_x_at GAPDH glyceraldehyde-3-phosphate dehydrogenase
AFFX-HUMGAPDH/ GAPDH glyceraldehyde-3-phosphate dehydrogenase
M33197_M_at
Table 11: Probe sets with gene symbol and gene name that are signiﬁcant after three
steps of sequential validation of the order "GSE31210→ Jacob→ GSE31547"
as well as in the validation meta-analysis when dataset GSE31210 is used for
preselection.
Like above the gene CDCP1 is in the overlap, again. It is conspicuous that two probe
sets of the gene "GAPDH" that encodes the enzyme glyceraldehyde-3-phosphate dehy-
drogenase are in the list of the overlap. From literature it is known that GAPDH is
overexpressed in lots of tumors (Sirover 1999, Said et al. 2009) and that overall survival
and the relapse-free survival are reduced in patients whose level of GAPDH expression
is enhanced (Révillion et al. 2000). These results can be conﬁrmed with our ﬁndings (cf.
Figures 23 and 24 in the appendix). The estimates for the hazard ratio in all studies are
highly correlated for the two probe sets. We see a slightly smaller p-value for probe set
"212581_x_at", because here the estimated hazard ratio of GSE19188 and GSE29013
points towards the right direction compared to probe set "M33197_M_at".
In conclusion, it can be claimed that the ordinary meta-analysis is an excellent method
for the analysis of several datasets, most signiﬁcant features that hold a FDR 1% can be
found by the application of this procedure. But apart from neglecting the validation idea,
important genes were not identiﬁed by the ordinary meta-analysis, e.g. CDCP1. The
assessment of study quality with the stepwise validation approach described in Section
3.2 might be useful, but it remains diﬃcult in most cases. If the number of signiﬁcant
features in combination with intrinsic noise are considered as quality criteria, the Rot-
terdam cohort seems to be of highest quality of the breast cancer studies. Among the
non-small cell lung cancer datasets the Jacob cohort and GSE31210 seem to have the
highest quality. If we take a closer look, it is obvious that the "good" datasets consist
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of only one histological subtype. In addition to sample size and noise, something like
biological comparability or rather consistency must be included in the constitution of
quality. Therefore, the deﬁnition of quality remains challenging and should be reconsid-
ered for every problem.
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4 Diﬀerential gene expression networks
The reconstruction of biological, i.e. gene-gene, protein-protein or gene-protein, networks
is a recent research topic (e.g. Juric et al., 2007; Gill et al., 2010). It is known that genes
do not act independently, but groups of genes act and interact with each other. The
estimation of gene regulatory networks is challenging.
The dependence structure of g genes is often of interest. Though we get an impression
of the overall correlation structure by calculating the ordinary correlation coeﬃcients
ρil, i, l = 1, . . . , g, the actual dependencies are not recognizable, because ordinary corre-
lation coeﬃcients do not distinguish between direct and indirect interactions. A direct
interaction between two variables w.l.o.g. X1 and X2 occurs if X1 has a direct inﬂuence
on X2 or vice versa. This is in contrast to an indirect interaction where X1 and X2 are
e.g. both inﬂuenced by X3 and conditioned on X3 they become independent. Ordinary
(estimated) correlations are therefore only weak evidence for real direct dependencies
between two genes, while the absence of correlation argues for independence. Hence, an
adaption is required that considers the dependence structures of other given variables.
Precisely the partial correlation coeﬃcient accounts for this issue. It quantiﬁes the cor-
relation between two variables X1 and X2 conditioning on serveral other variables, or in
other words, it is deﬁned as the correlation between the residuals of a linear regression
explaining X1 and X2, respectively, with the other variables as covariates (Fujikoshi et
al., 2010).
In the following we denote random variables by capital letters, the corresponding obser-
vations by small form letters. Matrices are printed bold, vectors are marked by an arrow
" ⇀ " and estimators are labeled by "ˆ" above the letter. Figure 9 i) shows a direct
interaction of A and B, where A is a parent of B. This means A has a direct inﬂuence
on child node B. In Figure 9 ii) we see a directed path from B to A. But conditioned
on C, A and B are independent, as well as in Figure 9 iii), where C has the children
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Figure 9: Examples for a i) direct interaction between A and B, ii) indirect interaction
between A and B and iii) interaction of A and B by regulation by a common
gene C.
A and B, and A and B are not adjacent. While for situations i) to iii) of Figure 9 the
ordinary Pearson correlation coeﬃcient will recognize a non-zero correlation between A
and B, the partial correlation for the indirect interaction between A and B in ii) and the
apparent interaction of A and B due to a common regulator C in iii) will 0. We see, the
ordinary correlation is weak evidence for measuring dependence, since in our example
more or less all gene pairs will have non-zero correlation. In contrast, partial correlations
provide only a weak criterion for independence, since most partial correlation vanish,
but it oﬀers a strong measure of dependence.
In this thesis we go one step further. Our focus will not lie on the reconstruction of
genetic networks, but it is on the detection of diﬀerential networks. Therefore, we intro-
duce several methods for the identiﬁcation of diﬀerential networks in the next section.
Afterwards, we present some approaches for the detection of diﬀerential genetic net-
works and subsequently conduct an extensive simulation study on tests for recognizing
diﬀerential networks. In Section 4.4 the results will be summarizied.
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4.1 Methods for diﬀerential network analysis
A popular tool for the analysis of gene association networks are Graphical Gaussian
Models (GGMs), also named Covariance Selection Models following Dempster (1972)
who ﬁrst suggested to ﬁt models with zeros in the oﬀ-diagonal elements of the concen-
tration matrix, i.e. the inverse of the covariance matrix. The basis of GGMs form so
called partial correlations as measures of conditional independence. In contrast to rel-
evance networks (see e.g. Butte et al., 2000) that use the standard pearson correlation
coeﬃcient and a predeﬁned threshold, GGMs are able to distinguish between direct in-
teractions between two genes, indirect interactions, and regulation by a third common
gene.
In the following Section 4.1.1 the link between probability theory and graph theory is
clariﬁed. After the general deﬁnition of a graphical model, GGMs as graphical mod-
els under the assumption of a multivariate normal distribution are introduced. Partial
correlations that form the basis of GGMs are introduced in Section 4.1.2. Since partial
correlations require a reliable estimation of the covariance matrix a shrinkage approach
for the latter is described in chapter 4.1.3. How a Graphical Gaussian Model is obtained
by the use of a heuristic mixture model approach is explained in Section 4.1.4.
After the estimation of the GGMs, we go a step further and want to discover diﬀerences
in gene association networks under two conditions. Hence, several measures for the com-
parison of two networks are introduced in Section 4.1.5. Since the developed measures
follow no known probability distribution, permutation tests are required that are brieﬂy
reviewed in Section 4.1.6.
4.1.1 The link from probability theory to graph theory
A graph G is a pair G = (V , E) consisting of a ﬁnite set of nodes (or vertices) V and
a ﬁnite set of edges E between the edges in V , i.e. E ∈ V × V (Edwards, 2000). An
undirected edge between nodes δ, γ ∈ V can therefore be written as (δ, γ) or (γ, δ) and
it is visualized by a line. If all edges are undirected we call such a graph undirected.
In contrast, if we consider a graph G ‘ = (V ‘, E ‘), where the edges are directed, i.e. if
(γ, δ) ∈ E but (δ, γ) /∈ E , we call it directed. Since we focus on undirected graphs in this
thesis, we restrict to those in the introduction of notation, terminology, and properties
in the following.
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A path is deﬁned as a sequence of edges (not necessarily directed) that is connected
(Lauritzen, 1996). A subgraph GA is a graph restricted to a subset of nodes A ⊆ V and a
subset of vertices EA = E ∩ (A× A). We call a graph complete if all nodes are connected
by edges. If there is an edge between δ and γ, they are said to be neighbours or adjacent
and δ and γ are called non-adjacent, if no line between the two vertices exists. The
set of vertices that are connected to δ is denoted by ne (δ). For a subset A ⊆ V the
collection of neighbours of nodes in A is deﬁned as the union of neighbours that are not
in A, ne (A) =
⋃
δ∈A ne (δ) \ A. If we speak of undirected graphs the set of neighbours
ne (A) is also referred to as boundary of A. The union of A and ne (a) is called closure,
cl (A) = ne (A) ∪ A. A subset B ⊆ V separates two vertices δ and γ if all paths from δ
to γ intersect B. For A,B,C ⊆ V we say that B separates A from C, if B separates all
nodes δ ∈ A from γ ∈ C.
A toy example for illustration is given in Figure 10. We deﬁne the subsets A ≡
{X1, X2, X3}, B ≡ {X4}, and C ≡ {X5, X6}. Then the collections of neighbours for the
three distinguished subsets are ne(A) = {X4}, ne(B) = ne({X4}) = {X2, X3, X5, X6},
and ne(C) = {X4}, while the closure of A is given by cl(A) = {X1, X2, X3, X4}, the
closure of B by cl(B) = {X2, X3, X4, X5, X6}, and analogous the closure of C by
cl(C) = {X4, X5, X6}. B or rather X4 separates A = {X1, X2, X3} from C = {X5, X6}
because all paths from nodes of A to those of C intersect X4.
The idea for the link between graph theory and probability theory is to use a graph for the
illustration of an association structure of random variables. Thereby, nodes stand for the
random variables and edges represent (conditional) independence structures among the
variables (Lauritzen, 1996). Hence, we clarify the concept of conditional independence
ﬁrst.
Let X1, X2, and X3 be random variables with a joint distribution P . Then X1 is
conditionally independent of X2 given X3 under P if for any measurable set A1 in the
sample space of X1 P (A1|X2, X3) = P (A1|X2), i.e. the conditional probability of A1
given X2 and X3 is independent of X3 and we write X1⊥X2|X3 [P ], or short X1⊥X2|X3.
If the random variables have a continuous density it holds that
X1⊥X2|X3 ⇔ fX1X2X3 (x1, x2, x3) fX3 (x3) = fX1X3 (x1, x3) fX2X3 (x2, x3) .
Let U = h(X1) be an arbitrary measurable function on the sample space of X1 and X4
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Figure 10: Toy example.
another random variable. And let X1 be conditional independent of X2 given X3, i.e.
X1⊥X2|X3. An algebraic structure that satisﬁes
(G1) X2 is conditionally independent of X1 given X3, i.e. X2⊥X1|X3;
(G2) U is conditionally independent of X2 given X3, i.e. U⊥X2|X3;
(G5) X1 is conditionally independent of X2 given X3 and U , i.e. X1⊥X2| (X3, U);
(G4) If in addition X1 is conditionally independent of X4 given X2 and X3, then X1 is
conditionally independent of X2 and X4 given X3, i.e. X1⊥ (X2, X4) |X3;
where U ⊆ X1 and X1, X2, X3 are disjoint and ﬁnite subsets, is called semi-graphoid. If
X1, X2, X3 are disjoint and the joint distribution of all variables is positive and contin-
uous
(G5) If in addition X1 is conditionally independent of X3 given X2, then X1 is condi-
tionally independent of X2 and X3, i.e. X1⊥ (X2, X3).
will hold and the algebraic structure is called graphoid.
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The concept of graph separation is an example of an algebraic structure that fullﬁlles
the semi-graphoid axioms, so
A
G
⊥ C|B ⇔ B separates A from C .
If the subsets A,B, and C are disjoint the algebraic structure satisﬁes the graphoid
axioms (G1)-(G5). Coming back to the toy graph in Figure 10 we see that A is indepen-
dent of C given B because B = {X4} separates A = {X1, X2, X3} from C = {X5, X6}.
For an undirected graph G = (V , E) and a collection of random variables (Xδ)δ∈V that
take values into probability space three so called Markov properties are deﬁned as fol-
lows:
(P) All non-adjacent pairs of vertices are independent conditional on the remaining
nodes: If for a given graph and all non-adjacent nodes, δ, γ ∈ V , it holds that
δ⊥γ | V\ {δ, γ} ,
the probability measure is said to obey the pairwise Markov property.
(L) Conditional on the adjacent vertices, any vertex is independent of the remaining
nodes: A probability measure satisﬁes the local Markov property if for any vertex
δ ∈ V , δ is independent of V with the closure of δ given the boundary of δ, i.e.
δ⊥V\cl (δ) | bd (δ) .
(G) Any two disjoint subsets of nodes separated by a third subset is conditionally
independent given the vertices in the third subset: The global Markov property
is fulﬁlled by a probability measure if B separates A from C in G for all disjoint




The global Markov property implies the local, while the local implies the pairwise Markov
property. If property (G5) of the graphoid axioms is satisﬁed all three Markov properties
are equivalent, and therefore graph separation satisﬁes the graph axioms.
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Since conditional independence is highly related to factorization, so are the Markov
properties. Let A ⊆ V be a complete subset of G. We say a probability distribution P
factorizes according to G if for all such A exists a non-negative function ψA that depends





where x = (xv, v ∈ V ) and xA = (xv, v ∈ A). In general, it holds that for every undi-
rected graph the factorization property implies the global Markov property. Hammersley
and Cliﬀord (1971; Cliﬀord, 1990) showed that if a probability distribution satisﬁes the
pairwise Markov property and has a positive and continuous density if and only if it
factorizes according to G.
An undirected graph G = (V , E) with a set of random variables that satisﬁes the local
Markov property is called a Markov network or graphical model (Kindermann and Snell,
1980).
As a result of the theorem of Hammersley and Cliﬀord it is suﬃcient to show the pairwise
Markov property, if the probability distribution has a positive and continuous density, to
proof the required local Markov property for graphical models. A special case of graph-
ical models are so called Covariance Selection Models or Graphical Gaussian Models
(GGMs). As the name suggests the underlying probability distribution of the random
variables is a multivariate normal (Gaussian) distribution. Let
⇀
X be a random vector







, where Σ is







‘, where X1 and X2
are random variables and
⇀
X3= (X3, . . . , Xp)
‘ denotes a vector of random variables. In
Lauritzen (1996, Proposition 5.2, p.129) it is shown that
X1⊥X2|X3 ⇔ ω12 = 0,
where Ω = {ωil}i,l∈{1,...,p} = Σ−1 is the concentration matrix of the multivariate normal
distribution. We see, the multivariate normal distribution is positive and continuous
and it obeys the pairwise Markov property and thereby also the local and global Markov
properties and the factorization property.
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In the next section, partial correlations that form the basis of Graphical Gaussian Models
due to the association with the concentration matrix are derived.
4.1.2 Partial correlations
Let w.l.o.g. X1 and X2 be two random variables,
⇀
X3= (X3, . . . , Xp)
‘ denotes a vector





‘ with corresponding mean vector
⇀
µ and







































 , and x3 =

x31 · · · xp1
...
...
x3n · · · xpn
 .
As mentioned above partial correlation can be described by the correlation of the resid-
uals of linear models where the variables of interest (X1 and X2) are explained by the
remaining variables that are considered (
⇀
X3). In general, the best linear predictor can
by obtained by the least squares estimator that is given by
yˆ = βˆz,
where βˆ = (β1, . . . , βp)‘ is the least squares parameter vector and z is the design matrix











x2, respectively, and x¯3 = (x¯33, . . . , x¯3p)‘ is a sample mean vector, as
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transformations of the observations and





− x¯i ∈ Rn, i = 1, 2
as transformations of the estimated values.
We look at the predictor for the transformed values
xˆ?i = x
?
3 · βˆi. (1)










i , i = 1, 2.













(x3 − x¯3)‘ (x3 − x¯3)
]−1
























= Σˆ−133 · σˆ3i,
where σˆi3 and Σˆ
−1
33 are estimates of σi3 and Σ
−1
33 , respectively. If we insert this in expres-
sion (1), we yield
xˆ?i = x
?
3 · Σˆ−133 · σˆ3i
⇔ ⇀x i −x¯i = (x3 − x¯3) · Σˆ−133 · σˆ3i
⇔ ⇀x i = x¯i + (x3 − x¯3) · Σˆ−133 · σˆ3i
⇔ ⇀x i = x¯i +
(
σˆ‘3i · Σˆ−133 · (x3 − x¯3)‘
)‘
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∈ R, the best linear predictor

















X?i := Xi − li(
⇀
X3), i = 1, 2,
are deﬁned as the remaining portion of Xi, i = 1, 2, after removing the linear eﬀects of

















































Σ−133 (⇀X3 − ⇀µ3)


























































(Σ−133 )‘ (⇀σ31 ⇀σ32)

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Like the ordinary population correlation (e.g. Fujikoshi et al., 2010) between two vari-





the correlation between the residuals X?1 and X
?
2 or rather partial correlation between









































. At least we want to transform the partial correlation in a consistent form.
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We deﬁne
Σ−1··|1...p\{··} := Ω =

ω11 ω12 . . . ω1p




ωp1 ωp2 . . . ωpp
 ,


























































) := ρ12|3...p 1
 ,
where ? is a place marker for an irrelevant entry of the matrix due to our aim. Since the
expression in the right matrix is the partial correlation between X1 and X2 given
⇀
X3,
ρ12|3...p can be written as
ρ12|3...p = − ω12√
ω11ω22
.
An estimation of the partial correlation is given by
ρˆ12|3...p = − ωˆ12√
ωˆ11ωˆ22
.
As we discovered, the elements of the inverse covariace matrix are related to the partial
correlation. Hence, a reliable estimation of the covariance matrix is required.
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4.1.3 Shrinkage estimation of the covariance matrix
Especially in situations of "small n, large p", when much more variables than observa-
tions shall be considered, neither the maximum likelihood estimate SML nor the unbiased








(xji − x¯i) (xjl − x¯l) ,
are good approximations of the true covariance matrix Σ, not even if the number of
variables and observations are approximately the same (Schäfer and Strimmer, 2005a).
A property of the true covariance matrix is positive deﬁniteness, if we assume that
all considered random variables have non-zero variances. Yet, neither the unbiased
nor the maximum likelihood estimator satisfy this requirement. Besides, it is desirable
that a good covariance estimator is well-conditioned, i.e. the ratio of its minimum and
maximum singular value is quite large, it has full rank and therefore, it can be easily
inverted. This characteristic can be found in general neither in the maximum likelihood
nor in the unbiased estimator.
A general approach to improve a covariance estimator is to reduce its variance. The
mean squared error (MSE) of the sample covariance can be decomposed to variance and
bias, i.e.
MSE(S) = Bias(S)2 + Var(S).
Since S is unbiased by construction, the overall accuracy of the unbiased estimator can
only increase by the reduction of variance. Various approaches have been proposed for
this issue and all procedures have serious disadvantages, e.g. to reduce the variance by
bootstrap aggregation of the empirical covariance matrix (cf. Schäfer and Strimmer,
2005b) that becomes computationally highly expensive with increasing numbers of vari-
ables. A computationally inexpensive and simultaneously well performing "shrinkage"
or rather "biased estimation" approach is described by Schäfer and Strimmer (2005a).
It is based on the theorem of Ledoit and Wolf (2003), which is now brieﬂy introduced.
Let Φ = (φ1, . . . , φp) be the parameters of a high-dimensional unrestricted model of
interest, and let Θ = (θ1, . . . , θp) denote the matching parameters of a restricted lower
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dimensional submodel, for instance parameters might be all equal, i.e. θ1 = . . . = θp. The
estimates of Φ and Θ are denoted by U and Y , respectively. Y is also called shrinkage
target. Due to the large number of parameters it is obvious that the unbiased estimate
U will have a comparatively high variance, but Φ might have a considerable high bias.
In a linear shrinkage approach both estimates are combined to a new estimator
U ∗ = λY + (1− λ)U ,
where λ ∈ [0, 1] is the shrinkage intensity that has to be selected. Apparently, for λ = 0
the regularized estimate U ∗ is equal to the unbiased estimator, while for λ = 1 the
shrinkage target Y is recovered. This combined estimator can outperform the unbiased
as well as the constrained estimator in terms of accuracy and eﬃciency.
Besides the choice of the shrinkage target the selection of the optimal shrinkage intensity
remains. For the selection of the latter various procedures have been proposed. It is
possible to ﬁx the shrinkage intensity to a given value or a function that depends on the
sample size. A computationally expensive approach for an optimal λ is cross-validation
(e.g. see Friedman, 1989). In an empirical Bayes context, E(Y ) is interpreted as prior
mean and λ as a hyper-parameter that has to be estimated from the data by optimizing
the marginal likelihood (cf. Daniels and Kass, 2001). In this thesis we use a procedure
where λ is choosen in a data-driven way by minimizing a risk function, here the mean





















λ2Var (yi) + (1− λ)2 Var (ui)
+ 2λ (1− λ)Cov (ui, yi) + [λE (yi − ui) + Bias (ui)]2 .
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By minimizing this expression with respect to λ, we yield
λ∗ =
∑p





From this expression we can derive that λ∗ becomes small if the variance of U decreases.
We see, the shrinkage target Y looses its inﬂuence when sample size increases. Further-
more, the correlation between U and Y inﬂuences the shrinkage intensity. If the two
are positively correlated λ∗ decreases as well as if the mean squared diﬀerence between
U and Y increases which protects the regularized estimator U ∗ against erroneously cho-
sen shrinkage targets. Moreover, if U is biased towards the shrinkage target Y , λ∗ will









For the estimation of λ∗ Schäfer and Strimmer (2005a) propose to replace all expec-




i=1 V̂ar (ui)− Ĉov (yi, ui)− B̂ias (ui) (yi − ui)∑p
i=1 (yi − ui)2
.







Transferring the lemma of Ledoit and Wolf (2003) to the covariance estimation issue we
yield in matrix setting
L (λ) = ‖S∗ −Σ‖2F






(λyil + (1− λ) sil − σil)2 ,
where ‖·‖2F denotes the Frobenius norm which is the eqivalent to the squared error loss
function in matrix setting.
Finally the choice of the covariance shrinkage target is still pending. In Schäfer and
Strimmer (2005a) several suitable shrinkage targets are presented. In this thesis we use
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the "diagonal, unequal variance" target, where
yil =
sii , i = l0 , i 6= l,
which shrinks only the oﬀ-diagonal elements of S , and does not shrink the variances.
Thus, λˆ∗ reduces to
λˆ∗ =
∑




since s is unbiased, the covariances Ĉov (yil, sil) = 0, ∀i 6= l and in the denominator
yil = 0, ∀i 6= l.
Thereby, it is reasonable to parameterize the covariance matrix in terms of variances




sii · sll, i, l =
1, . . . , p, because this formulations has two advantages. On the one hand, the (partial)
correlations derived from the resulting, regularized covariance matrix S∗ are independent
of scale and location transformations of the data matrix. And on the other hand the
oﬀ-diagonal elements determining the shrinkage intensity are on the same scale. The
corresponding λˆ∗ is simpliﬁed to
λˆ∗ =
∑





The resulting shrinkage estimator for Σ





will have the desired properties. Since a convex combination of a positive deﬁnite matrix
(Y ) and a positive semi-deﬁnite matrix (S) leads to a positive deﬁnite matrix, U ∗ will
be positive deﬁnite, too, and can be inverted.
The obtained regularized covariance estimator may be used to calculate partial correla-
tions as introduced in Section 4.1.2. These form the basis for the Graphical Gaussian
models that are also called as covariance selection models.
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4.1.4 The local False Discovery Rate
The next critical part of inferring Graphical Gaussian Models is model selection, i.e.
to determine whether an edge is absent (null edge) or present (non-null edge). In gene
association networks we expect most of the edges, and therefore the partial correlations,
to vanish (Schäfer and Strimmer, 2005b). Therefore, we assume the distribution of
observed partial correlations ρˆ across edges is given as a mixture
f(ρˆ) = η0 · f0(ρˆ, κ) + (1− η0) · fA(ρˆ),
of the null distribution f0 and the distribution of partial correlations corresponding to
the actually existing edges fA. η0 is the (unknown) proportion of null, i.e. non-existing
edges. The naturally longer tailed density fA is here assumed to be a uniform distribution
from −1 to 1. The proportion of null-edges η0 can be determined from the data, for
algorithms see Efron (2004) and Storey (2002), respectively. In this thesis, proportion
of η0 = 0.95 proposed by Schäfer and Strimmer (2005a) is assumed. The density of the
absent egdes can be easily computed in a closed form by























that is given in Hotelling (1953), where Be (κ ; a , b) denotes the β−distribution and κ
is the degree of freedom. If we consider a large sample setting with n > p, the degree of
freedom is κ = n− p + 1. Thus, the number of observations n must be larger than the
number of variables p as we can see from the formula. If n < p the distribution has the
same form as mentioned above but the degree of freedom is not a simple function of n
and p and has to be estimated from the data (Schäfer and Strimmer, 2005a).
The posterior probability of a null edge given the observed partial correlation may be
written as
P (null edge|ρˆ) = P (null edge) · P (ρˆ|null edge)
P (ρˆ)
=
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which is deﬁned as the local False Discover Rate (lFDR)
lFDR (ρˆ) :=
ηˆ0 · f0 (ρˆ, κˆ)
f (ρˆ)
given the observed partial correlation for a speciﬁc edge (Schäfer and Strimmer, 2005a).
Following Efron (2005) we assume an edge to be signiﬁcant, i.e. present if its local FDR
is smaller than 0.2.
4.1.5 Measures for the comparison of two undirected graphs
Our aim is to compare two genetic networks that are obtained from two conditions of two
groups of patients. Therefore, both networks are estimated separately and afterwards
the diﬀerence or similarity of the networks is determined by a suitable measure. In the
following a collection of such measures is introduced.
Let
⇀
X= (X1, . . . , Xp)
‘ be a vector of random variables with population correlation matrix
rˆ = (rkj)k,j∈{1,...,p} and let ρˆ = (ρkj|{1,...,p}\{k,j})k,j∈{1,...,p} be the matrix of estimated
partial correlations. Denote the enties of the upper triangular matrix of estimated
ordinary correlations and partial correlations by
⇀
r c= (rˆci)i=1,...,E and
⇀
ρ c= (ρˆci)i=1,...,E,
respectively, where c = 1, 2 are the two conditions or groups and E = p(p−1)
2
is the
number of possible egdes.
In the folloowing we introduce 14 measures for the comparison of two networks. An
overview of these measures is given in Table 12.
Maximum absolute distance of partial correlations (MaxDApC)
For all edges the absolute deviations of the partial correlations between two networks is
calculated. The MaxDApC quantiﬁes the diﬀerence of two networks by considering only
the largest distance of all estimated partial correlations between the two groups. A high











argues for at least one diﬀerence between two networks under the regarded conditions.
However, this measure does not take the number of diﬀerences into account. A moderate
change in partial correlations through several edges might remain undiscovered.
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abbreviation description
T1 MaxDApC Maximum absolute distance of partial correlations
T2 MDApC Mean absolute distance of partial correlations
T3 MDQpC Mean quadratic distance of partial correlations
T4 MDE Mean diﬀerence of edges
T5 χE χ
2 statistic based on edges
T6 MDAR Mean absolute distance of ranks
T7 MDQR Mean quadratic distance of ranks
T8 MDARE Mean absolute distance of ranks of present edges
T9 MDQRE Mean quadratic distance of ranks of present edges
T10 CORpCE Pearson correlation of partial correlations corresponding to present edges
T11 RCORpCE Spearman correlation of partial correlations corresponding to present edges
T12 MaxDAC Maximum absolute distance of ordinary correlations
T13 MDAC Mean absolute distance of ordinary correlations
T14 MDQC Mean quadratic distance of ordinary correlations
Table 12: Overview of measures for the comparison of two networks.
Mean absolute distance of partial correlations (MDApC)
For the calculation of the MDApC (cf. Gill et al., 2010) again all absolute deviations
of the partial correlations between two networks are calculated. Then the MDApC is













|ρ1i − ρ2i| .
Like for MaxDApC high values of MDApC suggest diﬀerences between the two graphs.
One modiﬁed partial correlation leads to alterations of partial correlations of adjacent
nodes, thus MDApC might detect smaller diﬀerences between the networks.
Mean quadratic distance of partial correlations (MDQpC)
The MDQpC is quite similar to the MDApC but it considers the quadratic distances













(ρ1i − ρ2i)2 .
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Therefore, we expect MDQpC to respond more sensitive to larger diﬀerences of partial
correlations.
Mean diﬀerence of edges (MDE)
For the MDE the local FDR must be calculated for every edge ﬁrst to decide whether an
edge is present or absent. The MDE counts the diﬀerences of existing and non-existing
edges and divides this number by the number of possibly existing edges to take the size
















1 , lFDR(ρci) ≤ 0.20 , lFDR(ρci) > 0.2
denotes the indicator function for signiﬁcant edges. This measure is straight forward
but it is heavily dependent of the proposed threshold of 0.2. Obviously, a large value
indicates large diﬀerences between the groups.
χ2 statistic based on edges (χE)
After determining which edges are present or absent in the two networks denote the
numbers as follows in a contingency table:
network 1
number of edges present absent
∑
network present e11 e10 e1·
2 absent e01 e00 e0·∑
e·1 e·0 E
From this table we are able to calculate the χ2 statistic with Yates' continuity correction
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E · (|e11 · e00 − e10 · e01| − E2 )2
e1· · e·1 · e0· · e·0
and use it as a measure of indepence for the networks of two groups. For the applica-
tion of a χ2-test requires the assumption of a discrete probability of observed binomial
frequencies can be approximated by the continuous χ2 distribution which introduces
some bias (Yates, 1934). This error should be corrected by the modiﬁed statistic as
implemented as default in R (R Core Team, 2013) which has advantages especially in
case of small expected cell frequencies. A small value of χE argues for independence and
thus, for diﬀerences between the groups. Hence, we set T5 := −T˜5 to unify the interpre-
tation of the measures. However, the χE statistic only measures the deviance between
observed and expected number of edges. Hence, it does not detect changes from positive
to negative partial correlations, or vice versa, as long as the edge is present according to
the local FDR.
Mean absolute distance of ranks (MDAR)
To receive a more robust measure, we order the absolute partial correlations indepen-
dently for both groups and assign ranks to them. The MDAR is closely related to the














where rk denotes ranks of the observations.
Mean quadratic distance of ranks (MDQR)














(rk (ρ1i)− rk (ρ2i))2 .
We might expect an advantage in recognizing larger diﬀerences compared to the MDAR.
The interpretation of both statistics, the MDAR and MDQR, remains the same. High
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values of them indicate large diﬀerences between the networks.
Mean absolute distance of ranks of present edges (MDARE)
The MDARE is highly related to the MDAR. For the MDARE we restrict to edges that













|rk (ρ1i)− rk (ρ2i)| ,
where sig denotes the set of signiﬁcant, i.e. present edges in at least one graph. The
idea is to eliminate irrelevant information that might cause noise.
Mean quadratic distance of ranks of present edges (MDQRE)
For the MDQRE we take the ranks calculated for MDARE and average the quadratic













(rk (ρ1i)− rk (ρ2i))2 ,
where sig denotes the set of signiﬁcant, i.e. present edges in at least one graph as before.
Pearson correlation of partial correlations corresponding to present edges (CORpCE)
The CORpCE is deﬁned as the ordinary Pearson correlation of the partial correlations










i∈sig (ρ1i − ρ1) · (ρ2i − ρ2)√∑
i∈sig (ρ1i − ρ1)2 ·
∑
i∈sig (ρ2i − ρ2)2
.
In contrast to most measures introduced above a high value of CORpCE argues for a
strong similarity of the network under both conditions. Again, to unify the interpreta-
tion of the statistics, we set T10 := −T˜10.
Spearman correlation of partial correlations corresponding to present edges (RCORpCE)
For a more robust measure we use the Spearman correlation coeﬃcient on the signiﬁcant
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(i.e. present in at least one graph) edges and exclude all non-signiﬁcant edges as before























·∑i∈sig (rk(ρ2i)− rk(ρ2))2 .
Like for χE and CORpCE deﬁne T11 := −T˜11 to ensure a consistent interpretation of all
statistics.
All measures presented above (cf. Lohr et al., 2010) are based on partial correlations
since Graphical Gaussian models outperform relevance networks, and hence, partial cor-
relations have advantages compared to ordinary correlations because they able to rec-
ognize indirect interactions (Schäfer and Strimmer, 2005a). Nevertheless we will have a
closer look on three measures based on ordinary correlations.
Maximum absolute distance of ordinary correlations (MaxDAC)
On the lines of the MaxDApC the maximum of all absolute deviations between the two
groups is considered for MaxDAC but here the diﬀerences of the ordinary population










|r1i − r2i| .
Mean absolute distance of ordinary correlations (MDAC)
Also for the MDApC we deﬁne a population correlation based counterpart, named













|r1i − r2i| .
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Mean quadratic distance of ordinary correlations (MDQC)














as MDQC as a distance measure for the comparison of two networks.
4.1.6 Permutation tests for the quantiﬁcation of diﬀerential networks
After the calculation of the above mentioned measures a criterion is required to assess
whether the value of a speciﬁc statistic argues for diﬀerences between the two consid-
ered networks. An obvious strategy is to test the hypothesis of diﬀerential networks
and compute p-values. Since none of the statistics follows an established distribution we
need to simulate it via permutation test technique (cf. Lohr et al., 2010).
Let
⇀
X= (X1, . . . , Xp) be a random vector and let
⇀
x1, . . . ,
⇀
xn denote independent and
identically distributed samples of this random vector
⇀
X. Further, we assume the Graph-


































may have diﬀerent distributions. With per-
mutation tests we intend to test the hypothesis H0 : "GGM1 and GGM2 are identical"
against H1 : "GGM1 and GGM2 are not identical".



















, respectively, and compute the
statistic of interest Ty, y ∈ {1, . . . , 14} to quantify the diﬀerence between the networks



















into a single sample and use a random permuation ζ[h] to re-arrange
the elements of the pooled sample ζ[h]
(
⇀




. Afterwards the re-arranged sample




















n . From these subsamples the statistic of interest Ty,h is computed.
After recording the H values from the permutations of the considered statistic compute








where I†y(Ty,h ≥ Ty) = 1 if Ty,h ≥ Ty, and zero otherwise. Since for all our statistics high
values indicate diﬀerences between the networks of the two groups, we can interpret the
fraction qy as one-sided permutation test p-value.
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4.2 Detection of diﬀerential genetic networks
One crucial point for diﬀerential network analysis is the selection of genes for which
diﬀerences in the interaction structure can be assumed between two groups of individu-
als. In the following we present two diﬀerent hypothesis generating concepts to detect
diﬀerential genetic networks.
4.2.1 Predeﬁned networks from literature
The ﬁrst strategy is the examination of predeﬁned gene groups that arises from biologi-
cal knowledge. Large databases and bioinformatic initiatives like Gene Ontology (GO),
Kyoto Encyclopedia of Genes and Genomes (KEGG), or the Reactome database can be
screened for diﬀerences in genetic networks.
The Reactome database is free, open-source, curated and peer reviewed, available on
http://www.reactome.org/. It aims to provide "intuitive bioinformatics tools for the vi-
sualization, interpretation and analysis of pathway knowledge to support basic research,
genome analysis, modeling, systems biology and education" (Milacic et al., 2012, and
Croft et al., 2008). The user is able to download pathways of the following categories
for Homo sapiens: Apoptosis, Binding and Uptake of Ligands by Scavenger Recep-
tors, Cell Cycle, Cell-Cell communication, Cellular responses to stress, Circadian Clock,
Developmental Biology, Disease, DNA Repair, DNA Replication, Extracellular matrix
organization, Gene Expression, Hemostasis, Immune System, Meiosis, Membrane Traf-
ﬁcking, Metabolism, Metabolism of proteins, Muscle contraction, Neuronal System, Re-
production, Signal Transduction, SUMOylation, and Transmembrane transport of small
molecules. Further sub-categories in hierarchical order can be selected and downloaded
in the required formats. Pathways are also provided for other organisms.
KEGG is a free database that provides tools for "understanding high-level functions
and utilities of the biological system, such as the cell, the organism and the ecosystem,
from genomic and molecular-level information"(KEGG, http://www.kegg.jp/kegg/ ). It
represents biological systems, and combines genomic and chemical information with
systems information. KEGG consists of sixteen main databases, at which the KEGG
Pathway database is the most relevant for us. It contains pathway maps in 7 main cate-
gories, namely "Metabolism", "Genetic Information Processing", "Environmental Infor-
mation Processing", "Cellular Processes", "Organismal Systems", "Human Diseases",
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and "Drug Development", for which hundreds of pathways for diﬀerent organisms are
available for download or online visualization.
The aim of the GO project is to unify the representation of genes and gene products
across diﬀerent organisms and databases (Ashburner et al., 2000). It is an international
bioinformatic initiative to maintain and develop its controlled vocabulary and to anno-
tate gene and gene product attributes and to provide tools for easy access to all aspects
of the data provided by the project, available on http://www.geneontology.org/. GO
consists of the onlogies "biological process", "molecular function", and "cellular compo-
nent". The three ontologies contain genes and can be described by a directed acyclic
graph, such that all downstream nodes are a subset of the upstream node above it. In
this way the gene groups become more speciﬁc in descending hierarchical order.
Furthermore, some disease-speciﬁc databases, like the "Genes-to-Systems Breast Cancer
Database" (G2SBC) can be found on the internet. The G2SBC database provides a
collection of data about genes, transcripts and proteins which have been reported in
literature to be altered in breast cancer cells and includes mathematical models on can-
cerogenesis, tumour growth and tumour response to treatments (Mosca et al., 2010). It
provides breast cancer genes, common molecular alterations in breast cancer, common
KEGG pathways and enriched GO terms if a pathway or GO group is assumed to be
breast cancer related. However, one needs to have some prior knowledge which gene
group might by interesting. On cellular systems level it is also possible to assess lists of
genes that are related to phenotypes, e.g. "grade 1(2) vs. 3". Another interesting aspect
of this database is the section "Mathematical models related to cancerogenesis, tumour
growth and response to treatments", but this section is quite obsolete, since all models
were published between 1995 and 2007.
Instead of genome-wide screening for gene groups of pathways that diﬀer between two
conditions or phenotypes, a literature search for gene groups previously identiﬁed as
phenotype-related made sense. e.g. in squamous lung cancer Wang (2012) found the
GO groups "GO:0005576" (Extracellular region), "GO:0050828" (Regulation of liq-
uid surface tension), and other GO terms to be signiﬁcantly metastasis-related. The
term "MHC protein complex" (GO:0042611) was shown to be cancer related in dif-
ferent tumor tissues. Gene signatures known to be associated with some phenotype
can also be a starting point, e.g. Liu et al. (2007) found a 186-gene-signature that
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predicts the invasiveness of breast tumors, Invshina et al. (2006) present a 264-gene-
signature for the prediction of the histological grade, and van`t Veer et al. (2002) devel-
oped a 70-gene-signature, known as "MammaPrint" genes commercialised by Agendia
(http://www.agendia.com/pages/mammaprint/21.php) to predict prognosis (Tian et al.,
2010).
We take the MammaPrint genes as basis for further investigations of diﬀerences in inter-
action networks between breast cancer patients of the Mainz cohort (cf. Section 2.2.1).
86 probe sets that correspond to 52 genes are present on the Aﬀymetrix HG-U133A
array, i.e. 18 genes are not represented by any probe set. Since the histological grade
is highly correlated with prognosis, we split the patients according to tumor grade. 151
patients with grade I or II are grouped to the ﬁrst class and 49 patients with grade III
to a second class.
In van`t Veer et al. (2002) it was shown that the MammaPrint genes are pognostic,
however, it cannot be supposed that these genes build a genetic network with changing
interactions. Therefore, we performed a gene set enrichment analysis by testing the
independence of the two events 1. gene i is in the list of (interesting) MammaPrint
genes and 2. gene i is a member of GO term with Fisher`s exact test (e.g. Lehmann
and Romano, 2005) which is implemented in the R package topGO (Alexa et al., 2006).
The p-value depicts the probability of observing at least the same amount of enrichment
when interesting genes are randomly selected out of all genes. Hence, a small p-value
gives strong evidence for an over-representation of MammaPrint genes in a speciﬁed GO
term. Applying this test to all GO terms of all three ontologies that contain 10 to 100
probe sets, we yield 58 GO groups with a raw p-value < 0.01, i.e. MammaPrint genes
are over-represented in 40 GO terms of the ontology biological process, in 11 terms of
the molecular function ontology, and in 7 GO terms of the ontology cellular component.
To the 58 GO terms enriched with MammaPrint genes we apply permutation tests using
signiﬁcant tests 0 1 2 3 4 5 6 7 8
GO terms 23 7 14 2 7 2 1 1 1
Table 13: Number of signiﬁcant tests (referred to α = 0.05) for 58 enriched GO terms
for MammaPrint genes.
the statistics introduced in Section 4.1.5. Table 13 gives an overview of the frequencies
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of signiﬁcant permutation tests for the considered GO terms. 1000 permutations were
conducted. The range goes from 0 to 8 signiﬁcant tests per GO group. For 23 GO terms
no test is signiﬁcant on an α-level of 5%. Applying the permutation tests to the original
MammaPrint genes signiﬁcance can be observed for the tests using MDAR, MDAC, and
MDQC. An overview of the most noticable GO groups with description of the term,
number of probe sets and the associated ontology can be found in Table 14.
GO term description probe sets ontology sign. tests
GO:0032332 positive regulation of chondrocyte diﬀerentiation 22 BP 8
GO:0070628 proteasome binding 12 MF 7
GO:0031663 lipopolysaccharide-mediated signaling pathway 59 BP 6
GO:0031532 actin cytoskeleton reorganization 70 BP 5
GO:0008608 attachment of spindle microtubules to kinetochore 25 BP 5
Table 14: Overview of most noticeable of the enriched GO terms for MammaPrint.















Table 15: Number of signiﬁcant GO groups (referred to α = 0.05) of 58 enriched GO
terms for MammaPrint genes for all considered tests.
In Table 5 in the appendix the results of the 14 tests for all 58 GO terms are shown.
All p-values are unadjusted and therefore considered as descriptive measures. The tests
using MDAC and MDQC, MDApC and MDQpC, MDAR and MDQR, MDARE and
MDQRE, and CORpCE and RCORpCE as test statistics agree in signiﬁcance on an
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α-level of 5% for most GO terms, but this is due to their similar design. For 16 GO
groups the tests using MDAC and MDQC can reject the null-hypotheses of no diﬀerences
between the networks of patients with tumor grade I or II and grade III, which makes
MDAC and MDQC the tests with most signiﬁcant ﬁndings by far (cf. Table 15). In
contrast, with the test using MaxDApC we yield no noticeable GO group. Of course, the
properties of the proposed tests must be analysed, i.e. if the tests hold a given α-level,
which is done in Section 4.3.
4.2.2 DiNGS - Gene selection for diﬀerential networks
In this section we present a novel approach for the detection of diﬀerential networks
between two groups of patients. The idea is to search iteratively for features that maxi-
mize the diﬀerence of the resulting network under two conditions or between two groups.
That is we perform a kind of forward selection adapted for diﬀerential networks, similar
to model selection for regression models by AIC (Akaike, 1974) or BIC (Schwarz, 1978).
Penalized regression, like ridge regression (Hoerl and Kennard, 1970) or Lasso regression
(Tibshirani, 1996) have been applied for inferring Graphical Gaussian Models by Mein-
shausen and Bühlmann (2005) that could also be implicitly used for model selection.
We need to go one step further, because our aim is to detect diﬀerential networks. For
that purpose we introduce a heuristic Diﬀerential Network Gene Selection (DiNGS)
algorithm. The general DiNGS proceeding with a default setting that is subsequently
applied to the Mainz breast cancer dataset is shown in Figure 11. Next each step is
descripted in detail.
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Input: Gene expresssion dataset, criterion to split the patients in two groups
Output: Diﬀerential probe set network
Algorithm:
Step 1. Preselection of probe sets
Reduce dataset by selecting e.g. 100 probe sets with highest variance
Step 2. Deﬁnition of a starting probe set or starting probe set-pair
For k = 1, . . . , R:
• Sample a fraction of the reduced number of preselected probe sets and
calculate partial correlations for each group;
• determine the minimal partial correlation per edge for each group and
compute the distance of partial correlations per edge;
• deﬁne probe sets with maximum distance of partial correlations as start
pair
Step 3. Addition of probe sets
Find probe set with largest distance of partial correlations between the two
groups of patients out of the remaining probe sets and add this probe set to
the previously selected probe sets
Step 4. Assessment of diﬀerence between the selected probe set networks
Calculate the partial correlations of the current probe set selection for both
groups of patients and build the mean squared diﬀerence
Step 5. Criterion to stop the algorithm
If the mean squared diﬀerence is below a threshold e.g. υu = 0.1 stop and reject
the candidate probe set, else go to Step 3.
Figure 11: DiNGS algorithm with standard settings as subsequently used on Mainz
breast cancer dataset.
1. Selecting a diﬀerential network out of 20 000 or even 50 000 probe sets is challenging
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and the computation of (partial) correlation matrices will be computationally expensive
or even impossible. Hence, a preselection of probe sets is required. This can be done
in many ways. One straightforward idea is to take probe sets with the highest variance
across all samples. Thus, it is guaranteed to avoid genes or rather probe sets that are
not expressed at all. To ensure selecting probe sets whose expression diﬀers between
both groups on the basis of variance, we propose to choose the probe sets with smallest
values of
V (probe seti) =
Var1 (probe seti) + Var2 (probe seti)
Var (probe seti)
,
where Vark (probe seti) , k = 1, 2 denotes the variance of probe set i in group k. An-
other concept would be to cluster the probe sets e.g. by k-means or PAM (Kaufman and
Rousseeuw, 2005) with (1− correlation) as distance matrix and take the cluster with
the highest average correlation as preselected group. Of couse, the number of clusters
must be selected carefully. The best way might be to deﬁne a preselected set due to
biological prior knowledge, e.g. be a larger sized GO term or KEGG pathway, where
diﬀerences in a well-deﬁned path or subset are expected. Furthermore, the eﬀects of
diﬀerent preselection methods are described and discussed in the bachelor thesis from
Cyris (2011).
2. After a subset of probe sets is selected we need to deﬁne one probe set or a pair or
probe sets to start with, i.e. for building the network around it. Again, the probe set
with the highest variance could be taken for that purpose, or analogously to the prese-
lection the probe set with smallest within variance in the groups compared to the overall
variance V (probe seti) to ensure diﬀerences between the two groups. Certainly, the def-
inition of a starting gene or rather probe set by biological prior knowledge is possible. In
contrast to the three approaches mentioned above, the following two criteria will lead to
a starting pair instead of a single probe set. We propose to start with the pair with the
highest correlation or, trying to take the diﬀerence of the groups into account, the pair
with the maximal diﬀerence of minimal partial correlations. For assessment of minimal
partial correlations, we condition the correlation on a subset of the preselected probe
sets, e.g. R = 100 times (cf. Step 2 in DiNGS algorithm in Figure 11). The minimal
partial correlation per edge out of 100 repeats is recorded, because we assume that this
describes the actual correlation after removing the eﬀect of all other inﬂuences at best.
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3. Addition of probe sets : For the actual forward selection another criterion is required.
Probe set i could be added to the previously selected group if it has the highest correla-
tion or partial correlation conditioned on the previously selected probe sets either across
all samples or in a reference group, e.g. healthy people. Again, the measure V (probe seti)
can be used to extend the gene set. Another option is to select the (si + 1)-th probe set
for the network by maximizing the sum of distances of partial correlations conditioned





|ρ1i − ρ2i| ,
where E = (si+1−1)si+1
2
denotes the number of possible edges of the advanced network.
This criterion guarantees to add the node that maximizes the overall diﬀerence. The
maximization of the distance between partial correlations of the candidate node with an
already included node could also be considered, thus diﬀerence of previously aﬃliated
probe sets may decrease through the inﬂuence of the recent node.
4. To assess the diﬀerence between the selected probe set network the MaxDApC, the
MDApC, but also one of the other statistics for the quantiﬁcation of diﬀerence proposed
in Section 4.1.5 can be deployed. Another option is to consider as before the diﬀerences
of edges concerning only the recently aﬃliated probe set.
5. Finally, a criterion to stop the algorithm on the basis of a measure to assess the
diﬀerence (chosen before in 4.) is required. We might stop the algorithm and take
the current set of probe sets for further investigations if none of the remaining probe
sets lead to a diﬀerence of (partial) correlations above a threshold υu, which must be
speciﬁed. One could also stop if the used statistic, determined in step 4, drops below
a cut point υl or the previously determined maximal number of probe sets is achieved.
A more time-expensive method would be to permute the data and compare the orig-
inal ﬁndings with the random results in terms of average of maximal partial correlations.
Of course, not all combinations of the mentioned approaches are suitable for the detec-
tion of diﬀerential genetic networks and other combinations may be suitable for diﬀerent
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aims. E.g. for detecting networks where partial correlations diﬀer preferably between
all edges we need to select measures that consider the average distance of partial cor-
relations. If we are interested in ﬁnding a network that is maximal diﬀerent in e.g. one
path, but the interaction structure retained in both groups should also be considered,
we should use an approach based on a maximal diﬀerence of partial correlations but
add further nodes by smallest (partial) correlation. Exampliﬁed we show the results for
one suitable combination and analyze the stability of ﬁndings (cf. the bachelor thesis of
Windgassen, 2011).
As preselected group we take the 100 probe sets with highest variance in the breast can-
cer cohort from Mainz and split the patients in a group with metastasis within 5 years
after surgery and a second group without metastasis which are followed-up for at least
5 years. The groups contain 28 and 136 patients, respectively. Although the number
of 100 features is pretty small and it might not be necessary here, we sample R = 500
times 20 probe sets of the 100 and the minimal partial correlation is recorded per edge.
Afterwards, the absolute diﬀerences per edge are calculated and the corresponding probe
sets of the maximum distance are taken as start pair. Subsequently, the starting probe
sets are deleted from the list of preselected features. The partial correlations for each
of the remaining probe sets with the selected features are calculated separately for both
groups of patients and we build the absolute diﬀerences of partial correlations between
the groups. After adding the probe set that corresponds to the maximum distance across
all partial correlations to the selected set of features, the mean squared diﬀerence of par-
tial correlations between the groups is computed. This step is repeated until the mean
squared diﬀerence of partial correlations drops below a predeﬁned threshold of υl < 0.1.
Finding the probe set pair to start with is the only random process in this variant of
the algorithm. To analyze the stability of this selection we draw stratiﬁed bootstrap
samples. In general, bootstrapping is a statistical method to assess the precision of an
estimate (Hastie et al., 2001). Here, we sample n times with replacement of n sam-
ples B times, where B is 200 in this thesis. Unstratiﬁed sampling might cause datasets
containing only patients of one group. Hence, we sample n1 and n2 samples according
to the sizes of the original groups for each bootstrap sample. Calculating the maximal
distance of minimal partial correlations as described above, we record the frequencies of
beeing part of the ﬁnal set for each probe set. The most frequently selected probe sets
(in at least 40% of the iterations) are listed in Table 16.
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probe set frequency symbol gene name
212094_at 0.7 PEG10 paternally expressed 10
212092_at 0.65 PEG10 paternally expressed 10
204351_at 0.475 S100P S100 calcium binding protein P
205509_at 0.46 CPB1 carboxypeptidase B1 (tissue)
202018_s_at 0.45 LTF lactotransferrin
214087_s_at 0.445 MYBPC1 myosin binding protein C, slow type
207430_s_at 0.435 MSMB microseminoprotein, beta-
203535_at 0.43 S100A9 S100 calcium binding protein A9
209301_at 0.415 CA2 carbonic anhydrase II
206022_at 0.405 NDP Norrie disease (pseudoglioma)
206457_s_at 0.395 DIO1 deiodinase, iodothyronine, type I
209278_s_at 0.385 TFPI2 tissue factor pathway inhibitor 2
205242_at 0.38 CXCL13 chemokine (C-X-C motif) ligand 13
218332_at 0.38 BEX1 brain expressed, X-linked 1
218002_s_at 0.37 CXCL14 chemokine (C-X-C motif) ligand 14
209612_s_at 0.36 ADH1B alcohol dehydrogenase 1B (class I), beta polypeptide
203290_at 0.355 HLA-DQA1 major histocompatibility complex, class II, DQ alpha 1
37892_at 0.355 COL11A1 collagen, type XI, alpha 1
205357_s_at 0.35 AGTR1 angiotensin II receptor, type 1
214079_at 0.345 DHRS2 dehydrogenase/reductase (SDR family) member 2
213492_at 0.34 COL2A1 collagen, type II, alpha 1
222379_at 0.34 KCNE4 potassium voltage-gated channel, Isk-related family, member 4
203355_s_at 0.33 PSD3 pleckstrin and Sec7 domain containing 3
205513_at 0.33 TCN1 transcobalamin I (vitamin B12 binding protein, R binder family)
219768_at 0.33 VTCN1 V-set domain containing T cell activation inhibitor 1
204475_at 0.325 MMP1 matrix metallopeptidase 1 (interstitial collagenase)
205916_at 0.325 S100A7 S100 calcium binding protein A7
205239_at 0.31 AREG amphiregulin
213664_at 0.305 SLC1A1 solute carrier family 1 (neuronal/epithelial high aﬃnity
glutamate transporter, system Xag), member 1
213831_at 0.305 HLA-DQA1 major histocompatibility complex, class II, DQ alpha 1
Table 16: Most frequently selected probe sets for ﬁnal set obtained by stratiﬁed boot-
strapping for the starting pair.
We see, two probe sets, namely "212094_at" and "212092_at" are most frequenctly
selected by far. It is also the pair that is chosen as starting pair in 56% of all bootstrap
samples. That is conspicuous, because both probe sets represent the same gene "pater-
nally expressed 10" (PEG10) which encodes the retrotransposon-derived protein. The
PEG10 gene includes two overlapping reading frames of the same transcript encoding
distinct isoforms (Lux et al., 2005) and it is known to be overexpressed e.g. in hepatocel-
lular carcinomas (Tsuji et al., 2011) and gallbladder adenocarcinoma (Liu et al., 2011).
The change of partial correlation between metastatic and non-metastatic patients might
indicate a change of association between diﬀerent isoforms resulting from alternatively
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spliced transcript variants of PEG10.
To summaries it, our selection approach based on the maximal diﬀerence of partial cor-
relations adding further nodes by minimal partial correlation has two advantages: First,
it is applicable also for larger preselected gene groups and second, through randomness
diﬀerent potentially interesting pairs may be found. The algorithm should be conducted
several times.
Figure 12: Results of the stratiﬁed bootstrap analysis for selection of diﬀerential genetic
networks in the Mainz breast cancer cohort. Boxplots of the mean squared
diﬀerences of partial correlations for each number of included probe sets are
drawn. The red line indicates the boundary of 0.1 to stop at (reproduced
from Windgassen, 2011).
In Figure 12 boxplots of the mean squared distance for all bootstrap samples ordered by
the number of selected nodes are shown. The red line indicates the stop criterion. We see,
mean and variance decrease with growing number of selected features. Most times the
selected set contains between 19 to 38 features until it stops. It is conspicuous that the
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algorithm stopped with merely the starting pair. Here, an improper pair of probe sets is
selected to start with. But once another probe set is added to the starting pair the mean
squared diﬀerence of partial correlations inceases above 0.1 for all bootstrap samples.
Although the number of features varies from 19 to 38, the core probe sets remain the
same. Thus, the variant of the DiNGS algoritm is just partial stable, it produces an
appropriate number of features to apply further diﬀerential network analyses to.
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4.3 A simulation study for the detection of diﬀerential neworks
To analyze the properties of the permutation tests with test statistics proposed in 4.1.5
we conduct an extensive simulation study. Therefore, we describe the design of simulated
data and the settings ﬁrst. Afterwards, we check whether the tests hold the α-level.
Finally the power properties are explored.
4.3.1 Design of data
For the construction of data we take the well-studied RAF signalling pathway, also
known as RAF-MEK-ERK pathway, (Sachs et al., 2005; Dougherty et al., 2005) that is
often used as a gold standard network (e.g. Werhli et al., 2006). This signalling cascade
describes the interaction of 11 phosphorylated proteins and phospholipids in human im-
mune system cells. The central RAF protein is known to be involved in the regulation
of cellular proliferation in immune cells through cell division cycle, apoptosis, cell diﬀer-
entiation, and cell migration. Dysfunctions in the regulation of the RAF pathway lead
to uncontrolled growth and may cause proliferation in many cancers, e.g. melanomas
and Hodgkin disease (cf. Zheng et al., 2003). Since several compounds are known that
are able to inhibit various steps of the RAF signalling pathway, it is obvious to use this
point of contacts as potential drug targets (e.g. Orton et al., 2005; Hilger et al., 2002;
McCubrey et al., 2007). The ability to inhibit single compounds of the signalling cascade
made it possible to infer the network structure via interventional data obtained using
for example kinase-speciﬁc inhibitors (Sachs et al., 2005; Pearl et al., 2000).
The simpliﬁed network structure of the RAF signalling pathway is illustrated in Figure
13. The graph of this pathway consists of 11 nodes that are connected by 20 directed
vertices. Albeit the proposed methods base on undirected network it is eligible and
probably mandatory to construct directed data because our intention is to apply the
proposed tests to real genetic networks and pathways that are necessarily directed.
Based on its network structure we are going to generate synthetic data to control the
dependencies among the variables. To consider all dependencies correctly we need to
assign a topological order. Therefor, we ﬁrst introduce two deﬁnitions for directed
graphs.
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Figure 13: Model of the RAF signalling pathway.
For a directed graph we say node δ is a parent of γ if there is an edge from δ to γ (δ, γ)
(cf. notation introduced in section 4.1.1) and (δ, γ) 6= (γ, δ), δ, γ ∈ V , or the other way
round, γ is said to be a child of δ. A topological order is an arrangement of nodes such
that every node is ranked after all its parents (e.g. Lauritzen, 1996).
It is obvious that PIP3 is the only node in the graph that has no parents. Hence, PIP3
has to be top in a topological order. PLCG, PIP2, and AKT are the children of PIP3.
The next node in a topological order has to be PLCG, because AKT has other two more
parent nodes that are not yet ranked, and PIP2 is also a child of PLCG. If we continue,
following this precept we might yield the topological order: PIP3−PLCG−PIP2−PKC−
PKA−JNK−P38−RAF−MEK−ERK−AKT. This order is ambiguous, another possible
order is PIP3−PLCG−PIP2−PKC−PKA−P38−JNK−RAF−MEK−ERK−AKT,
since JNK and P38 have the same parents.







, i = 1, . . . , 11
where the random variable Xi denotes the expression of node i with realizations
⇀¯
x i, N (·)
denotes a normal distribution, pi are the parent nodes of node i, wipi is the strength of
interaction between node i and its parents nodes and x˜pi are the standardized values as
realisations of the random variable X˜pi denoting the expression of the parent node pi
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We standardize the values to avoid increasing variance along the topological order. σ is
a noise term.
Sampling data from this model serveral parameters can be varied. As default, the in-
teraction strength or rather coeﬃcients wipi are independently sampled from an uniform
distribution over the interval [0.5; 2] and provided with a randomly sampled sign follow-
ing Werhli et al. (2006). We vary the noise in the data by setting the variance from
small values σ = 0.01 to large values of 16. Since we intend to analyze tests for the
diﬀerence of two networks we need to simulate networks for two groups and establish
one or more diﬀerences between them. The sample sizes are considered as from small
samples sizes with 20 observations per group to large balanced and unbalanced sample
sizes with 200/200 and 300/100 observations per group, respectively, which are quite
realistic sample sizes in real data. As diﬀerences the knockout of the central node PKC
only or of the three nodes PIP2, PKC, and PKA, is considered and reported in this
thesis. Other knockouts have been analyzed, but no major diﬀerences were found in
principal. As knockout we mean the expression to disappear and therefor assume the
corresponding underlying random variable or rather random variables to be normally
distributed with mean zero which means no inﬂuence of other variables. Thus, all edges
that pointed towards the knockout node will vanish.
Parameter settings for simulation of data
variance of noise term 0.01; 0.1; 0.5; 1; 2; 4; 8; 16
sample sizes per group 100/100; 150/50; 180/20; 50/50; 20/20; 200/200; 300/100
knockout of node PKC; (PIP2, PKC, PKA)
number of additional nodes 0; 5; 10; 20; 50
Table 17: Overview of settings for simulation of data based of the graph of the RAF
signalling pathway.
In real data situations it is challanging to extract exactly these nodes belonging to the
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network of interest as seen in Section 4.2. Hence, we generate a number of additional
noise nodes whose expression assumed to be normally distributed with mean zero to the
data. A complete overview of all parameter settings is given in Table 17.
All combinations of parameter settings are considered and for each combination 100
datasets are generated to analyze the properties of the permutation tests for the quan-
tiﬁcation of diﬀerences in two undirected networks. The results are described in the
following section.
4.3.2 Properties of tests for the quantiﬁcation of diﬀerential networks
Analyzing the α-level
A crucial point to know is whether a test holds the given signiﬁcance level. Therefore,
we simulate data without systematic diﬀerences, i.e. without any knockouts, between
the two groups and apply the permutation tests proposed in Section 4.1.5 and 4.1.6. All
combinations of settings listed in Table 17 in Section 4.3.1 except for the knockout of
nodes are conducted. Considering all 100 datasets for every setting the proportion of re-
jected null-hypothesis for every signiﬁcance level αs ∈ [0 ; 1] is determined. The decision
of a test can be considered to be a random variable W with two feature characteris-
tics. Let W1, . . . ,W∆ be sampling variables of W that are independent and identically
distributed (i.i.d.) with
Wζ =
1 , null-hypothesis is rejected0 , null-hypothesis is not rejected,
with ζ = 1, . . . ,∆. Hence, W can be assumed to be Bernoulli distributed with success
probability pi, i.e. pi is the probability of rejecting the null-hypothosis (if H0 is true). It
is known that the sum of ∆ Bernoulli distibuted variables is binomial distibuted with
parameters ∆ and pi,
∑∆
ζ=1Wζ ∼ Bin (∆, pi). Therefore, we can test the hypothesis
H0 : pi ≤ αs against H1 : pi > αs
using a Binomal test (e.g. Genschel and Becker, 2005). In the below-mentioned ﬁgures
the upper boundary of the 95% conﬁdence interval ﬁrst given by Clopper and Pearson
(1934) is plotted. By estimating and testing the proportion of rejected hypothesis we
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test whether a permutation test in a speciﬁed scenario rejects too often under the null-
hypothesis, i.e. it does not hold the given α-level.
Examplary, in Figure 14 the results of the scenarios with 20 samples per group and a
high variance of 16 without any systematic diﬀerences between the groups are shown.
The same plots for all other scenarios can be found in Figures 25 to 79 in the appendix.
For every signiﬁcance level αs ∈ [0 ; 1] on the x-axis, the corresponding proportion of re-
jected null-hypothesis, i.e. the estimated type I error, is drawn on the y-axis. Each plot
corresponds to one of the permutation test statistics introduced in 4.1.5. The diﬀerent
colors indicate scenarios with diﬀerent numbers of additional nodes, where light colors
correspond to small numbers and dark colors to larger numbers of additional nodes.
The red dashed line denotes the upper boundary of the 95% conﬁdence interval for pi
described above.
For the permutation tests using the MaxDApC, MDApC, MDQpC, MDAR, MDQR,
MaxDAC, MDAC, and MDQC as test statistics the proportion of rejected hypothesis
under the null-hypothesis is less or equal to the upper boundary of the conﬁdence inter-
val for pi in all scenarios. i.e. the mentioned tests do not reject the null-hypothesis too
often, except for some random exceedings around signiﬁcance levels around 0.5 mainly
in permutation tests based on partial correlations. Noticeable are the runs of the curves
of the MDE, χE, MDARE, and MDQRE as well as CORpCE and RCORpCE.
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Figure 14: Proportion of misleadingly rejected hypothesis for simulated setting of 20
samples per group and noise 16.
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Adding 50 nodes as described in Section 4.3.1 the proportion of rejected null-hypothesis
is 0 from αs between 0 and 0.5 for the permutation tests using MDE, χE, MDARE, and
MDQRE. At an α-level close to 0.5 the curve sharply increases to 1, i.e. all hypotheses
are rejected above this level. This means that all p-values are approximately 0.5. This
is an artefact of the permutation tests with test statistics that use the local FDR and a
ﬁxed threshold to distinguish between signiﬁcant and non-signiﬁcant edges. Considering
a local FDR of 0.2, no edges are present in the networks. With decreasing number of
additional nodes, the rise of the curve is less abrupt because in some iterations we ﬁnd
present edges in one or both networks. Thus, the permutation tests with test statistics
MDE, χE, MDARE, and MDQRE are improper, at least for small sample sizes and large
number of nodes in the network.
Also the permutation tests using CORpCE and RCORpCE seem inappropriate for
testing the diﬀerence of two networks with small samples sizes and a large number
of vertices. As we see in Figure 14, the permutation tests reject the null-hypothesis
much too often or, in case of 50 additional nodes, always, and therefore, they do not
hold the signiﬁcance level. The same results as for the CORpCE and RCORpCE per-
mutation tests with 20 observations can be found for the scenario simulating 180 and 20
samples per group with a variance of 16 for the permutation test using the χE statistic
(cf. Figure 48 in the appendix). Yet, in this scenario the χE permutation test does not
hold the signiﬁcance level for less or no additional nodes for smaller α`s.
All permutation tests using statistics not mentioned above hold the signiﬁcance level
for every αs ∈ [0 ; 1]. Especially the MDAC and MDQC permutation tests that depend
on ordinary correlations instead of partial correlations do not exhaust the acceptable
proportion of rejected null-hypotheses when the noise level and the number of nodes
in the network decreases. This means, the permutation tests become more conservative
with smaller noise level and a smaller number of nodes independent of the sample sizes.
General power properties
In this section we analyze the power properties of the proposed tests. We simulate 100
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datasets for each setting described in Section 4.3.1 with knockout of node PKC or nodes
PIP2, PKC, and PKA. Since the network is diﬀerent by construction, we are under the
alternative hypothesis. Hence, the proposed tests should reject the null-hypothesis at
best 100 times. Such a test would have a power of 1 or 100%, but this seems unrealistic
under all conditions of sample size and noise. To assess an estimate for the power of
the proposed tests we count the fraction of rejected hypotheses of all tested hypothe-
ses for each scenario. For rejecting a null-hypothesis a threshold of an α-level of 5%
is determined. For the scenario where 100 samples per group are assumed and node
PKC lost its parents the results can be found in Figure 15. The results of simulations
assuming low variance of the noise term are drawn in light colors (yellow) and with in-
creasing variance the power curves are marked in darker colors (blue). Since we merely
simulated a discrete number of 0, 5, 10, 20, and 50 nodes, the ﬁlled dots represent the ac-
tual obtained power estimates. The curves are just rough interpolations for visualisation.
In general, the power decreases with growing number of additional nodes in the net-
works and higher variance of the noise term, while the power generally increases with
the sample size (cf. Figure 15 and Figures 80 to 85 in the appendix). However there are
some exceptions which are described in the following paragraphs.
99




























































































































































































































































































































































































































































































































































































































































































































































l l l l
l



































































































































































































Figure 15: Proportion of rejected hypothesis for simulated setting of 100 samples per
group and knockout of node PKC.
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variance of noise term 0.01 variance of noise term 16
number of additional nodes number of additional nodes
test statistic 0 5 10 20 50 0 5 10 20 50
MaxDApC 0.76 0.33 0.16 0.07 0.16 0.33 0.17 0.14 0.11 0.24
MDApC 0.76 0.81 0.71 0.66 0.68 0.20 0.17 0.17 0.17 0.11
MDQpC 0.77 0.80 0.65 0.57 0.70 0.27 0.23 0.21 0.20 0.13
MDE 0.57 0.58 0.59 0.50 0.51 0.06 0.10 0.11 0.06 0.11
χE 0.37 0.68 0.57 0.41 0.51 0.11 0.06 0.07 0.11 0.02
MDAR 0.79 0.66 0.49 0.27 0.03 0.14 0.08 0.04 0.04 0.07
MDQR 0.77 0.57 0.37 0.18 0.03 0.18 0.09 0.07 0.06 0.10
MDARE 0.52 0.71 0.60 0.50 0.52 0.10 0.13 0.11 0.05 0.14
MDQRE 0.54 0.67 0.60 0.46 0.52 0.12 0.16 0.14 0.04 0.15
CORpCE 0.71 0.80 0.68 0.73 0.67 0.27 0.22 0.17 0.07 0.23
RCORpCE 0.57 0.73 0.60 0.61 0.59 0.07 0.08 0.11 0.09 0.05
MaxDAC 0.86 0.86 0.87 0.83 0.74 0.58 0.54 0.47 0.45 0.34
MDAC 0.84 0.89 0.84 0.82 0.59 0.43 0.33 0.23 0.19 0.07
MDQC 0.85 0.92 0.88 0.88 0.77 0.52 0.40 0.37 0.31 0.14
Table 18: Proportion of rejected null-hypotheses of all considered tests if 100 samples
per group and a noise term of 0.01 on the left side and a noise of 16 on the
right side are assumed and a diﬀerence between the networks was created by
eliminating the inﬂuence of the parents on node PKC. The rows corresponds
to the diﬀerent tests, the columns indicate the number of nodes added to the
RAF-network structure as noise factor.
We see, assuming the parameters as speciﬁed above for Figure 15, that most permu-
tation tests reach a power of approximately 70 − 80% when no additional nodes and a
small variance of the noise term are simulated. For small variances, the tests with MDE,
χE, MDARE, MDQRE, and RCORpCE as test statistics have less power considering no
additional nodes, but reach their maximal power when 5 or 10 nodes are added to the 11
nodes of the RAF-network. For larger variances of the noise term this eﬀect cannot be
observed. Table 18 shows, the estimated power for 100 samples per group and knockout
of node PKC for the smallest and the highest considered variances of the noise term,
0.01 and 16, respectively.
The tests using MaxDAC, MDAC, and MDQC based on ordinary correlations have
most power in both variance settings. But with growing number of additional nodes the
MDAC loses more power than MaxDAC and MDQC. MDAR and MDQR perform quite
well without additional nodes and low variance, but otherwise the power becomes very
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small. The power of the test using CORpCE is the highest one of all considered tests
that base on edges, i.e. where the local FDR is considered to decide whether an edge is
present or absent.
In Figure 83 in the Appendix where the setting with only 20 samples per group is
shown, we see that the power of the latter mentioned test increases dramatically with
50 additional nodes and higher variances. This is not a desirable property and arises
from the fact that no edges are signiﬁcant on a local FDR of 0.2 in both groups. The
permutation test depending on MaxDApC rejectes about 75% of the null-hypotheses in
the simplest setting with 100 samples per group, i.e. with variance of the noise term of
0.01 and no additional noise nodes. But the power decreases severely with increasing
number of nodes in the network. MDApC and MDAQpC do not lose that much power
with increasing number of additional nodes. But the power of the tests using their ordi-
nary correlation based counterparts, namely MDAC and MDQC, is considerable higher,
especially in settings with higher variances of the noise term.
In Figures 86 to 92 in the appendix the results of all settings where nodes PIP2, PKC,
and PKA are modelled as normally distributed noise without inﬂuence of the corre-
sponding parents are shown. Here, the diﬀerences are assumed to be larger than in the
settings where only one node is knocked out, hence, we expect the tests to reject the
null-hypotheses more often. Indeed, the power is generally higher.
Particularly, assuming 100 samples per group (cf. Figure 86 in the appendix), small vari-
ances of the noise term combined without any additional nodes the MaxDApC, MDApC,
MDQpC, MaxDAC, MDAC, and MDQC tests have power of 100%. The MaxDAC tests
even rejects all null-hypotheses up to a moderate noise level independently of the nodes
added to the RAF-network structure. If no additional nodes are considered the tests
using MaxDAC, MDAC, and MDQC have power above 90% for all variances of the noise
term, while MaxDApC, MDApC, and MDQpC lose power with increasing noise. For
MaxDAC, the power does not decrease below 60% in any setting where 100 samples
per group and a knockout of nodes PIP2, PKC, and PKA are assumed. But without
any additional nodes and high variance of the noise term the test using MDQC recog-
nizes the diﬀerence between the networks a little more often. Moreover, the power is
almost independent of the number of additional nodes for the tests using MaxDAC as
test statistic if the amount of noise is not too high.
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Decreasing power with unbalanced sample sizes
If we compare the results of the setting with 150 samples in the ﬁrst and 50 samples
in the second group where node PKC is knocked out (Figure 80 in the appedix) with
the one where nodes PIP2, PKC, and PKA are modelled as normally distributed noise
without inﬂuence of the corresponding parents (cf. Figure 87 in the appendix) the test
using MaxDApC reached considerably more power than the MDApC and MDQpC tests
in particular for larger numbers of additional nodes.
For both knockout settings the MDAC and MDQC tests have more power than their
counterparts based on partial correlations, namely MDApC and MDQpC. The MaxDAC
test has more power in almost all settings compared to the MaxDApC, except for the
scenario when we simulate 50 additional nodes, high variance and knock out of nodes
PIP2, PKC, and PKA. Here, the MaxDAC test has approximately 20% more power than
the MaxDApC test.
The power curves of the settings with 180 samples in the ﬁrst and 20 samples in the
second group look pretty similar to the settings with 150 and 50 samples. In comparison
to the settings with knockout of only node PKC the curves are shifted a little bit higher.
Comparing the power of the tests using MDApC and MDQpC of settings where unequal
sample sizes are simulate with settings with smaller, but balanced group sizes, e.g. 150
and 50 samples with 50 samples in both groups, it becomes obvious that the tests
have more power with smaller sample sizes. Exampliﬁed, we have a closer look on the
permutation test using MDApC as test statistic on the setting with variance of the
noise term of 1, and node PKC loses its parents (Figure 16). We compare the results
of 300/100 samples to those of 100 samples per group. The power curves for 300/100
samples are contrasted with the ones for 100/100 in Figure 16. The 95% conﬁdence
interval for the proportion of rejected hypotheses[
pˆi − 1.96
√
pˆi · (1− pˆi)
∆− 1 ; pˆi + 1.96
√







































































































































































































Figure 16: Comparison of power of the test using MDApC as test statistic between the
scenario with 300 in the ﬁrst and 100 in the second group and 100 samples
in both groups (cf. caption Table 18).
is drawn for every setting in this ﬁgure, where ∆ is the number of samples, here 100.
We see, the amout of power diﬀerence grows with increasing numbers of nodes added to
the original 11 nodes included in the RAF pathway. We have several speculations for
this phenomenon.
It might be up to the avarage that is used for the MDApC statistic, because the test
using MaxDApC is not aﬀected. Another reason might be that partial correlations are
used and we cannot see the eﬀect on tests using ordinary correlations. And it might
be due to the shrinkage of the covariance matrix that is used for the calculation of the
partial correlations, because the eﬀect does merely occur if unbalanced samples sizes are
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Figure 17: Comparison of shrinkage intensities in the scenario with 300 in the ﬁrst and
100 samples in the second group without (blue) and 50 additional nodes (red),
where variance of the noise term is 1, and node PKC is knocked out.
To understand the eﬀect we have a look on the shrinkage intensities of a scenario with
unequal sample sizes, ﬁrst.
In Figure 17 the shrinkage intensities of the group containing 300 samples are drawn
on the x-axis, and the shrinkage intensities of the group containing 100 samples on the
y-axis. The blue colored dots correspond to the shrinkage intensities obtained from the
dataset without any additional nodes, while red dots stand for intensities of the scenario
where 50 nodes are added to the 11 nodes of the RAF network structure. We see, the
shrinkage intensities of the group containing 100 samples are always greater than the
one estimated from the data of 300 samples. With growing number of additional nodes
the shrinkage intensities increase and the dots scatter wider. This is not only an eﬀect
of larger sample size in one group, it can also be observed with equal sample sizes (cf.
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Figure 93 in the appendix). These results can be easily explained by transforming the
formula for the estimation of the optimal shrinkage intensity:
λˆ? =
∑

































λˆ? increases if the ratio of samples and nodes decreases, i.e. if we have less samples or
more nodes to rely on. The other reason for increase of the shrinkage intensity can be
found in the denominator. If edges are deleted the correlations or rather covariances
decrease and the ratio becomes greater.
In Figure 94 in the appendix the histograms of MaxDApC statistic for 300 and 100 sam-
ples and 100 samples per group without and with 50 additional nodes are drawn. No
general diﬀerences in the distributions between 300 and 100 and 100 samples per group
can be observed. The distribution of the maximal distances might be a bit shifted to
right for the comparison of 300 and 100 samples which agrees with the slightly greater
power of the test using the MaxDApC statistic. The reversed eﬀect cannot be deter-
mined so easily for the mean distances that are equivalent to the MDApC statistic (cf.
Figure 95 in the appendix).
The reason becomes obvious when we consider the eﬀect of diﬀerent numbers of nodes
to condition on for estimating the partial correlations. The histograms of distances be-
tween partial correlations conditioned on the 11 original nodes of the RAF pathway and
conditioned on the original 11 plus 50 additional nodes for 300 samples and 100 samples,
where variance of the noise term is 1, can be seen in Figure 18. We take the previously
simulated datasets with 300 samples in the ﬁrst group and 50 additional nodes and the
datasets with 100 samples in the ﬁrst group without knockout (and 50 additional nodes)
and estimate two partial correlations for every edge in every dataset.
First, we calculate the partial correlation conditioned on all other 59 variables, second,
the additional nodes are removed and the partial correlation between the nodes of the
original RAF network are computed. The histograms of these distances in Figure 18
show that for 100 samples a lot of distances are close to 0, but we observe also larger
distances than for 300 samples. The many small distances can be explained by the
fact that most partial correlations are estimated smaller in general compared to those
estimated from 300 samples, because the covariances are shrinked more. Some partial
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correlations that are estimated pretty large when conditioned on only 9 variables, will be
more shrinked or rather the corresponding covariances, when we condition on 50 more
nodes.
300 samples



























Figure 18: Histograms of distances between partial correlations conditioned on the 11
original nodes of the RAF pathway and conditioned on the original 11 plus
50 additional nodes for 300 samples (left) and 100 samples (right), where
variance of the noise term is 1.
This reinforces the advantage in power for unbalanced sample sizes on the MaxDApC
test. We see, the change of partial correlations is diﬀerent for diﬀerent numbers of
samples, which increases the average diﬀerences for unequal sample sizes, also for per-
mutated data. Hence, the tests based on averages of partial correlation distances loose
power with growing number of nodes.
Estimation of partial correlations without shrinkage of the covariance matrix
Since the shrinkage of the covariance matrix seems to cause problems in several situa-
tions we perform the tests using MaxDApC, MDApC, and MDQpC again, but without
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any shrinkage of the covariance matrix. Of course, now we need to restrict on scenarios
where more samples per group than nodes are simulated. That means for setting with
50 samples in one or both groups the maximum number of additional nodes can be 20,
if we simulate only 20 samples in at least one group we can just add 5 nodes to the
11 nodes of the RAF network structure. In addtion to the diﬀerence between partial
correlations calculated with and without shrinkage of the covariance matrix of the three
tests, we compare the results with the correlation based tests. The three tests based on
the maximum, the mean absolute, and mean squared diﬀerence of (partial) correlations
are selected, because they demontrated highest power under the alternative and hold
the α-level in every setting.
In Table 19 the power diﬀerences of the tests using the maximum, the mean absolute,
and mean squared diﬀerence between ordinary correlations and partial correlations with
shrinkage of the covariance matrix are shown on the left and on the right side the dis-
tances between partial correlations with and without shrinkage. Distances are reported
for all settings regarding numbers of additional nodes and variances of the noise term for
100 samples per group. The tables for the other considered sample sizes can be found
in Tables 31 to 36 in the appendix. We see, in Table 19 the test using the maximal dis-
tance has considerably more power if ordinary correlations are used compared to partial
correlations with shrinkage of the covariance matrix, especially with increasing numbers
of additional nodes. If we compare the power between partial correlations with and
without shrinkage, it is an advantage to shrink to covariances if no additional nodes or
50 additional nodes are considered with the maximal distance based test. For 5 to 20
additional nodes there are no considerable diﬀerences in the power.
Considering the mean absolute and mean squared diﬀerence the tests based on partial
correlation with shrinkage of the covariance matrix have more power in each setting re-
garding number of additional nodes and variance of the noise term compared to the tests
based on partial correlations without shrinkage. If many additional nodes are simulated
the test using mean absolute distance with partial correlation with shrinkage has more
power than the one using ordinary correlations, especially for moderate noise levels. But
in general, we could rank the tests according to power, where ordinary correlation is bet-
ter than partial correlation with shrinkage that in turn is better than partial correlation
without shrinkage of the covariance matrix to recognize diﬀerences in two networks.
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Cor − pCor with shrinkage pCor with − pCor without shrinkage
variance number of additional nodes number of additional nodes
0 5 10 20 50 0 5 10 20 50
MaxDA 0.01 0.10 0.53 0.71 0.76 0.58 0.22 -0.14 -0.19 -0.28 -0.09
0.1 0.05 0.36 0.58 0.61 0.58 0.21 -0.08 -0.10 -0.26 -0.05
0.5 0.00 0.34 0.57 0.66 0.63 0.29 0.03 -0.17 -0.10 0.09
1 0.06 0.43 0.48 0.67 0.55 0.36 -0.04 -0.02 -0.02 0.15
2 0.13 0.48 0.62 0.66 0.58 0.32 -0.02 -0.10 -0.04 0.09
4 0.21 0.57 0.59 0.57 0.44 0.25 -0.12 0.04 -0.03 0.12
8 0.32 0.46 0.56 0.48 0.33 0.25 0.00 -0.03 0.04 0.21
16 0.25 0.37 0.33 0.34 0.10 0.18 0.05 0.05 0.03 0.17
MDA 0.01 0.08 0.08 0.13 0.16 -0.09 0.45 0.71 0.60 0.58 0.64
0.1 0.07 -0.01 0.03 0.07 -0.11 0.48 0.57 0.72 0.51 0.51
0.5 0.00 0.00 0.05 -0.01 -0.15 0.56 0.58 0.67 0.62 0.51
1 0.00 0.08 0.17 0.12 -0.15 0.63 0.53 0.43 0.53 0.64
2 0.25 0.26 0.30 0.16 -0.18 0.34 0.36 0.30 0.36 0.50
4 0.30 0.37 0.30 0.06 -0.12 0.25 0.16 0.24 0.38 0.36
8 0.40 0.41 0.18 0.12 -0.10 0.21 0.05 0.21 0.21 0.29
16 0.23 0.16 0.06 0.02 -0.04 0.09 0.13 0.14 0.12 0.06
MDQ 0.01 0.08 0.12 0.23 0.31 0.07 0.34 0.59 0.48 0.44 0.65
0.1 0.08 0.03 0.17 0.23 0.09 0.37 0.44 0.57 0.38 0.57
0.5 0.00 0.02 0.16 0.23 0.07 0.45 0.47 0.48 0.45 0.56
1 -0.03 0.11 0.23 0.31 0.05 0.61 0.46 0.38 0.44 0.64
2 0.07 0.27 0.29 0.34 0.15 0.48 0.28 0.33 0.30 0.51
4 0.20 0.39 0.48 0.23 0.08 0.37 0.19 0.21 0.34 0.36
8 0.34 0.43 0.23 0.28 0.06 0.29 0.08 0.24 0.26 0.29
16 0.25 0.17 0.16 0.11 0.01 0.16 0.20 0.20 0.17 0.07
Table 19: Comparison of power for the tests using MaxDA·, MDA·, and MDQ· as test
statistics based on partial correlations (pCor) with and without shrinkage of
the covariance matrix and ordinary correlations (Cor) considering 100 samples
per group.
For the mean distances in the settings with unequal samples sizes and moderate noise
levels, using partial correlations without shrinkage results in slightly higher power com-
pared with shrinkage, but the tests using ordinary correlations is still more powerful.
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An exception can be observed in case of small sample sizes of 20 or 50 samples per
group. Here, the test using the mean absolute distance of partial correlations has more
power levels than the same test based on ordinary correlations particularly for low noise,
though the latter is still more powerful than the one that uses partial correlations with-
out shrinkage of the covariance matrix.
Optimal distance for a test statistic to recognize diﬀerences in interaction net-
works
The questions which distance should be used to maximize the power is still to be ad-
dressed. Thereto, we record the maximum power over the ordinary correlation, partial
correlation with and without shrinkage for every of the three statistics.
The diﬀerences between tests based on the three statistics optimized for the correlation
exampliﬁed for 100 and 200 samples per group can be found in Tables 37 and 38 in the
appendix. The results for the settings with other sample sizes look very similar and
hence are not shown. The mean squared diﬀerences have more or approximate power
(in the setting where only 20 samples per group are assumed) than the test based on
mean absolute diﬀerences, particulary if many additional nodes are simulated and a high
variance of the noise term is assumed. Notably, with many additional nodes and high
variance the maximum distance is even more powerful than the mean squared distance.
For moderate combinations of noise and numbers of additional nodes both statistics lead
to similar results. However, the mean squared distance has advantages in terms of power
for small sample sizes and low levels of variances of the noise terms.
4.4 Summary
Genes usually do not act alone but in groups or pathways. The identiﬁcation and statis-
tical inference of these pathways under certain conditions from gene expression data has
become a recent research topic. Genes are treated as nodes and the interactions between
the genes are represented as edges. Many approaches for network inference have been
proposed. Relevance networks (Butte et al., 2000) derived from ordinary correlations of
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genes are computationally inexpensive but they have two major disadvantages. First,
the direction of the relationship can not be determined and second, we are not able to
distinguish between direct and indirect interactions which means two genes are inﬂu-
enced by a third gene but have no direct relationship. Bayesian networks derived via
Markov Chain Monte Carlo (MCMC) Simulations have the advantage to estimate pos-
terior probabilities for directed egdes but they are computationally expensive. Another
approach to estimate gene expression networks are Gaphical Gaussian Models (GGMs).
Using partial correlations that can be easily obtained from the inverse of the covari-
ance matrix direct interactions can be recognized and like relevance networks GGMs are
computationally inexpensive. Only the direction of interactions remains unclear and we
should keep in mind that a partial correlation depends on the other variables considered
in the network.
If we assume nodes to be random variables and interactions between genes or nodes
to be conditional independence structures we are able to extend the concept of condi-
tional independence with the so called Markov properties (cf. Section 4.1.1) to a set
of nodes and edges, i.e. a graph (cf. Section 4.1.1). Under the assumption that the
genes or rather underlying random variables follow a multivariate normal distribution
we speak of Graphical Gaussian Models. Lauritzen (1996, prop. 5.2, p. 129) shows that
in this case two genes are independent conditional on another gene if and only if the
conresponding entry of the concentration matrix, which is the inverse of the covariance
matrix, is equal to zero. This is the link to the matrix of partial correlations respresent-
ing the correlation of two variables given the values of other variables or phrased in a
diﬀerent way, the correlation of the residuals of the two variables ﬁtted by a linear model
with the other variables as independent variables. However, the covariance matrix can`t
be estimated if more observations than variables are considered which is often the case
for gene expression measurements. A loophole for that purpose is shrinkage or biased
estimation of the covariance matrix (Schäfer and Strimmer, 2005a, cf. section 4.1.3).
Based on the theorem of Ledoit and Wolf (2003) the covariances are shrinked towards
zero. The GGM estimated from these covariances outperforms GGM selection using
Lasso regression (Meinshausen and Bühlmann, 2005) and other estimators for partial
correlations that employ the pseudoinverse instead of the matrix inverse or that uses
bootstrapping to obtain a variance reduced positive deﬁnite estimate of the covariance
matrix (Schäfer and Strimmer, 2005b). Following Efron (2005) a mixture distribution
for the observed partial correlations is assumed in order to compute the probability for
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an existing edge, also reﬀered as local false discovery rate (cf. Section 4.1.4).
In this thesis we focus on the identiﬁcation of diﬀerences in gene expression networks
between two groups of patients or under two conditions. One can imagine that interac-
tions between genes change with progression of a tumor disease, e.g. paths might collapse
or activation of an oncogene might be increased through a certain signal transduction
cascade.
To assess the diﬀerences of two networks or of one network under two conditions, we
apply the mean absolute distance of partial correlations (Gill et al., 2010) and 13 novel
statistics (cf. Section 4.1.5). Most of them are described in Lohr et al. (2010). Some
statistics base on partial correlations, others on ordinary correlations. Some use the
local false discovery rate to decide whether an edge is present or absent and some just
depend on edges that are present in at least one network. To make it more robust ranks
are considered for some statistics. All measures are used as test statistics in permutation
tests (cf. Section 4.1.6), because they follow no known distribution.
But before we can test for diﬀerences in a network, a suitable set of genes that form a
biological network or pathway and of which we can assume to be diﬀerent between the
two groups must be explored. Several databases on the internet, e.g. Gene Ontology, Re-
actome or KEGG provide predeﬁned gene sets and pathway information from biological
knowledge. Since we have no knowledge about diﬀerential interactions in a particular
gene set, all gene sets need to be tested.
To avoid testing thousands of gene sets, we analyze gene signatures that are known to
be diﬀerential between two groups of patients, though they might not build an interac-
tion network. Therefore we perform a Gene Set Enrichment Analysis (GSEA, Mootha
et al., 2003) for genes of diﬀerential signatures in predeﬁned Gene Ontology gene sets.
Enriched gene sets are afterwards tested for diﬀerences in interaction networks with our
proposed statistics. The MammaPrint Genes (Tian et al., 2010) that are associated with
prognosis are signiﬁcantly enriched in 58 Gene Ontology gene sets. For 35 gene sets at
least one test for diﬀerences in interaction networks is signiﬁcant (p < 0.05). However,
large discrepancies in the number of signiﬁcantly diﬀerent networks across the statistics
are observed. The test depending on the maximum distance of partial correlations is not
signiﬁcant for any of the tested gene sets, while the two tests using the mean squared and
absolute distances of ordinary correlations recognize 16 diﬀerential interaction networks.
A novel approach for the detection of diﬀerential networks is introduced in Section 4.2.2.
The Gene Selection Algorithm for Diﬀerential Networks (DiNGS) for variable/gene se-
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lection consists of ﬁve steps. These are exchangeable and may be adapted according to
requirements. One basic version is described and analyzed for stability in the selection
of the gene pair to built the (diﬀerential) network around.
To analyze properties in terms of type I errors and power, we perform an extended
simulation study. Data has been generated based on the well-known structure of the
RAF pathway, which consists of eleven phosphorilated proteins connected by 20 directed
edges. Our tests base on partial or ordinary correlations that are only able to detect
undirected edges. We need to test them on directed data, because of the biological
rational that one protein or transcription factor inﬂuences another gene. Each node is
modeled as linear combination of its parent nodes and an additional noise. The noise,
the sample size of the groups that should be compared, the diﬀerences between the
groups as well as the number of additional nodes that would not belong to the network,
are varied. The additional nodes are generated to cause noise.
To check whether the proposed tests hold a given α-level, 1000 datasets without diﬀer-
ences between the two assumed groups have been generated. Considering small sample
sizes in at least one group, the tests using the local FDR to decide if an edge is present
or absent, do not hold the given α-level.
Afterwards, networks with varying diﬀerences between two groups are generated to as-
sess an estimate for the power of the proposed tests. In general, we can summarize that
the power decreases with increasing number of additional "noise" nodes and higher vari-
ance of the noise term and increases with higher sample size. Furthermore, the power
decreases signiﬁcantly for the tests based on mean squared or absolute distances of par-
tial correlations if the number of samples in one group is considerably higher than in
the other one, compared to groups with smaller but equal sample sizes. Three reasons
are suggested: First, the average might play a role, because the phenomenon is not ob-
served for the maximum distance. Second, considering partial correlation may cause the
eﬀect, because tests using ordinary correlations are not aﬀected, which lead to the third
point. The shrinkage of covariances might cause the eﬀect due to diﬀerent shrinkage
intensities caused by diﬀerent sample sizes. Therefore, we applied the three tests with
highest power - maximum distance, average of squared and absolute distances, once
more without shrinkage of the covariance matrix. Of course, only situations with more
observations than edges could be considered. A comparison with their counterparts with
shrinked covariances and ordinary correlations lead to the following:
The tests using maximum or mean squared ordinary correlation have highest power in
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all settings if the numbers of samples per group are equal and approximately twice as
many samples per group than nodes are to be tested. The permutation test with the
mean absolute distance of partial correlations (derived from shrinked covariances) as
test statistic has slightly less but also high power. Assuming small variances and small
sample sizes in conjuction with a small number of nodes in the network, the test using
mean squared distance of partial correlations (with shrinkage of the covariance matrix)
has the highest power. The latter can also be used for higher variances. In all other
settings, it is advisable to use the permutation test with the maximum distance of ordi-
nary correlations as test statistic. With increasing variance and numbers of nodes, the
more superior is the maximum distance of ordinary correlations compared to the mean
squared and absolute ordinary correlation and all other measures used as test statistics
for the permutation tests.
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5 Discussion and conclusions
High-dimensional gene expression data oﬀers the opportunity to gain deeper insights
into cancer biology which may help to develop novel therapies. The large amount of
data may indeed be useful for that purpose, however, appropriate analysis strategies are
required. Our goal was to improve statistical methods for extracting useful informa-
tion about diﬀerences in gene expression with a focus on two topics - the validation of
single genetic markers in multiple datasets and the detection of diﬀerential interaction
networks among two groups of patients under two conditions.
The identiﬁcation of diﬀerentially expressed genes between normal and tumor tissue,
prognostic and predictive markers, from gene expression datasets is a major research
topic. Due to the high number of measured genes, the chance of observing false positive
ﬁndings is high. Usually a procedure to control the number or the proportion of false
positive results is applied, but even after correcting for multiple testing we will obtain
some false positive ﬁndings. Validation on other datasets will help to gain conﬁdence in
signiﬁcant markers. By a strict adjustment on every considered dataset many interesting
markers will not be recognized. Powerful standard approaches to combine estimators
from diﬀerent studies like the common meta-analysis (Whitehead, 2002) do not take the
validation idea into account.
We proposed two strategies that trade adjustment for multiple testing in high-dimensional
data oﬀ against validation of ﬁndings. Following the ﬁrst, we screen for signiﬁcant fea-
tures in one dataset and afterwards a meta-analysis is performed for genes found to be
interesting in the ﬁrst step on other datasets to validate ﬁndings. Another strategy was
called sequential validation strategy. Starting on one dataset, we test for signiﬁcant
features and all non-signiﬁcant genes after adjustment are excluded from the next steps.
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The procedure is repeated on the second dataset, followed by the third dataset until all
datasets are tested and p-values were adjusted for an ever-decreasing number of features.
To assess the characteristics, advantages and disadvantages of the proposed methods, we
performed a simulation study and applied them to three real breast cancer ("Mainz",
"Rotterdam" and "TRANSBIG") and nine non-small cell lung cancer datasets. The
results were compared to those obtained by an ordinary meta-analysis.
Our two-step meta-analysis approach demonstrated its ability to identify additional
prognostic genes in non-small cell lung cancer that would not have been recognized if all
considered datasets were analyzed equally in an ordinary meta-analysis.
Applying the proposed sequential 3-step validation strategy, it seems suﬃcient for the
elimination of all false positive features to restrict on only three datasets. The over-
lap of signiﬁcant features of the latter strategy with an ordinary meta-analysis is even
smaller when compared to the two-step meta-analysis. The outcome of our sequential
validation strategy depends on the datasets used, the number of validation steps and
the order of datasets. Testing on one and validating the results on two more datasets
seems suﬃcient to exclude all false positive ﬁndings  at least in a simulation study.
Although it seemed suﬃcient in the simulation studies, two validation steps might not
be the optimal number to extract most signifcant but not false positive features since it
depends on many factors.
Homogeneity of datasets is important since the highest number of signiﬁcant genes after
two validation steps is observed analyzing non-small cell lung cancer if datasets contain-
ing only patients with the same histological subtype are considered. Hence, testing all
combinations and orders of datasets our approach oﬀers a selection of datasets that are
most homogeneous and therefore suitable for validating our ﬁndings.
In addition, we discovered that the sequential validation method enables us to draw
conclusions about the quality in terms of noise and sample size of datasets in relation
to each other. The breast cancer TRANSBIG cohort was identiﬁed to have the least
quality since the sample size is larger than in the Mainz cohort, but less signiﬁcant genes
than in the Mainz and Rotterdam dataset are found. The least quality might arise from
higher heterogeneity, since it is composed of samples from ﬁve European cancer centers.
Zehetmayer and Posch (2012) proposed to conduct a small pilot-study ﬁrst and validate
the ﬁndings on a larger one. But our results argue against this strategy. We discovered
that starting with the dataset with highest quality will result in increasing power.
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The analysis of single genes allows only limited insights in biological processes that are
disturbed in cancer. Considering interactions between genes in sub-networks seems to
be more promising for that purpose.
We proposed the DiNGS (Diﬀerential Networks Gene Selection) Algorithm to detect dif-
ferential interaction sub-networks. This algorithm can be used ﬂexibly to build networks
that, afterwards, can be tested explicitly for diﬀerences in the interaction structure. Since
all of the ﬁve steps are exchangeble we might detect networks that are overall diﬀerent
between two groups or, we could extract a network with maximal diﬀerences in a small
part, e.g. a path, in a graph. We are also free to build a larger network around the
assumed diﬀerences or to restrict on the basic diﬀerential network. This is an advanta-
geous feature, because genetic sub-networks cannot always be clearly distinguished from
other sub-networks.
To test the hypothesis of diﬀerences in an interaction structure of a sub-network obtained
by DiNGS or biological knowledge, we proposed a collection of measures and performed
extensive simulation studies. Results were only shown for knockout of nodes "PKC" and
"PIP2-PKC-PKA", while knockout of the other nodes led to similar ﬁndings.
We discovered that the permutation test with test statistic MADPC (mean absolute
distance of partial correlations) proposed by Gill et al. (2010) has always less power
than other statistics we proposed, e.g. maximum or mean squared distance of partial
or ordinary correlations. Although Graphical Gaussian Models (GGMs) that base on
partial correlations are known to have a better ability for network reconstruction than
relevance networks based on ordinary correlations (Schäfer and Strimmer, 2005a), our
tests using ordinary correlations have considerably more power.
The permutation tests using a local False Discovery Rate to decide whether an edge is
present or absent have major disadvantages in terms of power and holding the α-level.
A threshold of 0.2 as proposed by Efron (2005) might not be the best choice and could
be adapted in future studies.
Unbalanced sample sizes between the two groups caused issues in most proposed permu-
tation tests. Again, by using a test statistic with ordinary correlations instead of partial
correlations we avoid this issue. Therefore, we argue for using a test based on ordinary
correlation.
Although Schäfer and Strimmer (2005a) showed that GGMs using their shrinkage ap-
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proach outperforms GGMs selection using Lasso regression (Meinshausen and Bühlmann,
2005) and other estimators for partial correlation that employ the pseudoinverse instead
of matrix inverse or bootstrapping approaches, the concept of covariance shrinkage for
diﬀerential network recognition should be reassessed in future work.
An extension on larger networks is computationally feasible for all proposed measures,
but for these scenarios the properties of the tests will need to be investigated by ad-
ditional simulation studies. Especially, when we analyze larger sub-networks a closer
look into the structure will be necessary to explicitely ﬁnd the diﬀerences. Therefore, an
adaption of the testing procedure that tests at ﬁrst for diﬀerential modular structures,
then for diﬀerences in a sub-class of genes and ﬁnally for diﬀerential connectivity of
single genes, proposed by Gill et al. (2010), might be a good approach to gain further
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T1 Tumour =3 cm in diameter surrounded by lung or visceral
pleura, without invasion more proximal than lobar bronchus.
T1a Tumour =2 cm in diameter
T1b Tumour >2 cm but =3 cm in diameter
T2 Tumour >3 cm but =7 cm in diameter or tumour with:
-Involvement of the main bronchus =2 cm distal to the carina
-Invasion of visceral pleura
-Associated atelectasis or obstructive pneumonitis that does not
involve the entire lung.
T2a Tumour =5 cm in diameter
T2b Tumour >5 cm but =7 cm in diameter
T3 Tumour >3 cm but =7 cm in diameter or tumour with:
-Direct invasion of the chest wall, diaphragm, phrenic nerve
-Direct invasion of the mediastinal pleura or parietal pericardium
-Associated atelectasis or obstructive pneumonitis that involves
the entire lung.
-Tumour within the main bronchus < 2 cm to the carina, without
involvement of the carina.
-Satellite tumour nodule(s) in the same lobe.
T4 Tumour of any size with:
-Invasion of mediastinum
-Invasion of heart or great vessels
-Invasion of trachea, oesophagus, or recurrent laryngeal nerve
-Invasion of a vertebral body or carina
-Separate tumour nodules in a diﬀerent ipsilateral lobe.
Regional lymph node (N)
N0 No regional lymph node metastasis
N1 Involvement of ipsilateral hilar or peribronchial nodes
N2 Involvement of ipsilateral mediastinal or subcarinal nodes
N3 Involvement of contralateral mediastinal or hilar nodes, or
ipsilateral/contralateral scalene or supraclavicular nodes.
Distant metastasis (M)
M0 No distant metastasis
M1 Distant metastasis present
M1a Separate tumour nodule(s) in a contralateral lobe or tumour with
pleural nodules or malignant pleural/pericardial eﬀusion
M1b Distant metastasis
Table 20: Deﬁnition of TNM (7. edition, reproducted from Goldstraw et al., 2007).
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σhq = 0.7, σmq = 0.8, σlq = 1.8
Holm FDR
sequence 1st step 2nd step 3rd step 1st step 2nd step 3rd step
1: hq → mq → lq 58 / 0 58 / 0 22 / 0 92 / 5 92 / 0 74 / 0
2: hq → lq → mq 58 / 0 22 / 0 22 / 0 92 / 5 73 / 0 73 / 0
3: mq → hq → lq 45 / 0 45 / 0 20 / 0 85 / 4 85 / 0 69 / 0
4: mq → lq → hq 45 / 0 20 / 0 20 / 0 85 / 4 69 / 0 69 / 0
5: lq → hq → mq 1 / 0 1 / 0 1 / 0 4 / 0 4 / 0 4 / 0
6: lq → mq → hq 1 / 0 1 / 0 1 / 0 4 / 0 4 / 0 4 / 0
Table 21: Median true positives/false positives in each step of the six adjustment se-
quences for simulated gene expression data.
σhq = 0.8, σmq = 1.1, σlq = 1.5
FDR/Holm/Holm Holm/FDR/FDR
sequence 1st step 2nd step 3rd step 1st step 2nd step 3rd step
1: hq → mq → lq 85 / 4 74 / 0 39 / 0 45 / 0 45 / 0 42 / 0
2: hq → lq → mq 85 / 4 40 / 0 39 / 0 45 / 0 42 / 0 42 / 0
3: mq → hq → lq 52 / 2 52 / 0 32 / 0 17 / 0 17 / 0 16 / 0
4: mq → lq → hq 52 / 2 31 / 0 31 / 0 17 / 0 16 / 0 16 / 0
5: lq → hq → mq 15 / 1 15 / 0 15 / 0 4 / 0 4 / 0 4 / 0
6: lq → mq → hq 15 / 1 15 / 0 15 / 0 4 / 0 4 / 0 4 / 0
Table 22: Median true positives/false positives in each step of the six adjustment se-
quences for simulated gene expression data.
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sequence 1st step 2nd step 3rd step
Jacob → GSE31547 → GSE31210 258 0 0
Jacob → GSE31210 → GSE31547 258 120 18
GSE31547 → Jacob → GSE31210 0 0 0
GSE31547 → GSE31210 → Jacob 0 0 0
GSE31210 → Jacob → GSE31547 4355 241 21
GSE31210 → GSE31547 → Jacob 4355 0 0
Table 23: Numbers of signiﬁcant probe sets in each step for the six posiible validation se-
quences (using the Benjamini-Hochberg procedure for signiﬁcance adjustment
to restrict the FDR to 5%) for the three lung cancer datasets that aﬀord the
highest numbers of signiﬁcant probe sets after three adjustment steps.
sequence 1st step 2nd step 3rd step
Jacob → GSE3141 → GSE31547 258 19 5
Jacob → GSE3141 → GSE31210 258 19 11
Jacob → GSE31210 → GSE31547 258 120 18
Jacob → GSE31210 → GSE3141 258 120 13
GSE31210 → Jacob → GSE31547 4355 241 21
GSE31210 → Jacob → GSE3141 4355 241 12
Table 24: Numbers of signiﬁcant probe sets in each step for the validation sequences (us-
ing the Benjamini-Hochberg procedure for signiﬁcance adjustment to restrict
the FDR to 5%) that consider at least one signiﬁcant probe set after three




probe set symbol gene name
201037_at PFKP phosphofructokinase, platelet
202616_s_at MECP2 methyl CpG binding protein 2 (Rett syndrome)
204385_at KYNU kynureninase
205839_s_at BZRAP1 benzodiazapine receptor (peripheral) associated protein 1
207165_at HMMR hyaluronan-mediated motility receptor (RHAMM)
214710_s_at CCNB1 cyclin B1
218092_s_at AGFG1 ArfGAP with FG repeats 1
Table 25: Probe sets with gene symbol and gene name that are signiﬁcant in the com-
bined meta-analysis for all patients when Uppsala is used as basic dataset as
well if dataset GSE31210 is used for preselection.
number of network 1
nodes present absent
network 2 present 15 0
absent 5 35
Table 26: Theoretical contingency table for simulated networks without any additional









number of network 1
nodes present absent
network 2 present 15 0
absent 5 100
Table 27: Theoretical contingency table for simulated networks with 5 additional nodes.








number of network 1
nodes present absent
network 2 present 15 0
absent 5 190
Table 28: Theoretical contingency table for simulated networks with 10 additional nodes.










number of network 1
nodes present absent
network 2 present 15 0
absent 5 445
Table 29: Theoretical contingency table for simulated networks with 20 additional nodes.








number of network 1
nodes present absent
network 2 present 15 0
absent 5 1810
Table 30: Theoretical contingency table for simulated networks with 50 additional nodes.










Cor − pCor with shrinkage pCor with − pCor without shrinkage
variance number of additional nodes number of additional nodes
0 5 10 20 50 0 5 10 20 50
MaxDA 0.01 0.17 0.27 0.38 0.53 0.52 0.10 0.04 -0.01 -0.11 0.07
0.1 0.05 0.22 0.23 0.31 0.34 0.18 0.10 0.15 0.03 0.16
0.5 0.00 0.09 0.24 0.35 0.52 0.21 0.11 0.07 0.01 0.08
1 0.02 0.06 0.26 0.46 0.55 0.16 0.08 0.14 -0.09 0.04
2 -0.01 0.11 0.24 0.48 0.51 0.29 0.30 0.16 0.06 0.09
4 0.06 0.12 0.39 0.48 0.57 0.37 0.28 0.19 0.04 0.11
8 0.15 0.25 0.32 0.43 0.26 0.24 0.30 0.17 0.17 0.40
16 0.17 0.25 0.30 0.27 0.23 0.35 0.25 0.31 0.22 0.32
MDA 0.01 0.10 0.12 0.10 0.15 0.14 0.47 0.54 0.61 0.65 0.64
0.1 0.06 0.06 0.03 0.04 0.06 0.46 0.59 0.64 0.65 0.60
0.5 0.01 0.05 0.02 0.09 0.01 0.49 0.58 0.66 0.59 0.68
1 0.02 0.10 0.11 0.15 0.02 0.48 0.45 0.56 0.60 0.53
2 0.18 0.21 0.17 0.31 -0.01 0.38 0.48 0.53 0.36 0.55
4 0.30 0.34 0.50 0.34 -0.10 0.37 0.23 0.23 0.35 0.61
8 0.48 0.39 0.45 0.19 -0.12 0.10 0.24 0.19 0.28 0.37
16 0.43 0.37 0.26 0.08 -0.04 0.17 0.24 0.25 0.21 0.11
MDQ 0.01 0.14 0.15 0.15 0.27 0.17 0.27 0.29 0.47 0.50 0.70
0.1 0.05 0.07 0.04 0.13 0.12 0.27 0.42 0.55 0.57 0.60
0.5 0.02 0.02 0.01 0.13 0.10 0.38 0.48 0.59 0.50 0.68
1 0.01 0.04 0.04 0.18 0.13 0.36 0.45 0.51 0.53 0.57
2 0.08 0.06 0.13 0.27 0.15 0.35 0.54 0.55 0.41 0.55
4 0.06 0.15 0.37 0.32 0.13 0.51 0.40 0.35 0.42 0.56
8 0.25 0.29 0.39 0.26 0.18 0.27 0.31 0.28 0.32 0.39
16 0.30 0.32 0.32 0.22 0.10 0.29 0.39 0.30 0.24 0.14
Table 31: Comparison of power for the tests using MaxDA·, MDA·, and MDQ· as test
statistics based on partial correlations (pCor) with and without shrinkage of




Cor − pCor with shrinkage pCor with − pCor without shrinkage
variance number of additional nodes number of additional nodes
0 5 10 20 50 0 5 10 20 50
MaxDA 001 0.25 0.45 0.58 0.57 0.34 0.06 -0.21 -0.27 -0.31 0.03
01 0.03 0.37 0.40 0.42 0.29 0.21 -0.12 -0.11 -0.23 -0.06
05 0.07 0.29 0.45 0.28 0.30 0.11 -0.11 -0.15 0.03 0.04
1 0.03 0.21 0.30 0.35 0.32 0.08 -0.06 -0.08 -0.18 0.19
2 0.06 0.17 0.33 0.47 0.26 0.06 0.00 -0.12 -0.11 0.21
4 0.05 0.14 0.36 0.39 0.24 0.14 0.09 -0.02 -0.04 0.16
8 0.14 0.28 0.33 0.29 0.36 0.19 0.03 0.14 0.18 0.25
16 0.22 0.26 0.23 0.19 0.04 0.16 0.11 0.13 0.26 0.29
MDA 001 0.25 0.19 0.21 0.57 0.58 0.36 0.41 0.48 0.16 -0.05
01 0.04 0.02 0.14 0.59 0.55 0.43 0.49 0.54 0.08 0.01
05 0.08 0.19 0.38 0.71 0.63 0.32 0.44 0.21 -0.05 -0.10
1 0.23 0.30 0.52 0.67 0.57 0.30 0.21 0.03 -0.07 -0.07
2 0.31 0.52 0.63 0.64 0.45 0.15 0.00 0.01 -0.10 -0.03
4 0.49 0.59 0.69 0.53 0.36 0.11 -0.02 -0.16 -0.01 -0.05
8 0.51 0.56 0.58 0.44 0.23 0.08 0.06 0.04 -0.04 0.00
16 0.51 0.37 0.25 0.23 0.05 -0.02 0.00 0.00 -0.03 0.11
MDQ 001 0.25 0.21 0.22 0.58 0.79 0.22 0.24 0.24 0.02 -0.11
01 0.04 0.01 0.11 0.60 0.71 0.30 0.31 0.39 -0.10 -0.07
05 0.03 0.08 0.27 0.64 0.75 0.19 0.38 0.22 -0.10 -0.09
1 0.04 0.14 0.40 0.64 0.75 0.32 0.22 0.05 -0.18 -0.07
2 0.13 0.22 0.48 0.72 0.65 0.18 0.08 0.05 -0.16 0.00
4 0.29 0.33 0.68 0.64 0.62 0.15 0.08 -0.16 0.01 -0.05
8 0.37 0.52 0.64 0.57 0.44 0.10 0.11 0.03 -0.01 0.01
16 0.40 0.43 0.33 0.36 0.15 0.10 0.04 0.03 0.03 0.07
Table 32: Comparison of power for the tests using MaxDA·, MDA·, and MDQ· as test
statistics based on partial correlations (pCor) with and without shrinkage of
the covariance matrix and ordinary correlations (Cor) considering 300 samples
in the ﬁrst and 100 samples in the second group.
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Cor − pCor with shrinkage pCor with − pCor without shrinkage
variance number of additional nodes number of additional nodes
0 5 10 20 0 5 10 20
MaxDA 0.01 0.24 0.60 0.71 0.52 0.47 0.13 -0.31 -0.13
0.1 0.17 0.57 0.76 0.57 0.50 0.15 -0.24 -0.08
0.5 0.26 0.55 0.68 0.63 0.44 0.19 -0.26 0.03
1 0.26 0.46 0.69 0.61 0.51 0.19 -0.04 0.00
2 0.28 0.53 0.63 0.56 0.44 0.17 0.08 0.02
4 0.25 0.57 0.53 0.52 0.45 0.04 0.05 0.06
8 0.49 0.33 0.40 0.42 0.10 0.19 0.06 0.03
16 0.27 0.27 0.16 0.14 0.14 0.17 0.09 0.15
MDA 0.01 0.17 0.08 0.24 0.62 0.61 0.69 0.45 0.01
0.1 0.04 0.04 0.26 0.59 0.69 0.73 0.44 0.00
0.5 0.15 0.33 0.47 0.53 0.59 0.41 0.14 -0.07
1 0.33 0.59 0.55 0.58 0.44 0.08 0.08 -0.02
2 0.53 0.54 0.50 0.46 0.21 0.13 0.02 -0.04
4 0.57 0.47 0.42 0.35 0.12 0.06 0.02 0.03
8 0.41 0.29 0.24 0.31 0.12 0.13 0.01 0.03
16 0.26 0.28 0.17 0.06 0.11 0.01 0.00 0.07
MDQ 0.01 0.18 0.17 0.49 0.77 0.63 0.62 0.24 0.01
0.1 0.04 0.12 0.59 0.67 0.69 0.68 0.15 -0.03
0.5 0.08 0.29 0.54 0.69 0.65 0.47 0.08 -0.06
1 0.17 0.51 0.66 0.72 0.61 0.18 0.07 -0.04
2 0.37 0.55 0.61 0.64 0.37 0.15 0.04 -0.04
4 0.48 0.55 0.52 0.51 0.24 0.06 0.05 0.01
8 0.50 0.41 0.44 0.37 0.13 0.15 0.02 0.05
16 0.27 0.35 0.18 0.16 0.15 0.05 0.03 0.08
Table 33: Comparison of power for the tests using MaxDA·, MDA·, and MDQ· as test
statistics based on partial correlations (pCor) with and without shrinkage of
the covariance matrix and ordinary correlations (Cor) considering 150 samples
in the ﬁrst and 50 samples in the second group.
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Cor − pCor with shrinkage pCor with − pCor without shrinkage
variance number of additional nodes number of additional nodes
0 5 10 20 0 5 10 20
MaxDA 0.01 0.23 0.64 0.56 0.43 0.43 -0.04 -0.07 -0.04
0.1 0.12 0.59 0.57 0.53 0.56 0.04 -0.17 -0.07
0.5 0.16 0.61 0.67 0.53 0.57 -0.04 -0.13 0.02
1 0.21 0.54 0.68 0.55 0.40 0.06 -0.05 0.00
2 0.30 0.53 0.57 0.37 0.32 0.05 -0.05 0.06
4 0.36 0.53 0.41 0.33 0.27 0.00 -0.02 0.03
8 0.36 0.41 0.29 0.34 0.08 0.03 0.07 -0.01
16 0.25 0.12 0.09 0.09 0.04 0.05 0.02 0.01
MDA 0.01 0.08 -0.05 0.02 0.11 0.65 0.73 0.66 0.36
0.1 0.01 -0.03 0.00 0.07 0.68 0.70 0.52 0.40
0.5 -0.04 -0.04 0.06 0.04 0.71 0.58 0.48 0.35
1 -0.01 -0.01 0.12 -0.03 0.61 0.56 0.43 0.37
2 0.18 0.11 0.09 0.03 0.45 0.37 0.32 0.34
4 0.29 0.23 0.11 -0.03 0.28 0.14 0.20 0.28
8 0.17 0.11 0.02 -0.06 0.18 0.21 0.24 0.27
16 0.02 -0.01 0.01 -0.02 0.12 0.08 0.10 0.07
MDQ 0.01 0.10 0.27 0.33 0.36 0.66 0.48 0.43 0.22
0.1 0.02 0.14 0.36 0.30 0.70 0.57 0.24 0.30
0.5 -0.01 0.17 0.33 0.28 0.71 0.44 0.29 0.27
1 0.00 0.25 0.48 0.23 0.65 0.36 0.24 0.35
2 0.19 0.30 0.32 0.12 0.47 0.32 0.24 0.35
4 0.25 0.32 0.27 0.16 0.35 0.21 0.15 0.25
8 0.27 0.18 0.18 0.05 0.19 0.25 0.23 0.22
16 0.07 0.07 0.06 0.01 0.07 0.10 0.08 0.08
Table 34: Comparison of power for the tests using MaxDA·, MDA·, and MDQ· as test
statistics based on partial correlations (pCor) with and without shrinkage of




Cor − pCor with shrinkage pCor with − pCor without shrinkage
variance number of additional nodes number of additional nodes
0 5 0 5
MaxDA 0.01 0.51 0.60 0.04 -0.01
0.1 0.37 0.56 0.19 0.08
0.5 0.50 0.46 0.14 0.07
1 0.41 0.41 0.23 0.14
2 0.35 0.37 0.17 0.11
4 0.42 0.34 0.06 -0.01
8 0.37 0.21 -0.04 0.06
16 0.17 0.17 0.05 0.01
MDA 0.01 0.50 0.60 0.15 0.11
0.1 0.51 0.64 0.09 0.04
0.5 0.64 0.55 0.05 0.03
1 0.60 0.53 0.07 0.01
2 0.43 0.43 0.06 0.03
4 0.34 0.38 0.02 -0.05
8 0.34 0.18 -0.01 -0.01
16 0.10 0.05 0.07 0.03
MDQ 0.01 0.45 0.51 0.23 0.22
0.1 0.45 0.59 0.20 0.11
0.5 0.60 0.57 0.10 0.06
1 0.57 0.56 0.12 0.01
2 0.43 0.56 0.13 -0.02
4 0.37 0.39 0.07 -0.01
8 0.47 0.23 0.00 0.00
16 0.13 0.08 0.07 0.03
Table 35: Comparison of power for the tests using MaxDA·, MDA·, and MDQ· as test
statistics based on partial correlations (pCor) with and without shrinkage of
the covariance matrix and ordinary correlations (Cor) considering 180 samples
in the ﬁrst and 20 samples in the second group.
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Cor − pCor with shrinkage pCor with − pCor without shrinkage
variancenumber of additional nodes number of additional nodes
0 5 0 5
MaxDA 0.01 0.20 0.27 0.12 0.01
0.1 0.31 0.29 0.09 0.02
0.5 0.19 0.19 0.25 0.00
1 0.20 0.12 0.10 0.05
2 0.22 0.22 0.05 -0.02
4 0.20 0.10 0.08 0.01
8 0.10 0.08 -0.01 0.04
16 0.04 0.02 -0.03 0.02
MDA 0.01 -0.24 -0.02 0.62 0.46
0.1 -0.36 -0.13 0.69 0.48
0.5 -0.24 -0.06 0.59 0.34
1 -0.09 -0.02 0.45 0.27
2 -0.01 0.03 0.29 0.18
4 0.04 -0.02 0.13 0.07
8 0.06 -0.03 0.01 0.08
16 0.01 0.02 -0.02 0.02
MDQ 0.01 -0.08 0.35 0.57 0.19
0.1 -0.19 0.29 0.65 0.16
0.5 -0.18 0.27 0.57 0.11
1 0.03 0.18 0.42 0.12
2 0.15 0.16 0.26 0.16
4 0.08 0.08 0.15 0.07
8 0.10 0.01 0.01 0.06
16 0.01 0.02 -0.05 0.03
Table 36: Comparison of power for the tests using MaxDA·, MDA·, and MDQ· as test
statistics based on partial correlations (pCor) with and without shrinkage of




variance number of additional nodes
0 5 10 20 50
max MDQ - max MDA
0.01 0.01 0.03 0.04 0.06 0.09
0.1 0.01 0.01 0.04 0.03 0.14
0.5 0.00 0.00 0.01 0.10 0.12
1 0.03 0.00 0.06 0.10 0.05
2 0.00 0.02 0.03 0.11 0.16
4 0.05 0.09 0.13 0.15 0.09
8 0.03 0.10 0.09 0.21 0.05
16 0.09 0.07 0.14 0.12 0.03
max MDA - max MaxDA
0.01 -0.02 0.03 -0.03 -0.01 -0.06
0.1 0.02 0.00 -0.01 -0.02 -0.12
0.5 0.01 0.00 -0.01 -0.11 -0.20
1 -0.02 -0.02 -0.06 -0.09 -0.13
2 -0.03 -0.01 -0.04 -0.16 -0.23
4 -0.07 -0.06 -0.09 -0.20 -0.19
8 -0.07 -0.10 -0.15 -0.24 -0.25
16 -0.15 -0.21 -0.24 -0.26 -0.23
max MaxDA - max MDQ
0.01 0.01 -0.06 -0.01 -0.05 -0.03
0.1 -0.03 -0.01 -0.03 -0.01 -0.02
0.5 -0.01 0.00 0.00 0.01 0.08
1 -0.01 0.02 0.00 -0.01 0.08
2 0.03 -0.01 0.01 0.05 0.07
4 0.02 -0.03 -0.04 0.05 0.10
8 0.04 0.00 0.06 0.03 0.20
16 0.06 0.14 0.10 0.14 0.20
Table 37: Comparison of maximal power using on partial correlations (pCor) with or
without shrinkage of the covariance matrix or ordinary correlations (Cor) of




variance number of additional nodes
0 5



























Table 38: Comparison of maximal power using on partial correlations (pCor) with or
without shrinkage of the covariance matrix or ordinary correlations (Cor) of









Table 39: Overview of the results of the permutation tests for the enriched GO groups in the ontologies biological pro-
cess (top), molecular function (middle), and cellular component (bottom), separated by midrules, regarding
MammaPrint genes. p-values below 0.05 are marked in grey.
GO term MaxDApC MDApC MDQpC MDE χE MDAR MDQR MDARE MDQRE CORpCE RCORpCE MaxDAC MDAC MDQC
GO:0030949 0.936 0.045 0.071 0.978 0.966 0.050 0.057 0.692 0.661 0.547 0.273 0.210 0.022 0.024
GO:0044342 0.507 0.194 0.347 0.835 0.615 0.128 0.053 0.858 0.858 0.874 0.703 0.059 0.287 0.147
GO:0048630 0.098 0.845 0.857 0.036 0.810 0.797 0.671 1.000 1.000 0.392 0.977 0.312 0.672 0.632
GO:0001957 0.082 0.099 0.067 0.955 0.694 0.552 0.583 0.504 0.467 0.027 0.045 0.287 0.015 0.028
GO:0043569 0.288 0.918 0.902 0.815 0.031 0.588 0.657 0.888 0.873 0.020 0.072 0.696 0.710 0.682
GO:0014912 0.112 0.116 0.067 0.825 0.534 0.509 0.565 0.865 0.759 0.059 0.615 0.566 0.085 0.116
GO:0002063 0.541 0.266 0.303 0.367 0.381 0.178 0.158 0.383 0.336 0.315 0.474 0.408 0.060 0.101
GO:0032332 0.624 0.003 0.004 0.955 0.750 0.005 0.003 0.660 0.579 0.001 0.010 0.252 0.009 0.005
GO:0060056 0.446 0.698 0.814 0.036 0.006 0.228 0.379 0.704 0.710 0.968 0.908 0.161 0.522 0.560
GO:0040001 0.068 0.305 0.291 0.929 0.756 0.442 0.245 0.936 0.826 0.077 0.112 0.075 0.031 0.030
GO:0043568 0.112 0.508 0.775 0.873 0.724 0.032 0.013 0.854 0.840 0.359 0.665 0.244 0.351 0.262
GO:0071320 0.473 0.331 0.486 0.073 0.112 0.150 0.172 0.311 0.357 0.755 0.896 0.744 0.542 0.562
GO:0045668 0.715 0.244 0.162 0.049 0.022 0.245 0.137 0.034 0.027 0.132 0.090 0.528 0.308 0.279
GO:0031069 0.361 0.221 0.049 0.591 0.261 0.372 0.312 0.616 0.598 0.130 0.268 0.785 0.758 0.778
GO:0001958 0.571 0.528 0.628 0.544 0.586 0.404 0.423 0.739 0.702 0.947 0.841 0.377 0.343 0.345
GO:0032508 0.865 0.915 0.970 0.909 0.936 0.518 0.527 0.841 0.854 0.495 0.870 0.630 0.328 0.367
GO:0071407 0.352 0.070 0.099 0.768 0.802 0.477 0.510 0.625 0.673 0.186 0.613 0.238 0.218 0.221
GO:0017148 0.841 0.320 0.424 0.073 0.269 0.475 0.472 0.146 0.117 0.493 0.705 0.045 0.004 0.007
GO:0010508 0.162 0.649 0.331 0.984 0.799 0.948 0.946 0.956 0.956 0.564 0.481 0.278 0.230 0.186
GO:0038084 0.926 0.475 0.647 0.326 0.615 0.127 0.104 0.566 0.566 0.373 0.611 0.087 0.036 0.031
GO:0019852 0.486 0.579 0.717 0.306 0.619 0.410 0.312 0.200 0.213 0.597 0.746 0.032 0.450 0.099
GO:0070830 0.466 0.467 0.565 0.845 0.929 0.082 0.088 0.536 0.560 0.753 0.772 0.197 0.299 0.295
GO:0006940 0.708 0.579 0.658 0.636 0.693 0.464 0.351 0.696 0.656 0.671 0.674 0.864 0.368 0.431
GO:0031532 0.790 0.016 0.023 0.058 0.068 0.055 0.027 0.019 0.023 0.118 0.095 0.227 0.135 0.167
GO:0031032 0.314 0.051 0.056 0.941 0.876 0.718 0.565 0.866 0.891 0.096 0.373 0.325 0.340 0.369
GO:0030901 0.792 0.373 0.259 0.953 0.801 0.878 0.899 0.938 0.918 0.842 0.426 0.466 0.409 0.385
GO:0043552 0.512 0.132 0.185 0.780 0.689 0.088 0.110 0.546 0.508 0.088 0.140 0.516 0.082 0.081
GO:0002548 0.487 0.022 0.045 0.265 0.226 0.003 0.002 0.253 0.264 0.403 0.403 0.888 0.205 0.272
GO:0021670 0.839 0.657 0.766 0.070 0.163 0.042 0.052 0.068 0.070 0.634 0.503 0.546 0.129 0.112
GO:0051382 0.512 0.516 0.622 0.462 0.410 0.437 0.336 0.272 0.244 0.252 0.279 0.671 0.685 0.603
GO:0000281 0.101 0.111 0.148 0.724 0.212 0.055 0.030 0.676 0.621 0.139 0.168 0.420 0.146 0.196








Table 39: Overview of the results of the permutation tests for the enriched GO groups in the ontologies biological pro-
cess (top), molecular function (middle), and cellular component (bottom), separated by midrules, regarding
MammaPrint genes. p-values below 0.05 are marked in grey.
GO term MaxDApC MDApC MDQpC MDE χE MDAR MDQR MDARE MDQRE CORpCE RCORpCE MaxDAC MDAC MDQC
GO:0007076 0.295 0.182 0.085 0.973 0.202 0.637 0.778 0.904 0.904 0.003 0.005 0.131 0.060 0.064
GO:0048853 0.116 0.071 0.070 0.656 0.210 0.096 0.097 0.914 0.914 0.186 0.616 0.105 0.016 0.013
GO:0008608 0.178 0.026 0.047 0.710 0.778 0.108 0.219 0.832 0.836 0.824 0.935 0.003 0.028 0.030
GO:0000186 0.328 0.010 0.005 0.103 0.174 0.077 0.061 0.192 0.153 0.464 0.777 0.394 0.010 0.010
GO:0014068 0.109 0.050 0.044 0.411 0.383 0.246 0.086 0.372 0.359 0.212 0.331 0.331 0.020 0.023
GO:0034080 0.726 0.354 0.697 0.408 0.405 0.004 0.009 0.145 0.142 0.205 0.098 0.894 0.492 0.531
GO:0021772 0.740 0.966 0.981 0.875 0.819 0.381 0.437 0.770 0.737 0.481 0.560 0.885 0.313 0.362
GO:0006024 0.869 0.115 0.065 0.617 0.557 0.381 0.404 0.557 0.391 0.195 0.222 0.319 0.030 0.022
GO:0005520 0.511 0.179 0.191 0.396 0.493 0.166 0.075 0.225 0.217 0.253 0.095 0.193 0.104 0.088
GO:0001968 0.085 0.016 0.031 0.207 0.101 0.018 0.012 0.220 0.164 0.584 0.158 0.362 0.258 0.285
GO:0003678 0.866 0.788 0.877 0.857 0.831 0.057 0.034 0.841 0.853 0.385 0.757 0.266 0.095 0.111
GO:0005355 0.185 0.726 0.777 0.295 0.654 0.362 0.309 0.113 0.156 0.679 0.792 0.063 0.755 0.607
GO:0005021 0.934 0.452 0.640 0.353 0.624 0.114 0.081 0.607 0.607 0.371 0.608 0.101 0.028 0.027
GO:0051059 0.289 0.183 0.253 0.960 0.508 0.071 0.291 0.998 0.998 0.463 0.901 0.390 0.331 0.305
GO:0070628 0.191 0.001 0.001 0.364 0.346 0.017 0.009 0.540 0.433 0.160 0.651 0.029 0.005 0.010
GO:0004029 0.473 0.318 0.205 1.000 0.006 0.326 0.210 1.000 1.000 0.995 0.995 0.257 0.235 0.213
GO:0030276 0.599 0.214 0.220 0.910 0.840 0.433 0.302 0.723 0.803 0.242 0.388 0.551 0.469 0.448
GO:0008242 0.780 0.806 0.647 0.400 0.776 0.886 0.704 0.311 0.241 0.027 0.003 0.541 0.461 0.334
GO:0001085 0.087 0.022 0.019 0.119 0.264 0.013 0.052 0.078 0.090 0.236 0.311 0.447 0.115 0.087
GO:0000145 0.843 0.907 0.917 0.783 0.499 0.972 0.954 0.478 0.463 0.607 0.140 0.872 0.814 0.736
GO:0016942 0.188 0.074 0.147 0.492 0.303 0.060 0.081 0.914 0.835 0.908 0.751 0.228 0.168 0.158
GO:0034451 0.985 0.935 0.979 0.992 0.885 0.394 0.439 0.953 0.942 0.731 0.055 0.997 0.852 0.912
GO:0046581 0.135 0.339 0.302 0.676 0.092 0.690 0.841 0.524 0.511 0.008 0.012 0.339 0.615 0.569
GO:0005923 0.402 0.122 0.141 0.155 0.545 0.219 0.226 0.166 0.237 0.621 0.874 0.710 0.325 0.322
GO:0005587 0.294 0.439 0.220 0.775 0.703 0.862 0.802 0.134 0.098 0.548 0.058 0.250 0.027 0.033











































































































































Figure 19: Histogramms of the p-values of the Wald tests testing the hypothesis "H0 :

























































































































Figure 20: Histogramms of the p-values of the Wald tests testing the hypothesis "H0 :
HR = 1" for every probe set in the histological subgroup of adenocarcinomas







































 [1.23;  1.49]
 [1.16;  1.71]
 [1.21;  1.89]
 [1.14;  1.59]
 [0.83;  1.81]
 [2.11; 26.11]
 [0.77;  1.26]
 [0.86;  2.98]
 [1.61;  4.16]
 [1.09;  1.89]
 [0.64;  1.61]
CDCP1
p=0.0005
Figure 21: Forestplot of the meta-analysis for probe set "218451_at" that represents the
gene "CDCP1" including all nine non-small cell lung cancer datasets. The
p-value (bottom right) corresponds to the random eﬀects model.
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Figure 22: Visualisation of the signiﬁcant features at the end of the best 3-step sequential
validation approach, the combined meta-analysis for all patients comparing
the proceeding when GSE31210 is used as basic dataset, and the common
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 [0.53;  2.48]
 [0.58;  1.78]
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p=0.0002
Figure 23: Forestplot of the meta-analysis for probe set "212581_x_at" that represents
the gene "GAPDH" including all nine non-small cell lung cancer datasets.
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p=0.0027
Figure 24: Forestplot of the meta-analysis for probe set "M33197_M_at" that rep-
resents the gene "GAPDH" including all nine non-small cell lung cancer
















































































































































































































































































































































































































































































































































































Figure 25: Proportion of misleadingly rejected hypothesis for simulated setting of 100















































































































































































































































































































































































































































































































































































Figure 26: Proportion of misleadingly rejected hypothesis for simulated setting of 100















































































































































































































































































































































































































































































































































































Figure 27: Proportion of misleadingly rejected hypothesis for simulated setting of 100















































































































































































































































































































































































































































































































































































Figure 28: Proportion of misleadingly rejected hypothesis for simulated setting of 100
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Figure 83: Proportion of rejected hypothesis for simulated setting of 20 samples per
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Figure 86: Proportion of rejected hypothesis for simulated setting of 100 samples per




























































































































































































































































































































































































































































































































































































































































































































































































l l l l l



















































l l l l
l



























































l l l l l






















































Figure 87: Proportion of rejected hypothesis for simulated setting of 150 and 50 samples
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Figure 89: Proportion of rejected hypothesis for simulated setting of 50 samples per


















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Figure 90: Proportion of rejected hypothesis for simulated setting of 20 samples per
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Figure 91: Proportion of rejected hypothesis for simulated setting of 200 samples per
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Figure 92: Proportion of rejected hypothesis for simulated setting of 300 and 100 samples






























































































































Figure 93: Comparison of shrinkage intensities in the scenario with 100 samples per
group without (blue) and 50 additional nodes (red), where variance of the
noise term is 1, and node PKC is knocked out.
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Figure 94: Histogramms of the maximal distances of partial correlations in the scenario
with 300 samples in the ﬁrst and 100 samples in the second group (top) and
100 samples in both groups (bottom) without (left) and 50 additional nodes
(right), where variance of the noise term is 1, and node PKC is knocked out.
231
Appendix


















































Figure 95: Histogramms of the mean distances of partial correlations in the scenario
with 300 samples in the ﬁrst and 100 samples in the second group (top) and
100 samples in both groups (bottom) without (left) and 50 additional nodes
(right), where variance of the noise term is 1, and node PKC is knocked out.
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